No va r t i s  In s t i tu te s  fo r  B ioMed i ca l  Re sea r ch
LHW090
C l in i ca l  T r ia l  P ro to co l  CLHW090X2202
A  random ized ,  sponso r  open,s i te  and  sub jec t  doub le  b l ind,  
pa ra l le l  g roup ,  p lacebo- con t ro l led  s tudy to  ev a lua te  the  
sa fe ty and  e f f icacy  o f  LHW090  a f te r  4  w eeks  t rea tmen t  in  
pa t ien ts  wi th  res is tan t  hy pe r tens ion
Au tho rs :  
 
Do cumen t  t ype : AmendedP ro to co lVe r s ion
EUDRACT  numbe r : 2015- 001890- 42
Ve rs ion  numbe r : v05( C lean)
De ve lopmen t  pha se : I I
Re lease  da te : 22- Aug- 2016P e r s o n a l  D a t a
P rope r ty  o f  Nova r t is
Con f iden t ia l
May  no t  be  used ,  d ivu lged ,  pub l ished  o r  o the rw ise  d isc losed
w i thou t  the  consen t  o f  Nova r t is
No va r t i s Con f iden t ia l Page  2
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
S i te  Ope ra t ions  Manua l  (SOM )
A  S i t e  Op e r a t ion s  M anu a l  (SOM )  a c comp an i e s  th i s  p ro to co l ,  p rov id ing  th e  op e r a t ion a l  d e t a i l s  
fo r  s tudy  condu c t .
No t i f ica t ion  o f  se r ious  adve rse  even ts
R e f e r  to  S e c t i o n  9 . 2o f  t h e  p r o t o c o l  f o r  d e f i n i t i o n s  a n d  r e p o r t i n g  r e qu i r em e n t s  f o r  S e r i o u s  
A d v e r s e  E v e n t s  (w i t h i n  2 4  h o u r s  a f t e r  aw a r e n e s so f  th e  SAEto  th e  lo c a l  Nov a r t i s  D rug  S a f e t y  
and  Ep id em io logy  D ep a r tm en tand  no t i fy  t h e  Cl i n i c a l  T r i a l  L e a d e r . ) .  
C o n t a c t  i n f o rm a t i o n  i sl i s t e d  i n  t h e  S it e  O p e r a t i o n s  M a n u a l .  
No va r t i s Con f iden t ia l Page  3
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
Tab le  o f  con ten ts
S i t e  O p e r a t i o n s  M a n u a l  (SOM ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2
N o t i f i c a t i o n  o f  s e r i o u s  a d v e r s e  e v e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
T a b l e  o f  c o n t e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
L i s t  o f  t a b l e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
L i s t  o f  f i g u r e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
L i s t  o f  a b b r e v i a t i o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
P h a rm a c o k i n e t i c  d e f i n i t i o n s  a n d  s ymbo l s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0
P ro to co l  synop s i s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 3
1 I n t r o d u c t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 7
1 . 1 B a c k g r o u n d. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 7
1 . 1 . 1 R e l e v a n t  d a t a  s umm a r y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 8
1 . 2 S tudy pu rpo s e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 1
2 S tudy o b j e c t i v e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2
2 . 1 P r im a ry o b j e c t i v e ( s ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2
2 . 2 S e cond a ry o b j e c t i v e ( s ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2
2 . 3 Exp lo r a to ry o b j e c t i v e ( s ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2
3 I n v e s t i g a t i o n a l  p l a n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 3
3 . 1 S tudy d e s ign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 3
3 . 2 R a t i o n a l e  o f  s t u d y d e s i g n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
3 . 3 R a t i o n a l e  o f  d o s e / r e g im e n ,  d u r a t i o n  o f  t r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4
3 . 4  R a t i o n a l e  f o r  c h o i c e  o f  c om p a r a t o r . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 5
3 . 5 P u r p o s e  a n d  t im i n g  o f  i n t e r im  a n a ly s e s / d e s i g n  ad ap t a t ion s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 5
3 . 6 R i s k s  a n d  b e n e f i t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 6
4 Popu l a t ion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 6
4 . 1 I n c l u s i o n  c r i t e r i a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 7
4 . 2 E x c l u s i o n  c r i t e r i a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 7
5  Re s t r i c t i o n sfo r  S tudyS u b j e c t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 9
5 . 1 C o n t r a c e p t i o n  r e q u i r em e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 9
5 . 2  A l l ow a b l e  M e d i c a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 9
5 . 3 P r o h i b i t e d  t r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
3 0
No va r t i s Con f iden t ia l Page  4
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
5 . 4 D i e t a ry r e s t r i c t ion s  and  smok ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1
5 . 5 G e n e r a l  r e s t r i c t i o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1
6 T r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1
6 . 1 S tudy t r e a tm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1
6 . 1 . 1 I n v e s t i g a t i o n a l  t r e a tm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1
6 . 2 T r e a tm e n t  a rm s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1
6 . 3 P e rm i t t e d  d o s e  a d j u s tm e n t s  a n d  i n t e r r u p t i o n s  o f  s t u d y t r e a tm en t . . . . . . . . . . . . . . . . . . . . . . . . . 3 1
6 . 4 T r e a tm e n t  a s s i g nm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2
6 . 5 T r e a tm e n t  b l i n d i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2
6 . 6 Em e rg en cy b r e a k i n g  o f  a s s i g n e d  t r e a tm e n t  c o d e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
6 . 7 T r e a tm e n t  e x p o s u r e  a n d  c om p l i a n c e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
6 . 8 R e c omm e n d e d  t r e a tm e n t  o f  a d v e r s e  e v e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
6 . 9  R e s c u e  m e d i c a t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 3
6 . 1 0 C o n c om i t a n t  t r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
7 D i s c o n t i n u a t i o n  a n d  s t u d y  c om p l e t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4
7 . 1 D i s con t inu a t ion  o f  s tudy t r e a tm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4
7 . 2 S tudy comp l e t ion  and  po s t - s tudy  t r e a tm en t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5
7 . 2 . 1 L o s t  t o  f o l l ow- u p . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5
7 . 3 W i t h d r aw a l  o f  c o n s e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5
7 . 4 S tudy S t o p p i n g  r u l e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 6
7 . 5 E a r ly  s t u d y  t e rm i n a t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 6
8  P r o c e d u r e s  a n d  a s s e s sm e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 7
8 . 1 I n f o rm e d  c o n s e n t  p r o c e d u r e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 8
8 . 2 S u b j e c t  d em o g r a p h i c s / o t h e r  b a s e l in e  ch a r a c t e r i s t i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 8
8 . 3 E f f i c a cy /  P h a rm a c o d y nam i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9
8 . 3 . 1 Ambu l a to ry b lood  p r e s su r e  mon i to r ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9
8 . 4 S a f e ty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 9
8 . 4 . 1 Phys i c a l  ex am in a t ion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9
8 . 4 . 2 V i t a l  s i g n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9
8 . 4 . 3 H e i g h t  a n d  w e i g h t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0
8 . 4 . 4 L abo r a to ry e v a l u a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0
8 . 4 . 5 E l e c t r o c a r d i o g r am  (ECG ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0
8 . 5 P h a rm a c o k i n e t i cs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1
8 . 6 O t h e r  a s s e s sm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1
8 . 6 . 1 Exp lo r a to ry B i om a r k e r  a s s e s sm e n t s :  cGMP ,  A l d o s t e r o n e ,  
N e p r i ly s in . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1
No va r t i s Con f iden t ia l Page  5
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
9 S a f e ty  m on i t o r i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2
9 . 1 A d v e r s e  e v e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
9 . 2 S e r i o u s  a d v e r s e  e v e n t  r e p o r t i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4
9 . 2 . 1 D e f i n i t i o n  o f  SAE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4
9 . 2 . 2 SAE  r e p o r t i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5
9 . 3 L iv e r  s a f e ty mon i to r ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
9 . 4 R e n a l  s a f e ty  m o n i t o r i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 9
9 . 5 P r egn an cy r epo r t ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0
9 . 6 P r o s p e c t i v e  s u i c i d a l i t y a s s e s sm en t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0
9 . 7 E a r ly  p h a s e  s a f e ty  m o n i t o r i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0
1 0D a t a  r e v i ew  a n d  d a t a b a s e  m a n a g em e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 1
1 0 . 1 S i t e  mon i to r ing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 1
1 0 . 2  D a t a  c o l l e c t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 1
1 0 . 3 D a t a  M o n i t o r i n g  C omm i t t e e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 3
1 0 . 4 A d j u d i c a t i o n  C omm i t t e e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 3
1 1D a t a  an a lys i s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 3
1 1 . 1 An a lys i s  s e t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 3
1 1 . 2  S u b j e c t  d em o g r a p h i c s  a n d  o t h e r  b a s e l i n e  c h a r a c t e r i s t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 3
1 1 . 3 T r e a tm e n t s  ( s t u dy  d r u g ,  r e s c u e  m e d i c a t i o n ,  o t h e r  c o n c om i t a n t  t h e r a p i e s ,  
c om p l i a n c e ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 3
1 1 . 4 An a lys i s  o f  th e  p r im a ry  v a r i ab l e ( s ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 4
1 1 . 4 . 1 V a r i a b l e ( s ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 4
1 1 . 4 . 2 S t a t i s t i c a l  mod e l ,  hyp o th e s i s ,  a n d  m e t h o d  o f  a n a l y s i s. . . . . . . . . . . . . . . . . . . . . . . . . . 5 4
1 1 . 4 . 3 H a n d l i n g  o f  m i s s i n g  v a l u e s / c e n s o r i n g / d i s c o n t i n u a t i o n s. . . . . . . . . . . . . . . . . . . . . . . 5 4
1 1 . 4 . 4 S u p p o r t i v e  a n a ly se s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 5
1 1 . 5 An a lys i s  o f  s e cond a ry  and  exp lo r a to ry  v a r i a b l e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 5
1 1 . 5 . 1 E f f i c a cy /  P h a rm a c o d y nam i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 5
1 1 . 5 . 2 S a f e ty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 5
1 1 . 5 . 3 P h a rm a c o k i n e t i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 6
1 1 . 5 . 4 P h a rm a c o k i n e t i c  /  p h a rm a c o dy n am i c s  i n t e r a c t i o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 6
1 1 . 5 . 5 O t h e r  a s s e s sm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 6
1 1 . 6  S am p l e  s i z e  c a l c u l a t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 7
1 1 . 7 P ow e r  f o r  a n a ly s i s  o f  k ey  s e cond a ry  v a r i ab l e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 7
1 1 . 8 I n t e r im  a n a l y s e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 7
1 2E t h i c a l  c o n s i d e r a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 8
1 2 . 1 R egu l a to ry  and  e th i c a l  comp l i an c e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 8
No va r t i s Con f iden t ia l Page  6
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
1 2 . 2 R e spon s ib i l i t i e s  of  t h e  i n v e s t i g a t o r  a n d  IRB / IEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 8
1 2 . 3 Pub l i c a t ion  o f  s tudy p r o t o co l  a n d  r e s u l t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 9
1 3P r o t o c o l  a d h e r e n c e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 9
1 3 . 1 P r o t o c o l  Am e n dm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 9
1 4R e f e r e n c e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 0
L is t  o f  tab les
T a b l e  8- 1 A s s e s sm e n t  s c h e d u l e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7
T a b l e  9- 1 L i v e r  E v e n t  a n d  L a b o r a t o r y T r igg e r  D e f in i t ion s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 7
T a b l e  9- 2 F o l l ow  U p  R e q u i r em e n t s  f o r  L i v e r  E v e n t s  a n d  L a b o r a t o r y  T r i g g e r s. . . 4 7
T a b l e  9- 3 S p e c i f i c  R e n a l  A l e r t  C r i t e r i a  a n d  A c t i o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 9
L is t  o f  f igu res
 
F i g u r e  3- 1 S tudy d e s ign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
2 4
No va r t i s Con f iden t ia l Page  7
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
L is t  o f  abb rev ia t ions
ABPM Ambu l a to ry b lood  p r e s su r e  mon i to r
ACE A n g i o t e n s i n- c o n v e r t i n g - en zy m e  
AEAd v e r s e  e v e n t
ALT A l a n i n e  am i n o t r a n s f e r a s e
ALP Al k a l i n e  p h o s p h a t a s e
ARB A n g i o t e n s i n  R e c e p t o r  B l o c k e r
ASH / ISH Am e r i c a n  S o c i e ty  o f  Hyp e r t e n s i o n  a n d  th e  I n t e r n a t io n a l  S o c i e ty  o f  
Hyp e r t e n s i o n
ANP A t r i a l  n a t r i u r e t i c  p e p t i d e
AST As p a r t a t e  am i n o t r a n s f e r a s e
BM I B o dy  M a s s  I n d e x
BNP B -ty p e  n a t r i u r e t i c  p e p t i d e
BPB l o o d  p r e s s u r e
CABG Co ron a ry a r t e ry  by p a s s  g r a f t ing
CD- ROM Com p a c t  d i s c  –r e a d  o n l y  m em o r y
CNP C -ty p e  n a t r i u r e t i c  p e p t i d e
CFR C o d e  o f  F ed e r a l  R eg u l a t i o n
cGMP Cyc l i c  g u a n o s i n e  m o n o p h o s p h a t e
CKCr e a t i n e  k i n a s e
CRF C a s e  R e p o r t /R e c o r d  F o rm  ( p ap e r  o r  e l e c t r o n i c )
CR I C h r o n i c  r e n a l  im p a i rm e n t
CRO C o n t r a c t  R e s e a r c h  O r g a n i z a t i o n
C -SSRS  Co lumb i a  Su i c id e  S ev e r i ty R a t i n g  S c a l e
CVCo e f f i c i e n t  o f  v a r i a t i o n
DD I D rug- d r u g  i n t e r ac t ion
ECE t h i c s  c omm i t t e e
ECG E l e c t r o c a r d i o g r am
EDC E l e c t r o n i c  D a t a  C a p t u r e
ESC E u r o pe a n  S o c i e t y  fo r  C a rd io logy
FDA F o o d  a n d  D r u g  A dm i n i s t r a t i o n
F IH F i r s t  i n  h um a n
No va r t i s Con f iden t ia l Page  8
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
GCP G o o d  C l i n i c a l  P r a c t i c e
GFR G l om e r u l a r  f i l t r a t i o n  r a t e
hh o u r
IC [ADDRESS_1133181] o g e n a s e
LLOQ l ow e r  l im i t  o f  q u a n t i f i c a t i o n
M e dDRA Med i c a l  d i c t ion a ry  fo r  r egu l a to ry  a c t iv i t i e s  
mgMi l l i g r am ( s )
m lMi l l i l i t e r ( s )
NEP N a t r i u r e t i c  p e p t i d e s
NSA IDS N o n s t e r o i d a l  a n t i- in f l amm a to ry  d rug s
PAPo s t e r o a n t e r i o r
PC I P e r cu t an eou s  co ron a ry i n t e r v e n t i o n
PDPh a rm a c o dy n am i c ( s )
PKPh a rm a c o k i n e t i c ( s )
p . o .O ra l ( l y )
RBC Re d  b l o o d  c e l l ( s )
REB R e s e a r c h  E t h i c s  B o a r d
RHT R e s i s t an t  hyp e r t e n s i o n
SAE Se r i o u s  a d v e r s e  e v e n t
SBP Sys t o l i c  b l o o d  p r e s s u r e
SDSt a n d a r d  d e v i a t i o n
SOM Si t e  o p e r a t i o n s  m a n u a l
S[LOCATION_003]R S u s p e c t e d  U n e x p e c t e d  S e r i o u s  A d v e r s e  R e a c t i o n s
TBL To t a l  b i l i rub in
T IAT r a n s i e n t  i s c h em i c  a t t a c k
No va r t i s Con f iden t ia l Page  9
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
ULN Up p e r  l im i t  o f  n o rm a l
WBC Wh i t e  b l o o d  c e l l ( s )
WHO W o r l d  H e a l t h  O r g a n i z a t i o n
No va r t i s Con f iden t ia l Page  10
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
Pha rmacok ine t ic  de f in i t ions  and  symbo ls
AUC 0- t T h e  a r e a  und e r  t h e  p l a sm a  c o n c e n t r a t i o n - t im e  c u r v e  f r om  t im e  z e r o  to  t im e  
‘ t ’  w h e r e  t  i s  a  d e f i n e d  t im e  p o i n t  a f t e r  a dm i n i s t r a t i o n  [ n gx  h r/  mL ]
AUC l a s t T h e  a r e a  und e r  t h e  p l a sm a  c o n c e n t r a t i o n - t im e  c u r v e  f r om  t im e  z e r o  to  th e  
t im e  o f  t h e  l a s t  q u a n t i f i a b l e  c o n c e n t r a t i o n  [n gx  h r/  mL]
Cm a x Th e  ob s e rv ed  m ax imum  p l a sm a  con c en t r a t ion  fo l low ing  d rug  adm in i s t r a t ion  
[n g/  mL]
Tm a x T h e  t im e  t o  r e a c h  t h e  m ax im um  c o n c e n t r a t i o n  a f t e r  d r u g  a dm i n i s t r a t i o n  [h r ]
No va r t i s Con f iden t ia l Page  11
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
No va r t i s Con f iden t ia l Page  12
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
No va r t i s Con f iden t ia l Page  13
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
P ro toco l  synops is
P ro toco l  numbe r LHW090X2202
T i t le A  random ized ,  sponso r  open ,  s i te  and  sub jec t  b l ind,  pa ra l le l  g roup ,  p lacebo-
con t ro l led  s tudy  t o  eva lua te  the  sa fe ty  and  e f f icacy o f  L HW090  a f te r  4  weeks  
t rea tmen t  in  pa t ien ts  w i th  res is tan t  hype r tens ion
B r ie f  t i t le Sa fe tyand  e f f icacy s tudy  o f  LH W090  in  res is tan t  hype r tens ion  pa t ien ts
Sponso r  and  C l in ica l  
PhaseNova r t is  
Phase  I I
In te rven t ion  type D rug
S tudy  type In te rven t iona l  
Pu rpose  and  
ra t iona leTo  de te rm ine  whe the r  LHW090  d isp lays  the  c l in ica l  sa fe ty  and  e f f icacyp ro f i le  
to  suppo r t  fu r the r  deve lopmen t  in  pa t ien ts  w i th  res is tan t  hype r tens ion .
P r ima ry  Ob jec t ive (s ) To  assessthe  sa fe ty  and  to le rab i l i ty  o f  LHW 090  fo r  4  weeks  on  a  
backg round  o f  conven t iona l  an t i- hype r tens ive  med ica t ions  in  pa t ien ts  
w i th  res is tan t  hyper tens ion .  
 To  eva lua te  the  e f fec t  o f  LHW090  on  p lacebo- ad jus ted  mean  day t ime  
sy s to l ic  b lood  p ressu re  (SBP )  a f te r  4  weeks  in  pa t ien ts  w i th  res is tan t  
hype r tens ion .
Seconda ry  
Ob jec t ives To  eva lua te  the  pha rmacok ine t ics  (PK )  o f  LHW090  and  i ts  ac t ive  
metabo l i te  LHV527  in  pa t ien ts  w i th  res is tan t  hype r tens ion .
S tudy  des ign Th is  is  a  non- con f i rma to ry ,  random ized ,  sponso r  open ,  s i te  and  sub jec t  b l ind,  
pa ra l le l  g roup ,  p lacebo- con t ro l led  s tudy  t o  eva lua te  the  sa fe ty  and  e f f icacy  o f  
4  weeks  t rea tmen t  w i th  LHW090  in  pa t ien ts  w i th  res is tan t  hype r tens ion .  
Pa t ien t s  w i th  uncon t ro l led  hype r tens ion  as  de f ined  as  a  mean  day t ime  
sy s to l ic  b lood  p ressu re  ≥  135mmHg by a mbu la to r y  b lood  p ressu re  
mon i to r ing  (ABPM )  on  a  s tab le  (a t  leas t  1  mon th )  reg imen  o f  an  ang io tens in  
re cep to r  b locke r  (ARB )  p lus  a  d iu re t i c  p lus  a t  leas toneadd i t iona l  c lass  o f
an t i- hype r tens ive  med i ca t ion  w i l l  be  cons ide red  fo r  th i s  t r ia l .  Pa t ien ts  w i th  
re s i s tan t  hype r tens ion  w i l l  be  random ized  to  e i the r  p lacebo  o r  1  o f  2  do se  
reg imens  o f  LHW090 ,  i .e .  LHW090  100  mg o nce  da i lyo rLHW090  200  mg 
once  da i ly ,  as  an  add- on  to  the i r  an t i- hype r tens ive  reg imen  a t  base l ine .
Ea ch  sub jec t  w i l l  pa r t ic ipa te  in  an  approx ima te ly3  week  s c reen ing  pe r iod ,  a  
2 -week  s ing le  b l ind  p lacebo  run - in  pe r iod ,  base l ine  assessmen ts ,  a  4  week  
t rea tmen t  pe r iod ,  and  an  end  o f  s tudy  a ssessmen t .  Du r ing  the  2  week  
p la cebo  run - in  pe r iod ,  pa t ien ts  w i l l  rece ive  regu la r  rem inde rs  to  be  comp l ian t  
w i th  the i r  an t i- hype r tens ive  med i ca t ion s .  A t  the  end  o f  th i s  run - in  pe r iod ,  
pa t ien t s  who  demons t ra te  ≥80%  comp l ian ce  w i th  p lacebo  w i l l  be  
random ized .  Comp l iance  w i l l  be  es tab l ished  by p i l l  coun t  and  rev iew  o f  
med i ca t ion  d ia r y .  Sub jec ts  w i l l  be  adv ised  tha t  s tud y  en t ry  canno t  be  fu l ly  
de te rm ined  un t i l  the  comp le t ion  o f  the  run- in  pe r iod .  
No va r t i s Con f iden t ia l Page  14
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
On  Da y  - 2 ,  pa t ien t s  w i l l  commence  24  hou r  ABPM  mon i to r ing  and  re tu rn  the  
ne x t  day ( Day - 1 )  to  ha ve  the  ABPM  dev ice  removed  and  the  da ta  co l lec ted .  
Pa t ien t s  may h ave  add i t iona la t temp tsto  comp le te  a  success fu l  ABPM  
assessmen t  (de f ined  by s a t is fac to ry B P  da ta  samp l ing  o ver  the  24  hou rs  and  
s tanda rds  fo r  de v i ce  qua l i ty  check )  i f  the  f i rs t  a t temp t  i s  unsuccess fu l  
( O 'B r iene t  a l  2013) .  Upon  co l lec t ion  o f  sa t i s fa c to r y  base l ine  ABPM  
assessmen t ,  sub jec ts  w i l l  then  re tu rn  fo r  base l ine  pha rmacodynam ic  
assessmen ts  on  Day - 1  and  then  beg in  a c t i ve  t rea tmen t  on  Day 1 .  Pa t ien ts  
w i l l  be  random ized  to  e i the r :
 LHW090  100  mg  once  da i ly  fo r  28  days
 LHW090  200  mg  once  da i ly  fo r  28  days
 Ma tch ing  p lacebo  fo r  [ADDRESS_1133182]  the  op t ion  to  re tu rn  on  Day 3  f o r  v i ta l  s ign .  Sub jec ts  w i l l  then  
v i s i t  the  c l in ic  a t  week ly  in te rva ls  (Da y  7 ,  14  and  21 )  fo r  sa fe ty ,  PK ,  and  PD  
assessmen ts .  On  v is i t  days ,  sub jec ts  w i l l  be  ins t ruc ted  to  take  the i r  
med i ca t ion s  a t  the  s i te .  On  Day 2 7 ,  pa t ien ts  w i l l  commence  a  f ina l24  hou r  
ABPM  assessmen t  and  then  re tu rn  the  nex t  day t o  ha ve  the  dev ice  removed  
and  then  beg in  co l lec t ion  o f  Day 2 8  s teady- s ta te  PK  and  PD  assessmen ts .  
Pa t ien t s  w i l l  be  asked  to  re tu rn  a f te r  app rox ima te ly  1  week  fo r  end  o f  s tud y  
(EOS )  assessmen ts .
Popu lat ion The  s tud y  popu la t ion  w i l l  be  comp r ised  o f  pa t ien ts  w i th  uncon t ro l led  
hype r tens ion  (he re  de f ined  as  hav ing  a  mean  dayt ime  sy s to l ic  BP  
≥135mmHgby A BPM )  desp i te  t rea tmen t  w i th  op t ima ldoseso f  an  ARB  p lus  
a  d iu re t i cp lus  a t  leas t  one  add i t iona lc lass  o f  an t i- hype r tens ive  med ica t ions .  
App rox ima te ly  80  pa t ien ts  age  40  to  85  ye a rs  o ld  ( inc lus ive )  w i l l  be  en ro l led  
and  random ized  in  the  s tudy .
Inc lus ion  c r i te r ia W ri t ten  in fo rmed  consen t  mus t  be  ob ta ined  be fo re  any  assessmen t  is  
pe r fo rmed .
 Ma le  and  fema le  pa t ien ts ,  age  40  to  85  yea rs  inc lus ive .
 Demons t ra t ing  a  ≥  80%  med ica t ion  comp l iance  ra te  du r ing  the  s ing le-
b l ind  run- in  pe r iod .
 Pa t ien ts  w i th  uncon t ro l led  hype r tens ion  (he re  de f ined  as  hav ing  a  mean  
day t ime  sy s to l ic  BP  ≥  135mmHgby [CONTACT_818253] t  sc reen in g)  desp i te  
t rea tmen t  w i th  a  s tab le  (a t  leas t  1mon th )  reg imen  tha t  inc ludes  an  
op t ima l  dose  o f  an  ARB  p lus  op t ima l  doses  o fa  d iu re t ic  p lus  a t  leas t  one
add i t iona lc lass  o f  an t i- hype r tens ive  med ica t ion .
Fo r  the  pu rposes  o f  th is  t r ia l ,  op t ima l  doses  o f  an t i- hype r tens ive  
med ica t ions  a re  de f ined  as :
 the  h ighes t  dose  l is ted  in  the  c l in ica l  p rac t ice  gu ide l ine  f rom  the  
Ame r i can  So c ie t y  fo r  Hype r tens ion  and  the  In te rna tiona l  Soc ie ty  fo r  
Hype r tens ion  (Webe r  e t  a l  2014)o r
 the  h ighes t  a l lowab le  p resc r ibed  dose  pe r  the  manu fac tu re r 's  labe l  
o r
 the  h ighes t  dose  to le ra ted  by  [CONTACT_818254] l  pa t ien t  o r
 the  h ighes t  dose  app rop r ia te  fo r  an  ind iv idua l  pa t ien t  in  the  judgmen t  
o f  the  Inves t iga to r
No te :  documen ted  ABPM  va lues  w i th in  3  months  o f  sc reen ing  a re  
accep tab le .
 Sub jec ts  mus t  we igh  a t  leas t  [ADDRESS_1133183]  a  body  mass  index  (BM I )  w i th in  the  range  o f  18- 40kg /m2 .
No va r t i s Con f iden t ia l Page  15
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
 Ab le  to  commun ica te  we l l  w i th  the  inves t iga to r ,  to  unde rs tand  and  comp ly  
w i th  the  requ i remen ts  o f  the  s tudy .
Exc lus ion  c r i te r ia Pa t ien ts  w i th  an  es t ima ted  GFR  <60  m l /m in /1 .73m2 .
 Use  o f  ang io tens in  conve r t ing  enzyme inh ib i to rs  (ACE - inh ib i to rs ) .
No te :  Pa t ien ts  who  d iscon t inue  the i r  ACE- inh ib i to r  and  subs t i tu te  w i th  an  
ang io tens in  recep to r  b locke r  may  be  e l ig ib le  to  be  re- sc reened  p rov ided  
the i r  an t i - hype r tens ive  reg imen  has  been  s tab le  fo r  a t  leas t  1mon th .  An y  
subs t i tu t ions  o r  changes  to  a  pa t ien t 's  an t i - hype r tens ive  reg imen  shou ld  
be  done  unde r  the  gu idance  o f  the  pa t ien t 's  t rea t ing  phys ic ian .
 Seve re  hype r tens ion  as  de f ined  by  [CONTACT_818255] l ic  b lood  p ressu re  ≥180  mmHg  
o r  d ias to l ic  b lood  p ressu re  ≥110  mmHg  a t  sc reen ingo r  base l ine.
 A  h is to ry  o f  seconda ry  hype r tens ion  o f  any  e t io logy  inc lud ing  bu t  no t  
l im i ted  to  un i la te ra l  o r  b i la te ra l  rena l  a r te ry  s tenos is ,  po lyc y s t ic  k idney  
d isease ,  coa rc ta t ion  o f  the  ao r ta ,  p r ima ry hy pe ra ldos te ron ism ,  Cush ing 's  
d isease ,  pheoch romocytoma ,  and  d rug - induced  hype r tens ion .I fthe  
pa t ien t  has  no t  been  eva lua ted  fo r  seconda ry  hype r tens ion ,  inves t iga to rs  
a re  respons ib le  to  eva lua te  a l l  po ten t ia l  seconda ry  causes  o f  
hype r tens ion  cons ide r ing  c l in ica l  h is to ry ,  phys ica l  exam ina t ion ,  labo ra to ry  
inves t iga t ions  o r  o the r  re levan t  d iagnos t ic  measu res  in  acco rdance  w i th  
cu r ren t  p rac t ices  and  c l in ica l  gu ide l ines  be fo re  en te r ing  the  pa t ien t  in to  
the  s tud y  ( Choban iane t  a l  2003;  Manc ia  e t  a l  2013;  Webe r  e t  a l  2014) .
 Known  cu r ren t  s ign i f ican t  le f t  ven t r icu la r  ou t f low  obs t ruc t ion ,  such  as  
obs t ruc t ive  hype r t roph ic  ca rd iomyo pa thy  o r  s ign i f ican t  seve re  va lvu la r  
d isease  on  p r io r  o r  cu r ren t  echoca rd iog ram ) .
 A  h is to ry  o f  known  modera te  o r  ma l ignan t  hype r tens ive  re t inopa thy  
de f ined  as  mode ra te  ( re t ina l  s igns  o f  hemo r rhage ) ,  m ic roaneu ry sms ,  
co t ton- woo l  spo ts ,  ha rd  exuda tes ,  o r  a  comb ina t ion  the reo f )  o r  ma l ignan t  
(s igns  o f  mode ra te  re t inopa thy  p lus  swe l l ing  o f  the  op t ic  d isk ) .Pa t ien t s
w i th  a  s tab le  oph tha lmo log ic  h is to ry  in  the  pas t  6  mon ths  a re  e l ig ib le .  
Anynew  o r  p rog ress ive  re t ina l  changes ,  acu te  g laucoma  o r  o the r  
oph tha lmo log ic  cond i t ions  w i th in  the  pas t  6  mon ths  shou ld  be  eva lua ted  
by [CONTACT_941]  t rea t ing  oph tha lmo log is t  du r ing  sc reen ing .
 To  fac i l i ta te  ABPM  assessmen t ,  an  uppe r  a rm  ci rcum fe rence  g rea te r  
than  [ADDRESS_1133184]  sh i f t  o r  ove rn igh t  wo rke rs .
H is to ry  w i th in  the  p rev ious  [ADDRESS_1133185] ia l  in fa rc t ion ,  co rona ry  
a r te ry  by[CONTACT_6476]  g ra f t  (CABG ) ,  pe rcu taneous  co rona ry  in te r ven t ion  (PC I ) ,  
hype r tens ive  encepha lopa thy ,  s t roke ,  o r  t rans ien t  ischem ic  a t tack  (T IA ) .
Women  o f  ch i ld- bea r ing  po ten t ia l ,  de f ined  as  a l l  women  phys io log ica l ly  
capab le  o f  becom ing  p regnan t .
Inves t iga t iona l  and  
re fe rence  the rapySub jec ts  w i l l  be  ass igned  to  one  o f  the  fo l low ing  3  t rea tmen t  a rms  in  a  ra t io  o f  
1 :1 :2 :
S tudy  t rea tmen ts  a re  de f ined  as :
 A :   100  mg  LHW090  
 B :   200  mg  LHW090
 C :   ma tch ing  p lacebo
E f f icacy/PD
assessmen ts ABPM
No va r t i s Con f iden t ia l Page  16
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
Sa fe ty  assessmen ts V i ta l  s ign s
 Hema to logy
 Chem is t ry
 U r ina l y s i s
 ECG  eva lua t ion
 Phy sica l  exam
 AE /SAE s
O the r  assessmen ts
Da ta  ana lys is The  p r ima ry e f f icacy  v a r iab le  w i l l  be  the  change  in  the  [ADDRESS_1133186] rage  o f 
sy s to l ic  b lood  p ressu re  mea su red  by a mbu la to r y  b lood  p ressu re  mon i to r ing  
(ABPM )  28  days  fo l low ing  the  s ta r t  o f  t rea tmen t .  Ou t- o f- o f f ice  ABPM  i s  a  
more  re l iab le  measu re  o f  a  pa t ien t 's  b lood  p ressu re  than  o f f ice- ba sed  BP  
read ings  wh ich  may b e  fa lse ly  e leva ted  because  o f  "wh i te - coa t "  phenomena  
( Bak r is  e t  a l  2010) .  The  change  f rom  ba se l ine  in  the  p lacebo  g roup  w i l l  be  
compa red  to  the  change  f rom  ba se l ine  in  the  poo ledLHW090  doses .  
Thec r i te r ia  to  demon s t ra te  e f f icacy ( success )  w i l l  be  based  on  s ta t is t ica l ly  
s ign i f ican t  (1 - s ided  p<0 .1 )  g rea te r  reduc t ion  f rom  ba se l inein  mean  day t ime  
SBP  w i th  ac t ive  t rea tmen t  (poo led  doses )  than  w i th  p lacebo ,  as  we l l  as  an  
es t ima ted  med ian  reduc t ion  on  a c t i ve  t rea tmen t  (poo led  ac t ive  doses )  o f  a t  
lea s t  7  mmHg  h ighe r  than  on  p lacebo .  The  th resho ld  o f  a  7  mmHg  reduc t ion  
in  p lacebo- ad jus ted  sy s to l ic  BP  by A BPM  i s  cons ide red  c l in ica l ly  s ign i f ican t  
s ince  s im i la r  magn i tude  changes  we re  obse rved  in  a  phase  3  t r ia l  o f  an  
endo the l in- recep to r  an tagon is t ,  da rusen tan ,  fo r  the  same  ind ica t ion  
( Webe re ta l  2009) .
S tudy  pa t ien ts  w i l l  be  random ized  in to  one  o f  3  g roup s ,  p la cebo ,  100  mg 
LHW090  and  200  mg L HW090 ,  as  an  add- on  the rapy  to  conven t iona l  
backg round  an t i- hype r tens ive  the rapy .  40  pa t ien ts  w i l l  be  random ized  to  
p la cebo ,  and  20  to  ea ch  dose  o f  a c t i ve  t rea tm en t .  Th is  w i l l  g ive  a round  32  
comp le te r s  in  the  p lacebo  g roup  and  16  on  each  ac t ive  do se  g roup .  
Thep r ima ry a na lys is  o f  change  in  mean  dayt im e  sy s to l ic  b lood  p ressu re  w i l l  
be  pe r fo rmed  us ing  the  da ta  co l lec ted  du r ing  the  pe r iod  0900  to  2100  
con s i s ten t  w i th  recommenda t ions  f rom  the  Eu ropean  Soc ie ty f o r  
Hype r tens ion  ( O 'B r iene t  a l  2013) .  The  ave rage  o f  these  12  hou rs  o f  da ta  w i l l  
be  p roduced  us ing  da ta  f rom  the  ba se l ine  ambu la to r y  b lood  p ressu re  
mon i to r ing  on  Da y  - 2  and  Day  27 .
The  change  f rom  base l ine  in  mean  day t ime  SBP  w i l l  be  es t ima ted  f rom  a  
long i tud ina l  mode l  us ing  a l l  da ta  co l lec ted  fo r  eve ry  pa t ien t  un t i l  Day 2 7 .  
Themode l  w i l l  in c lude  f ixed  e f fec ts  fo r  ba se l ine ,  t rea tmen t  ( in c lud ing  dose ) ,  
and  v is i t ,  and  a  ra ndom  e f fec t  fo r  ea ch  sub jec t .  Th is  ana lys is  is  unb iased  
unde r  the  assump t ion  tha t  the  da ta  a re  m iss ing  a t  random  (MAR ) .
Key  wo rds Res is tan t  hype r tens ionC o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
No va r t i s Con f iden t ia l Page  17
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
1 In t roduc t ion
1 .1 Backg round
T h e  ad e q u a t e  a n d  t im e l y  c o n t r o l  o f  b l o o d  p r e s s u r e  in  p a t i e n t s  d i a g n o s e d  w i th  hy p e r t e n s i o n  i s  
a n  im p o r t a n t  pub l i c  h e a l th  g o a l .  Hyp e r t en s ion  i s  a  m a j o r  r i s k  f a c t o r  fo r  h e a r t  d i s e a s e ,  k idn ey  
d i s e a s e  a n d  s t rok e .  D e sp i t e  t h e  a v a i l a b l e  m ed i c a t ion s  t h a t  t r e a t  h igh  b l o o d  p r e s su r e ,  
hy p e r t e n s i o n  r em a i n s  u n c o n t r o l l e d  in  m o r e  t h a n  5 0%  o f  p a t i en t s  ( V a l d e r r am ae ta l2 0 12) .  
T h ep h e n om e n o n  o f  r e s i s t an t  hy p e r t e n s i o n  (RHT )  w a s  d e f i n e d  by  J NC  7  in  2 0 0 3  a s  b l o o d  
p r e s s u r e  t h a t  w a s  u n c o n t r o l l e d  d e s p i t e  t r e a tm e n t  w i th  t h r e e  o r  m o r e  a n t i- hy p e r t en s iv e  ag en t s ,  
o n e  o f  w h i c h  i s  a  d iu r e t i c  ( C h o b a n i a n  e t  a l  2003) .  M o r e  r e c en t ly ,  th e  E u r o p e a n  S o c i e ty  f o r  
C a rd io logy ( ESC )  a n d  th e  jo in t  Am e r i c a n  So c i e ty o f  Hyp e r t e n s i o n  and  t h e  I n t e r n a t i o n a l  
So c i e ty o f  Hyp e r t en s ion  (ASH / I SH )  h av e  i s su eds im i l a r  d e f in i t ion s  ( M a n c iae ta l2 0 1 3;  
W e b e re ta l2 0 1 4) .  P a t i en t s  w i th  RHT  a r e  m o r e  l ik e ly  t o  d i sp l ay  t h e  s e q u e l a e  o f  u n c o n t r o l l e d  
hy p e r t e n s i o n  s u c h  a s  a n  e n l a r g e d  h e a r t  or  k idn ey  d am a g e .  D e p e n d i n g  o n  t h e  p o p u l a t i o n  
e x am i n e d  a n d  t h e  l e v e l  o f  m e d i c a l  s c r e e n i n g ,  i t  h a s  b e e n  e s t im a t e d  t h a t  5  to  3 0%  o f  t h e  
hy p e r t e n s i v e  p o p u l a t i o n  m ay m e e t  th i s  d e f i n i t i o n  ( J am e s  e t  a l  2 0 1 4) ;  how ev e r ,  t h e  p r ev a l en c e  
i s  l ik e ly  t o  r i s e  w i th  a g i n g  o f  t h e  popu l a t ion  a n d  th e  i n c r e a s i n g  i n c i d e n c e  o f  d i a b e t e s ,  ob e s i ty ,  
and  ch ron i c  k idn ey  d i s e a s e .  
T h e  n a t r i u r e t i c  p e p t i d e  (NP )  f am i ly  m e d i a t e s  a  w i d e -r a n g i n g  n um b e r  o f  p o t e n t i a llys a lu t a ry  
e f f e c t s  o n  t h e  h e a r t ,  v a s cu l a tu r e ,  k idn ey  a n d  o th e r  t a r g e t  t i s s u e s .  T h e  NP  f am i ly  i s  c om p r i s e d  
o f  t h r e e  s t ru c tu r a l ly  r e l a t e d  p e p t i d e  h o rm o n e s—a t r i a l  n a t r i u r e t i c  p ep t id e  (ANP ) ,  B- ty p e  
n a t r i u r e t i c  p ep t id e  (BNP )  and  C -ty p e  n a t r iu r e t i c  p e p t i d e  (CNP ) .  ANP  and  BNP  a r e  p r ima r i l y  
e x p r e s s e d  in  th e  h e a r t  and  r e l e a s e d  by  c a rd iomy o cy t e s  in  r e s p o n s e  to  m e c h a n i c a l  s t r e t ch .  
B i n d i n g  o f  n a t r i u r e t i c  p ep t id e s  to  t h e i r  r e c ep to r s ,  NPR- A  a n d  NPR- B ,  a c t iv a t e s  a  g u a ny la t e  
cy c l a s e  r e s u l t i n g  in  i n c r e a s e d  i n t r a c e l l u l a r  l ev e l s  o f  cGMP .  Phys io log i c a l ly ,  NP s  h a v e  b e en  
s h ow n  to  s t im u l a t e  t h e  e x c r e t i o n  o f  sod ium  a n d  w a t e r  by  t h e  k idn ey s ,  i n d u c e  r e l ax a t ion  o f  
v a s c u l a r  sm o o t h  m u s c l e  c e l l s ,  a n d  h a v e  a n t i- f i b r o t i c  a n d  a n t i - hy p e r t r o p h i c  e f f e c t s  o n  t h e  h e a r t .  
ANP  i s  l a r g e l y  d eg r ad ed  by  a  t r a n sm em b r a n e  endo p e p t i d a s e  c a l l e d  n ep r i ly s in(NEP )  wh i l e  a  
sm a l l e r  f r a c t i o n  i s  r em o v e d  f r om  t h e  c i r cu l a t ion  by  b i n d i n g  toa  c l e a r a n c e  r e c e p t o r ,NPR- C .  
S tud i e s  sugg e s t  th a t  c i r cu l a t ing  l ev e l s  o f  ANP  c an  b e  in c r e a s ed  by [CONTACT_818256] i t ing  NEP .  Thu s ,  NEP  
inh ib i to r s  a r e  a  p o t e n t i a l  th e r ap e u t i c  t a rg e t  f o r  th e  t r e a tm e n t  o f  hy p e r t e n s i o n.  C l in i c a l ly,  NEP  
inh ib i to r s  g iv en  in  comb in a t ion  w i th  an  ang io t en s in  r e c ep to r  b lo ck e r  (ARB )  h av e  b e en  shown  
to  r e d u c e  b l o o d  p r e s s u r e  in  p a t i e n t s  w i th  e s s e n t i a l  hy p e r t e n s i o n  ( B av i sh i  e t  a l  2 0 1 5) .  
NEPi[INVESTIGATOR_818252] i t ion  i n  c om b i n a t i o n  w i t h  a n  ARB  m ay r e p r e s e n t  a n  a t t r a c t i v e  t h e r a p e u t i c  o p t i o n  f o r  
p a t i e n t s  w i t h  RHT .
LHW 0 9 0  i s  an  o r a l ly  a dm i n i s t e r e d  p r o d r u g ,  wh i ch  u p o n  e s t e r  hy d r o ly s i s  i s  m e t a b o l i z e d  t o  
LHV 5 2 7 ,  a  h igh ly  p o t en t  an d  s p e c i f i c  inh ib i to ro f  NEP.  LHW 0 9 0  w a s  s a f e  a n d  w e l l - to l e r a t ed  
w h e n  a dm i n i s t e r e d  to  h e a l thy  s u b j e c t s  a n d  sub j e c t s  w i th  b a s e l i n e  c h r o n i c  r e n a l  in su f f i c i en cy .
Th e  p u r p o s e  o f  th e  cu r r en t  s tudy  i s  t o  d e t e rm in e  w h e t h e r  LHW 0 9 0  d i sp l ay s  th e  c l i n i c a l  s a f e t y  
a n d  e f f i c a cy  p ro f i l e  to  suppo r t  fu r th e r  d ev e lopm en t  f o rRHT.
No va r t i s Con f iden t ia l Page  18
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n1 .1 .1 Re levan t  da ta  summa ry
No va r t i s Con f iden t ia l Page  19
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
No va r t i s Con f iden t ia l Page  20
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
No va r t i s Con f iden t ia l Page  21
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
1 .2 S tudy  pu rposeC o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
T h e  p u r p o s e  o f  t h e  p r e s en t  s tudy  i s  to  d e t e r m i n e  w h e t h e r  LHW 0 9 0  d i s p l a y s  th e  c l in i c a l  s a f e ty  
and  e f f i c a cy  p r o f i l e  t o  s u p p o r t  f u r t h e r  d e v e l o pm e n t  i n  p a t i e n t s  w i t h  r e s i s t a n t  h y p e r t e n s i o n .
No va r t i s Con f iden t ia l Page  22
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
2 S tudy ob jec t ives
2 .1 P r ima ry ob jec t ive (s )
Ob j e c t i v e Endpo in t
T o  a s s e s s  t h e  s a f e ty  a n d  t o l e r a b i l i t y  o f  
LHW 0 9 0  f o r  4  w e e k s  o n  a  b a c k g r o u n d  o f  
c o n v e n t i o n a l  a n t i - hy p e r t e n s i v e  m e d i c a t i o n s  
i n  p a t i e n t s  w i t h  r e s i s t a n t  h y p e r t e n s i o n .  Sa f e t y  e n d p o i n t s  (a d v e r s e  ev e n t s ,  
s e r i o u s  a d v e r s e  e v e n t s )  u p  t o  a n d  
i n c l u d i n g  e n d  o f  s t u d y  a s s e s sm en t s
T o  e v a l u a t e  t h e  e f f e c t  o f  LHW 0 9 0  o n  
p l a c e b o- a d j u s t e d  m e a n  d a y t im e  s y s to l i c  
b l o o d  p r e s s u r e  (SBP )  a f t e r  4  w e e k s  i n  
p a t i e n t s  w i t h  r e s i s t a n t  h y p e r t e n s i o n .C h a n g e  f r om  b a s e l i n e  d a yt im e  SBP  on  
w e e k  4  by  [CONTACT_818257] l a to ry b l o o d  p r e s s u r e  
mon i to r ing
2 .2 Seconda ryob jec t ive (s )
Ob j e c t i v e Endpo in t
T o  e v a l u a t e  t h e  p h a rm a c o k i n e t i c s  (PK )  o f  
LHW 0 9 0  a n d  i t s  a c t i v e  m e t a b o l i t e  
LHV 5 2 7  i n  p a t i e n t s  w i t h  r e s i s t a n t  
hy p e r t e n s i o n .PK  p a r am e t e r son  D ay  28  ( Cm ax ,  Tm ax ,  
AUC l a s t ,  AUC0 - t )
2 .3 Exp lo ra to ry ob jec t ive (s )
C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
No va r t i s Con f iden t ia l Page  23
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
3 Inves t iga t iona l  p lan
3 .1 S tudy  des ign
Th i s  i s  an o n - con f i rm a to ry ,  r andom i z ed ,  s p o n s o r  o p e n ,  s i t e  a n d  s u b j e c t  b l ind,  p a r a l l e l  g r o u p ,  
p l a c e b o- c o n t r o l l e d  s tudy  to  e v a l u a t e  th e  s a f e ty  a n d  e f f i c a cy  o f  4  w e e k son c e  d a i lyt r e a tm en t  
w i th  LHW 0 9 0  in  p a t i en t s  w i th  r e s i s t an t  hy p e r t en s ion .  P a ti en t s  w i th  un con t ro l l ed  hy p e r t e n s i o n
d e f i n e d  a s  a  m e an  d ayt im e  sy s to l i c  b lood  p r e s su r e  ≥  1 3 5mmHgby  [CONTACT_818258] l a to ry  b lood  p r e s su r e  
m o n i t o r i n g  (ABPM )  on  a  s t ab l e  ( a t  l e a s t  1  mon th )  r eg im en  o f  op t im a l  do s e s  o f  a n  ang io t en s in  
r e c e p t o r  b l o c k e r  (ARB )  p lu s  a  d iu r e t ic  p lu s  a t  l e a s t  o n ead d i t i o n a lc l a s s  o f  a n t i - hy p e r t en s iv e  
m e d i c a t i o nw i l l  b e  c o n s i d e r e d  f o r  th i s  t r i a l  ( W e b e r  e t  a l  20 1 4;V o n g p a t a n a s i n2 0 1 4;
C a l h o u ne ta l2 0 0 8) .  P a t i e n t s  w i th  r e s i s t a n t  hy p e r t e n s i o n  w i l l  b e  r a n d om i z e d  to  e i t h e r  p l a c e b o  
o r  1  o f  2  do s e  r eg im en s  o f  LHW090 ,  i . e .  LHW090  100  mg  on c e  d a i ly ,  L HW090  200  mg  on c e  
d a i ly ,  a s  a n  a d d - on  to  th e i r  an t i - hy pe r t e n s i v e  r e g im e n  a t  b a s e l i n e .
E a c h  p a t i e n tw i l l  p a r t i c i p a t e  in  a n  a p p r o x im a t e l y  3  w e e k  s c r e en ing  p e r iod ,  a  2 -w e e k  s ing l e  
b l ind  p l a c e b o  r u n - in  p e r iod ,  b a s e l i n e  a s s e s sm en t s ,  a  4  w e e k  t r e a tm e n t  p e r iod ,  a n d  a n  e n d  o f  
s tudy  a s s e s sm en t( F igu r e  3 - 1) .  Du r ing  t h e  2  w e ek  p l a c e b o  r u n - in  p e r iod ,  p a t i en t s  w i l l  r e c e iv e  
r e g u l a r  r em i n d e r s  by  t h e  s i t e  to  b e  c om p l i a n t  w i th  t h e i r  a n t i - hy p e r t en s iv e  m e d i c a t i o n s .  A t  th e  
e n d  o f  th i s  r u n - in  p e r iod ,  p a t i e n t s  w h o  d em o n s t r a t e  ≥  8 0%  c om p l i a n c e  w i th  p l a c e b o  w i l l  b e  
r a n d om i z e d .C om p l i a n c e  w i l l  b e  e s t a b l i s h e d  by  p i l l  c o u n t  a n d  r e v i ew  o f  m e d i c a t i o n  d i a ry .
P a t i e n t s  w i l l  b e  adv i s ed  th a t  s tudy en t ry  c anno t  b e  fu l ly  d e t e rm in ed  un t i l  th e  comp l e t ion  o f  th e  
r u n - i n  p e r i o d .  
O n  D ay - 2 ,  p a t i e n t s  w i l l  c omm e n c e  24  h o u r  ABPM  m o n i t o r i n g  a n d  r e t u r n  t h e  n ex t  d ay  
(D ay- 1 )  to  h a v e  t h e  ABPM  d e v i c e  r em o v e d  and  t h e  d a t a  c o l l e c t e d .  P a t i e n t s  m ay h av e  
a d d i t i o n a l  a t t em p t st o  c om p l e t e  a  s u c c e s s f u l  ABPM  a s s e s sm e n t  ( d e f i n e d  by  s a t i s f a c to ry  B P  
d a t a  s am p l i n g  ov e r  th e2 4  h o u r s  a n d  s t a n d a r d s  f o r  d e v i c e  qu a l i ty  c h e c k )  i f  t h e  p r ev iou s  
a t t em p t sa r e  un su c c e s s fu l  ( O 'B r i e n  e t  a l  2 0 1 3) .  U p o n  co l l e c t ion  o f  s a t i s f a c to ry  b a s e l in e  
ABPM  a s s e s sm e n t ,  p a t i e n t s  w i l l  t h e n  r e t u r n  f o r  b a s e l i n e  p h a rm a codyn am i c  a s s e s sm e n t s  on  
D ay - 1  a n d  t h e n  b eg in  a c t i v e  t r e a tm e n t  o n  D ay  1 .  P a t i e n t s  w i l l  b e  r a n d om i z e d  in  a  1 : 1 : 2  
f a s h i o n  t o  e i t h e r :
LHW 0 9 0  1 0 0  m g  o n c e  d a i l yfo r  28  d ay s
LHW 0 9 0  2 0 0  m g  o n c e  d a i l yfo r  28  d ay s
M a t c h i n g  p l a c e b ofo r  28  d ay s
P a t i e n t sh a v e  th e  op t ion  tor e t u r n  on  D ay 3  f o r  v i t a l  s i g n s .  P a t i e n t sw i l l  t h e n  v i s i t  t h e  c l i n i c  a t  
w e e k ly  in t e rv a l s  (D ay  7 ,  1 4  and  21 )  fo r  s a f e t y , P K ,  and  PD  a s s e s sm en t s .  O n  v i s i t  d ay s ,  
p a t i e n t sw i l l  b e  in s t ru c t ed  to  t ak e  t h e i r  m ed i c a t ion s  a t  t h e  s i t e .  On  D ay 2 7 ,  p a t i e n t s  w i l l  
c omm e n c e  a  f i n a l  2 4  hou r  ABPM  a s s e s sm e n t  and  th e n  r e t u r n  t h e  n ex t  d a y  to  h av e  th e  d ev i c e  
r em o v e d  a n d  t h e n  b eg in  c o l l e c t i o n  o f  D ay2 8  s t e ady - s t a t e  PK  a n d  PD  a s s e s sm en t s .A s  s t a t e d  
a b o v e ,  p a t i e n t s  m ay h av e  a d d i t i o n a la t t em p t sto  c om p l e t e  a  s u c c e s s f u l  ABPM  a s s e s sm en t  
( d e f i n e d  by  s a t i s f a c to ry  B P  d a t a  s am p l i n g  ov e r  th e  [ADDRESS_1133187] s  f o r  d e v i c e  qu a l i ty  
c h e c k )  a t  t h e  S p o n s o r ’ s  d i s c r e t i o n  i f  p r e v i o u sa t t em p t sa r eu n s u c c e s s f u l  ( O 'B r i e ne ta l2 0 1 3) .  
P a t i e n t s  w i ll  b e  a s k e d  to  r e t u r n  a f t e r  app rox im a t e ly  1  w e e k  fo r  end  o f  s tudy  ( EOS )  
a s s e s sm e n t s .
No va r t i s Con f iden t ia l Page  24
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
F igu re  3 -1 S tudy des ign
3 .2 Ra t iona le  o f  s tudy des ign
T h e  s tudy  d e s i g n  add r e s s e s  t h e  p r im a ry  o b j e c t iv e s  o f  e v a l u a t i n g  t h e  c l i n i c a l  s a f e t y  and  
e f f i c a cy  o f  LHW 0 9 0  in  p a t i en t s  w i th  r e s i s t a n t  hy p e r t e n s i o n  a s  a n  a d d- o n  t h e r a p y  to  
conv en t ion a l ly  p r e s c r ib ed  a n t i - hy p e r t e n s i v e  m ed i c a t ion s .  T h e  p a r a l l e l  d e s ign  w a s  c h o sen  to  
a l low  comp a r i son  o f  L HW090  to  p l a c ebo  in  a  r e a son ab l e  t im e f r am e .  Th e  2- w e ek  s ing l e- b l ind ,  
p l a c e b o  r u n - in  p e r iod  a l l ow s  f o r  a n  a s s e s sm en t  o f  t h e  p a t i en t ' s  c om p l i a n c e  w i th  a n t i-
hy p e r t e n s i v e  m ed i c a t ion s  p r i o r  to  e n t e r i n g  th e  spon so r  o p e n ,  s i t e  a n d  sub j e c t  b l indt r e a tm e n t  
p e r i o d .  T h e  r a n d om i z a t i o n  r a t i o  o f  1 : 1 : 2  w i l l  p r o v i d e  e q u a l  s am p l e  s i z e s  ( 1 : 1 )  in  t h e  
c om p a r i s o n  o f  t h e  LHW 0 9 0  p a t i e n t s  v e r su s  th e  p l a c e b o  p a t i en t s .   T h i s  r a t io  a l l ow s  fo r  th e  
mo s t  p ow e r f u l  c om p a r i s o n .   ABPM  i s  t h e  m e t h o d  o f  c h o i c e  f o r  me a s u r i n g  b l o o d  p r e s s u r e  
c h a n g e s  w i th  n ew  a n t i - hy p e r t en s iv e  d rug s  a s  i t  a l low s  a n  a s s e s sm e n t  o f  t h e  e f f e c t  o f  t h e  d r ug  
o v e r  a  2 4  h o u r  p e r i o d .  M o r e o v e r ,  o u t - o f - o f f i c e  BP  m e a s u r em e n t s  s u c h  a s  ABPM  a r e  
c o n s i d e r e d  a  m o r e  r e l i a b l e  m e a n s  o f  d i a g n o s i n g  a n d  mon i to ri n g  r e s i s t a n t  hy p e r t e n s i o n  s in c e  
o f f i c e- b a s ed  BP  m ay  b e  con found ed  by  'wh i t e - c o a t '  e f f e c t s .  T h o u g h  b o t h  s y s to l i c  and  d i a s to l i c  
b l o o d  p r e s s u r e  r e ad ing s  w i l l  b e  c o l l e c t e d  ov e r  a  2 4  hou r  p e r iod ,  c h a n g e s  in  th e  p a t i en t ' s  
d ay t im e  sy s to l i c  b lood  p r e s su r e  w i l l  b ea s s e s s e d  a s  th e  p r im a ry  ob j e c t iv e  in  o rd e r  to  m in im i z e  
d i f f e r e n c e s  i n  i n d i v i d u a l  s u b j e c t  v a r i a t i o n  i n  d a y t im e  v e r s u s  n i g h t t im e  b l o o d  p r e s s u r e s .
3 .3 Ra t iona le  o f  dose / reg imen ,  du ra t ion  o f  t rea tmen t
T h e  d o s e s  o f  LHW 0 9 0  w e r e  s e l e c t e d  b a s ed  o n  th e  s a f e t y  a n d  to l e r ab i l i t y  o b s e r v e d  in  t h e  F IH
s tudy .  T h e  a dm i n i s t r a t i o n  o f  mu l t ip l e  d o s e s  o f  LHW 0 90  in  h e a l thy  s ub j e c t s  u p  to  4 0 0mg  
o n c e  d a i ly  f o r  1 4  d ay s  w a s  s a f e  and  w e l l  to l e r a t ed  w i th  n o  d e a th s  o r  s e v e r e  a d v e r s e  ev en t s  
r e p o r t e d .  Mo s t  adv e r s e  e v e n t s  w e r e  m i ld  and  n o n e  o f  t h e  a d v e r s e  e v e n t s  l e d  to  th e  
d i s con t inu a t ion  o f  th e  sub j e c t s  f rom  th e  s tudy .  Th e  r e l a t ion sh ip  b e tw e en  expo su r e(AUC 2 4 h r )  
No va r t i s Con f iden t ia l Page  25
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
a n d  u r i n e  cGMP  e x c r e t e d  o v e r  2 4  h o u r s  w a s  an a ly z ed  in  h e a l t hy  sub j e c t s .  B a s e d  o n  Em a x  
m o d e l i n g ,  LHW 0 9 0  100  mg  on c e  d a i ly  w a s  e s t im at e d  to  b e  t h e  ED 90 .  E xp e r i e n c e  w i th  th e  
c om b i n e d  a n g i o t e n s i n  r e c e p t o r - n e p r i ly s in  inh ib i to r  c om p o u n d ,  LCZ 6 9 6 ,  a c r o s s  mu l t ip l e  
s t u d i e s  o f  p a t i e n t s  w i th  e s s en t i a l  hy p e r t e n s i o n ,  s u g g e s t s  t h a t  th e  ph a rm a cody n am i c  e f f e c t s  on  
u r i n e  cGMP  p e ak  a t  low e r  do s e s  th an  t h e  p e ak  BP  l ow e r i n g  e f f e c t s ;  th i s  i s  t h e  r a t ion a l e  fo r  
s tudy ing  t h e  2 0 0  mg  d o s e  l e v e l .Mo r eov e r ,  in  t h e  LCZ 6 9 6  s tud i e s ,  mo s t  o f  th e  
an t ihy p e r t en s iv e  e f f e c t  o f  LCZ 6 9 6  h a d  o c c u r r e d  by  t h e  f o u r t h  w e e k  o f  t r e a tm en t  
( Ru ilop ee ta l  2 0 1 0) .  T h e r e f o r e ,  a  fou rw e e k  du r a t ion  o f  t r e a tm e n t  w a s  s e l e c t e d  b e c au s e  a  
s h o r t e r  du r a t ion  o f  t r e a tm en t  m ay u nd e r e s t im a t e  t h e  f u l l  an t ihy p e r t en s iv e  e f f e c t  o f  LHW 0 9 0 .  
W i th  r e g a r d  to  PK ,  t h e  e x p o s u r e  o f  t h e  a c t i v e  m e t ab o l i t e  LHV 5 2 7  a t  1 0 0  m g  a n d  2 0 0mg  
d o s e s  a r e  e x p e c t e d  to  r em a in  a t  ≥  IC 90  l e v e l s  ( in  v i t r o  p l a sm a  inh ib i to ry  c o n c e n t r a t i o n s  fo r  
NEP  i n h i b i t i o n )  a c r o s s  t h e  2 4  h o u r  d u r a t i o n  a t  s t e a d y- s t a t e .
3 .4 Ra t iona le  fo r  cho ice  o f  compa ra to r
N o t  a p p l i c a b l e .
3 .5 Pu rpose  and  t im ing  o f  in te r im  ana lyses /des ign  adap ta t ions
C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No va r t i s Con f iden t ia l Page  26
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
3 .6 R isks  and  bene f i ts
Th i s  s tudy  w i l l  b e  c o n d u c t e d  in  p a t i e n t s  w i th  r e s i s t a n t  hy p e r t en s i o n .  T h e r e  i s  n o  b en e f i t  
e x p e c t e d  f o r  su b j e c t s  p a r t i c i p a t i n g  in  th i s  s tudy .  A l l  p a t i e n t s  w i l l  r e c e i v e  s tudy  m ed i c a t ion  o n  
t o p  o f  t h e i r  u s u a l  a n t i h y pe r t e n s i v e  m e d i c a t i o n s .
 
 
 
 
 
 
 
 
 
 
 
 
T h e r e  m ay b eunknown  r i sk s  o f  LHW 0 9 0wh i ch  m ay b e  s e r i o u s  a n d  u n f o r e s e e n .
4 Popu la t ion
T h e  s tudy  p o p u l a t i o n  w i l l  b e  c om p r i s e d  o f  p a t i e n t s  w i th  un con t ro l l ed  hy p e r t en s ion  
( h e r ed e f in ed  a s  h av ing  a  d ay t im e  sy s to l i c  BP  ≥  135  mmH g  by  [CONTACT_44117] )  d e sp i t e  t r e a tm en t  w i th  
o p t im a ld o s e so f  a n  ARB  p lu s  ad i u r e t i cp lu s  a t  l e a s t  o n e  ad d i t i o n a l  c l a s s  o f  a n t i - hy p e r t e n s i v e  
m e d i c a t i o n .
App rox im a t e ly  8 0  p a t i en t s,a g e d4 0  to  8 5  y e a r s  o ld  ( i n c l u s iv e ) ,w i l l  b e  e n r o l l e d  and  
r andom i z ed  in  th e  s tudy .
T h e  i n v e s t i g a t o r  mu s t  e n s u r e  t h a t  a l l  sub j e c t s  b e i n g  c o n s i d e r e d  f o r  th e  s tudy  m e e t  th e  
f o l l ow i n g  e l ig ib i l i ty  c r i t e r i a .  N o  a d d i t i o n a l  c r i t e r i a  s h o u l d  b e  a p p l i e d  by  t h e  i n v e s t i g a t o r ,  in  
o r d e r  t h a t  t h e  s t u dy  p o p ul a t i o n  w i l l  b e  r e p r e s e n t a t i v e  o f  a l l  e l i g i b l e  s u b j e c t s .
S u b j e c t  s e l e c t i o n  i s  to  b e  e s t a b l i s h e d  by  c h e ck ing  th rough  a l l  e l ig ib i l i tyc r i t e r i a  a t  s c r e e n i n g  
a n d  b a s e l i n e( d ay  - 2 ) .A  r e l e v a n t  r e c o r d  ( e . g .  c h e c k l i s t )  o f  t h e  e l ig ib i l i ty  c r i t e r i a  mu s t  b e  
s t o r e d  w i t h  t h e  s o u r c e  d o c um e n t a t i o n  a t  t h e  s t u d y  s i t e .
D e v i a t i o n  f r om  any  en t ry  c r i t e r ion  ex c lud e s  a  sub j e c t  f rom  en ro l lm en t  in to  th e  s tudy .
R e p l a c em e n t  su b j e c t s  w i l l  b e  e n r o l l e d  to  r e p l a c e  s u b j e c t s  w h o  d i s c o n t i n u et h e  s tudy  fo r  
r e a s o n s  o t h e r  t h a n  s a f e t y  o r  l a c k  of  e f f i c a cyC o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
.C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
No va r t i s Con f iden t ia l Page  27
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
4 .1 Inc lus ion  c r i te r ia
P a t i e n t s  e l i g i b l e  f o r  i n c l u s i o n  i n  t h i s  s t u d y h a v e  t o  f u l f i l l  a l l  o f  t h e  f o l l ow i n g  c r i t e r i a :
1 .W r i t t e n  i n f o rm e d  c o n s e n t  m u s t  b e  o b t a i n e d  b e f o r e  a n y a s s e s sm en t  i s  p e r fo rm ed .
2 .M a l e  a n d  f em a l e  p a t i e n t s ,  a g e  4 0  t o  8 5  y e a r s  i n c l u s i v e.
3 .D em o n s t r a t i n g  a  ≥  8 0%  m e d i c a t i o n  c om p l i a n c er a t e  d u r i n g  t h e  s i n g l e - b l ind  run- i n  p e r i o d .
4 .P a t i e n t s  w i t h  u n c o n t r o l l e d  h yp e r t en s ion  (h e r e  d e f in ed  a s  h a v i n g  a  m e a n  d a y t im e  sy s to l i c  
BP  ≥1 3 5mmH g  by  [CONTACT_818253] t  s c r e e n i n g )  d e s p i t e  t r e a tm e n t  w i t h  a  s t ab l e  ( a t  l e a s t  1mon th)  
r e g im e n  t h a t  i n c l u d e sop t im a l  do s eso f  a n  ARB  p l u s  a  d i u r e t i c  ( t h i a z i d e  o r  l o o p )  p lu sa t  
l e a s to n e  a d d i t i o n a lc l a s s  o f  a n t i - hy p e r t en s i v e  m e d i c a t i o n .
F o r  t h e  p u r p o s e s  o f  t h i s  t r i a l ,  o p t im a l  d o s e s  o f  a n t i- hy p e r t en s i v e  m e d i c a t i o n s  a r e  d e f i n e d  
a s :
th eh i g h e s t  d o s e  l i s t e d  i n  t h e  c l i n i c a l  p r a c t i c e  g u i d e l i n e  f r om  t h e  Am e r i c a n  S o c i e t y fo r  
Hyp e r t e n s i o n  a n d  t h e  I n t e r n a t i o n a l  S o c i e t y  f o r  Hy p e r t e n s i o n  ( W eb e r  e t  a l  2014)o r
t h e  h i g h e s t  a l l ow a b l e  p r e s c r i b e d  d o s e  p e r  t h e  m a n u f a c t u r e r ' s  l ab e l  o r
t h e  h i g h e s t  d o s e  t o l e r a t e d  b y  a n  i n d i v i d u a l  p a t i e n t  o r
t h e  h i g h e s t  d o s e  a p p r o p r i a t e  f o r  a n  i n d i v i d u a l  p a t i e n t  i n  t h e  j u d gm e n t  o f  t h e  
I n v e s t i g a t o r
N o t e :  d o c um e n t e d  ABPM  v a l u e s  w i t h i n  3  m o n t h s  o f  s c r e e n i n g  a r e  a c c e p t a b l e .
5 .S u b j e c t s  m u s tw e i g h  a t  l e a s t  4 5  k g  t o  p a r t i c i p a t e  i n  t h e  s t u d y and  mu s t  h av e  a  body  m a s s  
i n d e x  (BM I )  w i t h i n  t h e  r a n g e  o f  1 8 - 4 0kg /m2 .
6 .A b l e  t o  c omm u n i c a t e  w e l l  w i t h  t h e  i n v e s t i g a t o r ,  t o  u n d e r s t a n d  a n d  c om p l y  w i t h  t h e  
r e q u i r em e n t s  o f  t h e  s t u d y .
4 .2 Exc lus ion  c r i te r ia
P a t i e n ts  f u l f i l l i n g  a n y  o f  t h e  f o l l ow i n g  c r i t e r i a  a r e  no t  e l i g i b l e  fo r  in c lu s ion  in  th i s  s tudy .  
N oa d d i t i o n a l  e x c l u s i o n s  m ay b e  a p p l i ed  by  t h e  i n v e s t i g a t o r ,  in  o r d e r  to  e n s u r e  t h a t  t h e  s tudy  
p o p u l a t i o n  w i l l  b e  r e p r e s e n t a t i v e  o f  a l l  e l i g i b l e  p a t i e n t s .
1 .U s e  o f  o t h e ri n v e s t i g a t i o n a l  d r u g s  a t  t h e  t im e  o f  e n r o l lm e n t ,  o r  w i th in  3 0  d ay s  o r  5  h a l f-
l iv e s  o f  en ro l lm en t ,  wh i ch ev e r  i s  long e r ;  o r  long e r  i f  r equ i r ed  by  [INVESTIGATOR_48085] c a l  r egu l a t ion s ,  and  fo r  
any  o t h e r  l im i t a t i o n  o f  p a r t i c i p a t i o n  i n  a n  i n v e s t i g a t i o n a l  t r i a l  b a s e d  o n  l o c a l  r e g u l a t i o n s .
2 .H i s t o r y o f  h y p e r s e n s i t i v i t y  t o  a n y  o f  t h e  s t u d y  d r u g s  o r  t o  d r u g s  o f  s im i l a r  c h em i c a l  c l a s s e s .
3 .P a t i e n t s  w i th  a n  e s t im a t e d  GFR  < 6 0  m l /m in /[ADDRESS_1133188]  
e q u a t i o n .
4 .U s e  o f  a n g i o t e n s i n  c o n v e r t i n g  e n zym e  inh ib i to r s  (ACE - inh ib i to r s ) .
N o t e :  P a t i e n t s  w h o  d i s con t inu e  t h e i r  ACE- inh ib i to r  a n d  sub s t i tu t e  w i th  a n  a n g i o t e n s i n  
r e c e p t o r  b l o c k e r  m ay b e  e l i g i b l e  to  b e  r e - s c r e e n ed  p r o v i d e d  t h e i r  an t i - hy p e r t en s iv e  
r e g im e n  h a s  b e en  s t ab l e  f o r  a t  l e a s t  1  mon th .  Any s ub s t i tu t ion s  o r  c h a n g e s  to  a  p a t i e n t ' s  
a n t i - hy p e r t e n s i v e  r eg im en  s h o u ld  b e  d o n e  und e r  t h e  g u i d a n c e  o f  t h e  p a t i en t ' s  t r e a t ing  
phy s i c i a n .
5 .H i s to ry o f  ang io ed em a ,  d rug - r e l a t ed  o r  o th e rw i s e ,  a s  r epo r t ed  by  [CONTACT_3433] e  p a t i en t .
No va r t i s Con f iden t ia l Page  28
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
6 .C l in i c a l ly s i g n i f i c a n t  ECG  a b n o rm a l i t i e sa t  s c r e en inga s  d e t e rm i n e d  b y  t h e  I n v e s t i g a t o r .
7 .S e v e r e  hy p e r t e n s i o n  a s  d e f i n e d  by  a n  o f f i c e  sy s to l i c  b l o o d  p r e s s u r e  ≥180  mmH g  o r  
d i a s t o l i c  b l o o d  p r e s s u r e  ≥ 1 1 0  mmH g  a t  s c r e e n i n go r  b a s e l i n e.
8 .A  h i s to ry  o f  s e cond a ry  hy p e r t en s ion  o f  a n y  e t io logy  in c lud ing  bu t  no t  l im i t ed  to  un i l a t e r a l  
o r  b i l a t e r a l  r e n a l  a r t e ry  s t e n o s i s ,  po ly cy s t i c  k idn ey  d i s e a s e ,  co a r c t a t ion  o f  t h e  a o r t a ,  
p r im a ry  h y pe r a ldo s t e ron i sm ,  C u s h i n g ' s  d i s e a s e ,  ph eo ch romo cy t om a ,  and  d r u g- indu c ed  
hy p e r t e n s i o n .I f  t h e  p a t i e n t  h a s  no t  b e e n  e v a l u a t e d  f o r  s e cond a ry  hy p e rt en s ion ,  
i n v e s t i g a t o r s  a r e  r e s p o n s i b l e  toe v a l u a t e  a l l  po t en t i a l  s e cond a ry  c a u s e s  o f  hy p e r t en s ion  
c o n s i d e r i n g  c l i n i c a l  h i s to ry ,  phy s i c a l  ex am in a t ion ,  l abo r a to ry  i nv e s t ig a t ion so r  o t h e r  
r e l e v a n t  d i a g n o s t i c  m e a s u r e sin  a c c o r d a n c e  w i th  c u r r e n t  p r a c t i c e s  a n d  c l in i c a l  g u i d e l i n e s
b e f o r e  e n t e r i n g  t h e  p a t i e n t  in to  t h e  s tudy( C h o b a n i a n  e t  a l  2 0 0 3;  M a n c i a  e t  a l  2 0 1 3;  
W e b e re ta l2 0 1 4) .
[ADDRESS_1133189] iomy op a thy  o r  s i g n i f i c a n t  s e v e r e  v a l v u l a r  d i s e a s e  o n  p r i o r  o r  cu r r en t  
e c h o c a r d i o g r am ) .
1 0 .A  h i s to ry  o f  k n ow n  m o d e r a t e  o r  m a l i g n a n t  hy p e r t en s iv e  r e t i n o p a t h y  d e f in ed  a s  mo d e r a t e  
( r e t i n a l  s ign s  o f  h emo r r h a g e ) ,  m i c ro an eu rysm s ,  c o t t o n- w o o l  spo t s ,  h a rd  e x u d a t e s ,  o r  a  
c om b i n a t i o n  t h e r e o f )  o r  m a l i g n a n t  ( s i g n s  o f  mod e r a t e  r e t i n o p a t h y  p lu s  sw e l l i n g  o f  th e  
op t i c  d i sk ).P a t i en t s  w i th  as t a b l e  oph th a lmo logi c  h i s to ry  in  th e  p a s t  [ADDRESS_1133190] i a l  i n f a r c t i o n ,  co ron a ry  a r t e ry  b y pa s s  
g r a f t  (CABG ) ,  p e r c u t a n e o u s  co ron a ry  i n t e rv en t ion  (PC I ) ,  hy p e r t e n s i v e  e n c e p h a l o p a t h y , 
s t r o k e ,  o r  t r a n s i e n t  i s c h em i c  a t t a c k  (T IA ) .
1 3 .H em o g l o b i n  l e v e l s  b e l ow  9 . 0  g / dL  a t  s c r e e n i n g .
1 4 .H i s to ry o f  m a l ign an cy  o f  any  o r g a n  s y s t em  ( o t h e r  t h a n  l o c a l i z e d  b a s a l  c e l l  c a r c i n om a  o f  
t h e  s k i n  o r  in - s i tuc e r v i c a l  c a n c e r ) ,  t r e a t e d  o r  u n t r e a t e d ,  w i t h i n  t h e  p a s t  1  y e a r ,  r e g a r d l e s s  
o f  w h e t h e r  t h e r e  i s  e v i d e n c e  o f  l o c a l  r e c u r r e n c e  o r  m e t a s t a s e s .
1 5 .D o n a t i o n  o r  lo s s  o f  400  mL o r  mo r e  o f  b l o o d  w i th in  8  w e e k s  p r io r  to  in i t i a l  d o s i n g ,  o r  
l o n g e r  i f  r e q u i r e d  b y  l o c a l  re g u l a t i o n .
1 6 .P r e g n a n t  o r  n u r s i n g  ( l a c t a t i n g )  w om e n ,  w h e r e  p r e g n a n c y i s  d e f i n e d  a s  t h e  s t a t e  o f  a  f em a l e  
a f t e r  c o n c e p t i o n  a n d  un t i l  t h e  t e rm i n a t i o n  o f  g e s t a t i o n ,  c o n f i rm e d  by  a  p o s i t i v e  hCG  
l abo r a to ry  t e s t .
1 7 .Wom en  o f  c h i l d - b e a r i n g  po t en t i a l ,  d e f i n e d  a s  a l l  w omen  phy s io log i c a l ly  c a p a b l e  o f  
b e c om i n g  p r e g n a n t.
Wom en  a r e  c o n s i d e r e d  p o s t- m e n o p a u s a l  and  no t  o f  c h i l d  b e a r ing  po t en t i a l  i f  th ey  h av e  
h a d  1 2mon th s  o f  n a tu r a l  ( s p o n t a n e o u s )  am e n o r r h e a  w i th  a n  a p p r o p r i a t e  c l i n i c a l  p ro f i l e  
( e . g .  ag e  app rop r i a t e ,  h i s to ry  o f  va s om o t o r  sy mp tom s ) ,  to t a l  hy s t e r e c tomy  o r  h av e  h ad  
s u r g i c a l  b i l a t e r a l  oopho r e c tomy  ( w i th  o r  w i thou t  hy s t e r e c t om y )  o r  t u b a l  l i g a t i o n  a t  l e a s t  
s ix  w e e k s  a g o .  I n  t h e  c a s e  o f  o o p h o r e c t omy  a lon e ,  on ly  w h e n  t h e  r ep rodu c t iv e  s t a tu s  o f  
No va r t i s Con f iden t ia l Page  29
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
t h e  w om a n  h a s  b e e n  c o n f i rm e dby  f o l l ow  u p  h o rm o n e  l e v e l  a s s e s sm e n t  i s  s h e  c o n s i d e r e d  
n o t  o f  c h i l d  b e a r i n g  p o t e n t i a l .  
[ADDRESS_1133191] e r  to  p r ev en t  d e l iv e ry  o f  
t h e  d r u g  v i a  s em i n a l  f l u i d .
1 9 .Any s u rg i c a l  o r  m e d i c a l  c o n d i t i o n ,  w h i c h  in  t h e  o p i n i o n  o f  t h e  i n v e s t i g a t o r ,  m ay p l a c e  th e  
p a t i e n t  a t  h i g h e r  r i s k  f rom  h i s / h e r  p a r t i c i pa t i o n  in  t h e  s tudy ,  o r  i s  l i k e l y  to  p r e v e n t  th e  
p a t i e n t  f r om  c om p ly i ng  w i th  th e  r equ i r em en t s  o f  th e  s tudy  o r  comp l e t ing  th e  s tudy .
2 0 .O n  t h e  Co lumb i a-S u i c i d e  S e v e r i ty  R a t ing  S c a l e,s c o r e  “y e s ”  on  i t em  4  o r  i t em  5  o fth e  
S u i c i d a l  I d e a t i o n  s e c t ion  o f  th e  C -SSRS ,  i f  th i s  i d e a t i o n  o c c u r r e d  in  th e  p a s t  6  mon th s ,  o r  
“y e s ”  o n  a n y  i t em  o f  th e  S u i c i d a l  B e h a v i o r  s e c t ion ,  e x c ep t  f o r  t h e  “N o n -S u i c i d a l - S e l f  
I n j u r i o u s  B e h a v i o r ”  (qu e s t ion  a l s o  in c lud ed  in  t h e  S u i c i d a l  B e h a v i o r  s e c t i o n ) ,  i f  th i s  
b e h a v i o r  o c c u r re d  int h e  p a s t2  y e a r s .A ny  p a t i en t  m e e t i n g  th i s  ex c lu s ion  c r i t e r i o n  s h o u l d  
b e  r e f e r r e d  t o  a  m e n t a l  h e a l t h  c a r e  p r o f e s s i o n a l .
2 1 .V u l n e r a b l e  s u b j e c t s ,  e . g .  sub j e c t s  k e p t  in  d e t e n t i o n ,  s o l d i e r s  a n demp loy e e s  o f  t h e  s p o n s o r  
o r  a  c l i n i c a l  r e s e a r c h  o r g a n i z a ti o n ,  i n v o l v e d  i n  t h i s  s t u d y .
N o t e :  I n  t h e  c a s e  wh e r e  a  s a f e t yl abo r a to ry  a s s e s sm en ta t  s c r e e n i n g  andin i t i a l  b a s e l i n ei s  
o u t s i d e  o f  t h e  r a n g e  s p e c i f i e d  a b o v e ,  t h e  a s s e s sm e n t  m ay b e  r e p e a t e d  on c e  p r io r  to  
r a n d om i z a t i o n .  I f  t h e  r e p e a t  v a lu e  r em a in s  o u t s i d e  o fth es p e c i f i e d  r ang e s ,  t h e  sub j e c ti s  
e x c l u d e d  f r om  t h e  s t u d y .
N o  a d d i t i o n a l  e x c l u s i o n s  m ay b e  a p p l i e d  by  t h e  i n v e s t i g a t o r ,  in  o r d e r  to  e n s u r e  t h a t  t h e  s tudy  
p o p u l a t i o n  w i l l  b e  r e p r e s e n t a t i v e  o f  a l l  e l i g i b l e  p a t i e n t s .
5  Res t r ic t ionsfo r  S tudySub jec ts
P a t ie n t smu s tb e  in fo rm ed  a n d  r em i n d e d  o f  t h e  f o l l ow i n g  r e s t r i c t ion sf rom  s c r e e n i n g  un t i l  th e  
e n d  o f  t h e  s tudy  v i s i t :
5 .1 Con t racep t ion  requ i remen ts
N o t  a p p l i c a b l e .  O n ly  w om e n  o f  n o n- ch i ldb e a r ing  po t en t i a l  w i l l  b e  in c lud ed  in  th i s  s tudy .
5 .2 A llowab le  Med ica t ions
A l low a b l ea n t i - hy p e r t en s iv es( b e s i d e s  a n  ARB  an d  a  d iu r e t i c )  in c lud e
C a l c i um  c h a n n e l  b l o c k e rs
B e t a- b lo ck e r s
Po t a s s ium- s p a r i n g  d i u r e t i c s  s u c h  a s  sp i r o n o l a c t o n e ,  e p l e r e n o n e ,  o r  am i l o r i d e
D i r e c t  v a s o d i l a t o rs
A l p h a -b l o c k e r s
P a t i en t s  mu s t  b e  on  a  s t ab l e  r eg im en  th roughou t  th e  t r i a l ,  and  f o r  a t  l e a s t  on e  mon th  p r io r  to  
th e  s tudy .
No va r t i s Con f iden t ia l Page  30
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
5 .3 P roh ib i ted  t rea tmen t
U s e  o f  th e  fo l low ing  m ed i c a t ion s  i sno t  a l low ed  du r ing  th e  cou r s e  o f  th e  s tudy  f rom  s c r e en ing  
(V i s i t  1 )  to  t h e  end  o f  t h e  s tudy .  Sub j e c t s  who  a r e  r e c e i v i n g  s u c h  m ed i ca t i o n ( s )  w i l l  b e  
e x c l u d e d ,  o r  i f  e th i c a l ly  a n d  c l i n i c a l l y  ju s t i f i ed ,  t h e  m e d i c a t i o n ( s )  shou ld  b e  g r a d u a l l y  
w i t h d r aw n  b e f o r e  V i s i t  2 :  
1 .Any d rug  t h a t ,  i n  t h e  d i s c r e t i o n  o f  t h e  i n v e s t i g a t o r ,  m a y  a f f e c t  th e  a s s e s sm en t  o f  b lood  
p r e s s u r e  i n  t h i s  s t u d y  o r  c o n t r i b u t e  t o  d r u g - indu c ed  hy p e r t e n s i o ns u c h  a s :
Any an t i - d e p r e s s a n t  d r u g s  i n  t h e  MAO  i n h i b i t o r  c l a s s ,  t r i c yc l i c s ,  a n d  v e n l a f a x i n e ,  
d u l o x e t i n e ,  a n d  b u p r o p r i o n .  O t h e r  p sy c h o t r o p i c  d r u g s  s u c h  a s  b e n z o d i a z e p i n e s  a n d  
s e l e c t i v e  s e r o t o n i n  r e u p t a k e  i n h i b i t o r s  (SS R Is )a r e  p e rm i t t edi f  t h e  p a t i e n t  h a s  b e e n  o n  
a  s t a b l e  d o s e  f o r  t h e  p r e v i o u s  3  m o n t h s .
C h r o n i c  a dm i n i s t r a t i o n  ( d e f i n e d  a s  >  3  d a ys  p e r  w e e k )  o f  s ym p a t h om im e t i c  d r u g s  s u c h  
a s  t h o s e  f o u n d  i n  n a s a l  d e c o n g e s t a n t s ,  o r a l  d e c o n g e s t a n t s ,  d i e t  a i d s  a n d  
b r o n c h o d i l a to r s .  Do s e s  o f  sy m p a t h om im e t i c  d r u g s  u s e do c c a s ion a l ly  a r e  p roh ib i t ed  
2 4h o u r s  p r i o r  t o  t h e  s t u d y  v i s i t .
Thyr o i d  m e d i c a t i o n ,  e s t r o g e n - b a s e d  a n d /o r  a n d r o g e n- b a s ed  h o rm o n e  r e p l a c em e n t  
t h e r a p i e su n l e s s  o n  a  s t a b l e  r e g im e n  f o r  a t  l e a s t  3  m o n t h s  p r i o r  t o  V i s i t  1a n d  i s  n o t  
e x p e c t e d  t o  c h a n g e  d u r i n g  t h e  c o u r s e  o f  t h e  s t u d y .
E r g o t  a n d  s e r o t o n i n  ( 5- hy d roxy t ry p t am i n e )  r e c e p t o r  a g o n i s t  p r e p a r a t i o n s .
D r u g s  f o r  t h e  t r e a tm e n t  o f  a t t e n t i o n  d e f i c i t  hy p e r a c t i v i t y  d i s o r d e r  (ADHD ) ,  i n c l u d i n g  
m e thylp h e n i d a t e ,  am p h e t am i n e ,  a n d  a tomox e t in e .
C h r o n i c  a dm i n i s t r a t i o n  ( d e f i n e d  a s  >3  d ay s  p e r  w e e k )  o f  NSA ID s  o r  COX - 2  
i n h i b i t o r s .  T h e  l o n g - t e rm  c h r o n i c  u s e  o f  a s p i r i n  f o r  c a r d i o v a s c u l a r  p r o p h y l ax i s  i s  
a l l ow e d  p r o v i d e d  t h e  t o t a l  d a i l y  d o s e  d o e s  n o t  e x c e ed  3 2 5  m g .
O r a l  n i t r a t e s .  I n t e rm i t t e n t  u s e  o fs u b l i n g u a l  n i t r a t e s  a r e  a l l ow e d  b u t  m u s t  n o t  b e  u s e d  
w i th in  1 2  h o u r s  p r i o r  t o  a n y  s ch edu l ed  v i s i t .
C h r o n i c  a dm i n i s t r a t i o n  ( d e f i n e d  a s  >3  d ay s  p e r  w e e k )  o f  PDE 5  i n h i b i t o r s  ( e . g .  
s i l d e n a f i l ,  v a r d e n a f i l ,  t a d a l a f i l ) .  I n t e rm i t t e n t  u s e  o f  PDE 5  i n h i b i t o r s  a r e  a l l ow e d  b u t  
m u s t  n o t  b e  u s e d  w i t h i n  4 8  h o u r s  p r i o r  t o  a ny  s c h e d u l e d  v i s i t .
C h r o n i c  ( d e f i n e d  a s  >3  d ay s  p e r  w e e k )  t r e a tm e n t  w i t h  o r a l  o r  p a r e n t e r a l  c o r t i c o s t e r o i d  
t r e a tm e n t .T h e  u s e  o f  i n h a l a t i o n a l  c o r t i c o s t e r o i d s  i s  p e rm i t t e d .
2 .T h e  f o l l ow i n g  m e d i c at i o n s  a r e  p r o h i b i t e d  d u e  t o  p o t e n t i a l  f o r  p h a rm a c o k i n e t i c  d r u g - d rug
i n t e r a c t i o n s :  am o d i a q u i n e ,a t a z a n a v i r ,bo s en t an,bup rop ion ,  c e l e cox ib ,c im e t i d i n e ,
cy c l o s p o r i n e ,d i c lo f en a c ,e f a v i r e n z ,  e l t r om b o p ag ,g em f i b r o z i l,g ly b u r i d e ,g l im e p i r id e,
im a t i n i b ,  i r i n o t e c a n ,  i f o s f am i d e ,  l a p a t i n i b ,  l o p i n a v i r ,m e t h o t r e x a t e ,  m i t o x a n t r o n e ,  
p a c l i t a x e l ,ph eny to in ,  p i o g l i t a z o n e ,  p r o b e n e c i d ,   r e p a g l i n i d e ,r i f am p i n ,  r i t o n a v i r ,
s a q u i n a v i r ,t i p r a n a v i r ,  t o p o t e c a n ,a n d  w a r f a r i n .
3 .A l l  o t h e r  p r i o r  n o n- s t u d y  m e d i c a t i o n s  ( n o tsp e c i f i c a l ly  con t r a ind i c a t ed  in  th e  ex c lu s ion  
c r i t e r i a  w i l l  b ea l l ow e d ,  p r o v i d e d  t h e  p a t i e n th a s  b e e n  o n  as t an d a r d  t r e a tm e n t  r e g im en  
( a tl e a s t  4  w e e k s  o f  t h es am e  d o s e )  a n d  t h e  t r e a tm e n t  i s  n o t  p l a n n e d  t o  b e  c h a n g e d  d u r i n g  
t h e  c o u r s e  o f  t h e  s t u d y .
No va r t i s Con f iden t ia l Page  31
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
5 .4 D ie ta ryres t r ic t ions  and  smok ing
P a t i e n t s  s h o u l d  m a i n t a i n  t h e i r  u s u a l  d i e t  p r i o r  to ,  a n d  d u r i n g  t h e  s tudy .  A l t e r a t ion s  in  d i e t  c a n  
l e ad  to  ch ang e s  in  sod ium  and  po t a s s ium  in t ak e  wh i ch  cou ld  in f lu en c e  th e  r e su l t s  o f  th i s  s tudy .
N o  a l c o h o l  w i l l  b e  a l l ow e d  s t a r t i n g24  hou r s  p r io r  to  and  du r ing  s tudy  v i s i t s  a n d  ABPM  
a s s e s sm e n t s .
I n t a k e  o f  x a n t h i n e  ( e . g .c a f f e i n e )  c o n t a i n i n g  f o o d  o r  b e v e r a g e s  w i l l  b e  a l l ow e d  d u r i n g  t h e  
s tudy .  P a t i e n t s  s h o u l d  b e  i n s t r u c t e d  t o  m a i n t a i n  t h e i r  n o rm a l  d a i l y r o u t i n e .  H ow e v e r ,  t h e  
m o r n i n g  o fc l i n i c  v i s i t s ,  p a t i e n t s  s h o u l d  a v o i d  c o f f e e( a n d  o t h e r  c a f f e i n e  c o n t a i n i n g  f o o d  
o r  b e v e r a g e s ),  sm o k i n g  a n d  e x e r c i s e  f o r  a t  l e a s t  3 0m i n u t e s  p r i o r  t o  o f f i c e  BP  
m e a s u r em e n t s .   
I n  o r d e r  t o  a v o i d  w i d e  v a r i a t i o n s  i n  u r i n e  v o l um e so nco l l e c t ion  d ay s ,  s u b j e c t s  s h o u l d  b e  
e n c o u r a g e d  t o  h a v e  a  f l u i d  i n t a k e  o f  a p p r o x im a t e l y  24 0  mL  ev e ry  4  h o u r s  d u r i n g  t h e i r  
w a k i n g  h o u r s ,  i n  a d d i t i o n  t o  t h e  f l u i d  t a k e n  w i t h  m e a l s  a n d  m e d i c a t i o n .
5 .5 Gene ra l  res t r ic t ions
 W h i l e  w e a r i n g  t h e  ABPM ,  p a t i e n t s  s h o u l d  a v o i d  s t r e n u o u s  ex e r c i s e  o r  a c t iv i ty  a n d  
b a t h i n g  d u r i n g  t h e  2 4  h o u r  p e r i o d .
6 T rea tmen t
6 .1 S tudy  t rea tmen t
D e t a i l s  o n  t h e  s t o r a g e  and  m a n a g em e n t  o f  s tudy  m e d i c a t i o n ,  r andom i z a t ion  a n d  i n s t r u c t i o n s  
f o r  p r e s c r i b i n g  a n d  t a k i n g  s t u d y  t r e a tm e n ta r e  o u t l i n e d  i n  t h e  S i t e  O p e r a t i o n s  M a n u a l .
6 .1 .1 Inv es t iga t iona l  t rea tmen t
T h e  i n v e s t i g a t i o n a l  d r u g ,  LHW 0 9 0  1 0 0  mg and  m a t c h i n g  p l a c e b ow i l l  b e  p r e p a r e d  by  
N o v a r t i s  an d  s u p p l i e d  t o  t h e  I n v e s t i g a t o rs i t e  a s  s i n g l e  b l i n d e d  p a t i e n t  p a c k s.
6 .2 T rea tmen t  a rms
P a t i e n ts  w i l l  b e  a s s i g n e d  t o  o n e  o f  t h e  f o l l ow i n g  3t r e a tm e n t  a rm s  i n  a  r a t i o  o f  1 :1 :2:
S tudy t r e a tm e n t s  a r e  d e f i n e d  a s :
A :   1 0 0  m g  LHW 0 9 0  
B :   2 0 0  m g  LHW 0 9 0  
C :   m a t c h i n g  p l a c e b o  
6 .3 Pe rm i t ted  dose  ad jus tmen ts  and  in te r rup t ions  o f  s tudy t rea tmen t
S tudy d rug  d o s e  a d j u s tm e n t s  a n d / o r  in t e r rup t ion s  a r e  no t  p e rm i t t ed .I f  a  sho r t  t r e a tm e n t  
i n t e r r u p t i o n  b e c om e s  n e c e s s a ry  f o r  a n  impo r t an t  r e a s o n ,  th e  s u b j e c t  m ay r e s um e  th e  s tudy  
t r e a tm e n t .  How ev e r ,  d r u g  in t e r rup t ion  s h o u l d  end  a t  l e a s t  3  d ay s  p r io r  to  t h e  n ex t  s tudy  v i s i t .  
I n  a n y  c a s e ,  t h e  c om p l i a n c e  o f  t h e  s u b je c t s  w i l l  b e  m o n i t o r e d  a n d  r e c o r d e d .
No va r t i s Con f iden t ia l Page  32
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
I n  t h e  ev en t  t h a t  a  s u b j e c t  w i l l  b e  t r a n s i t i o n e d  t o  a n  ACE  inh ib i to r  a t  t h e  e n d  o f  t h e  s tudy  o r  
a f t e r  p r em a t u r e  d i s c o n t i n ua t i o n  o f  s tudy  m e d i c a t i o n ,  a  m inim um  o f  4 8h o u r s  mu s t  t r a n s p i r e  
b e tw e e n  t h e  l a s t  d o s e  o f  LHW 0 9 0  a n d  t h e  f i r s t  d o s e  o f  a n  ACE  i n h i b i to r .  C o n s i d e r a t i o n  
s h o u l d  a l s o  b e  g i v e n  to  t h e  e x i s t i n g  ARB  t r e a tm e n t  o f  s ub j e c t s  in  t h e  s tudy ;  c o n c om i t a n t  
t r e a tm e n t  w i th  a n  ACE  inh ib i to r  a n d  a n  ARB  s h o u l d  b e  a v o i d e d  a c c o r d i n g  to  cu r r en t  
hy p e r t e n s i o n  g u i d e l i n e s( J am e s  e t  a l  2 0 1 4;  M an c i a  e t  a l  2 0 1 3;  W eb e re ta l2 0 1 4)  a n d  in  
c om p l i a n c e  w i th  app l i c ab l el o c a l  p r e s c r i b i n g  i n f o rm a t i o nf o r  r e n i n  a n g i o t e n s i n  a l d o s t e r o n e  
(RAAS )  a g e n t s .
6 .4 T rea tmen t  ass ignmen t
Random i z a t ion  n um b e r sw i l l  b e  a s s i g n e d  in  a s c e n d i n g ,  s equ en t i a l  o r d e r  to  e l i g i b l e  p a t i e n ts  
( s e e  S i t e  O p e r a t i o n s  M a n u a lf o r  d e t a i l s ) .Th e  i n v e s t i g a t o r  w i l l  e n t e r  t h e  r a n d om i z a t i o n  
n um b e ro n  t h e  CRF .
T h e  r a n d om i z a t i o n  n um b e r s  w i l l  b e  g e n e r a t e d  u s ing  t h e  f o l l ow i n g  p r o c ed u r e  to  e n s u r e  t h a t
t r e a tm e n t  a s s ignm en t  i s  unb i a s ed  and  con c e a l ed  f rom  p a t i en t s  and  inv e s t ig a to r  s t a f f .  A  p a t i en t
r a n d om i z a t i o n  l i s t  w i l l  b e  p r o d u c e d  by  t h e  I n t e r a c t i v e  R e s po n s e  T e chno logy ( IR T )  p rov id e r
u s i n g  a  v a l i d a t e d  sy s t em  t h a t  a u tom a t e s  t h e  r a n d om  a s s i g nm e n t  o f  p a t i en t  n um b e r s  to
r a n d om i z a t i o n  n um b e r s .  T h e s e  r a n d om i z a t i o n  n um b e r s  a r e  l i n k e d  to  th e  d i f f e r e n t  t r e a tm en t  
a rm s .T h e  r a n d om i z a t i o n  s c h em e  f o r  p a t i e n ts  w i l l  b e  r e v i ew e d  a n d  a p p r o v e d  by  a  m em b e r  o f  
t h e  N o v a r t i s  I IS  R a n d om i z a t i o n  G r o u p .
P r io r  to  do s ing ,  p a t i e n t s  who  fu l f i l l  a l l  in c lu s ion / ex c lu s ion  c r i t e r i a  w i l l  b e  r andom i z ed  v i aIR T  
to  on e  o f  th e  t r e a tm en t  a rm s .  Th e  inv e s t ig a to r  o r  h i s /h e r  d e l eg a t e  w i l l  c a l l  o r  logon  to  th eIR T  
a n d  c o n f i rm  t h a t  th e  p a t i en t  f u l f i l l s  a l l  t h e  in c lu s ion / ex c lu s ion  c r i t e r i a .  T h e  IRT  w i l l  t h e n
a s s i g n  a  r a n d om i z a t i o n  n um b e r  to  t h e  p a t i e n t ,  w h i c h  w i l l  b e  u s e d  to  l i n k  t h e  p a t i e n t  to  a
t r e a tm e n t  a rm .   
6 .5 T rea tmen t  b l ind ing
Th i s  i s  a  s p o n s o r  o p en ,  s i t e  a n d  s u b j e c t  doub l e  b l ind  s tudy :  s u b j e c t s ,  inv e s t ig a to r  s t a f fa n d
p e r s o n s  p e r f o rm i n g  t h e  a s s e s sm e n t sw i l l  r em a i n  b l ind  to  t h e  id en t i ty  o f  s tudy  t r e a tm en t s  
a c c o r d i n g  to  t h e  sp e c i f i c a t ion s  p r o v i d e d  in  t h e  S i t e  O p e r a t i o n s  M a n u a l .D u r i n g  t h e  p l a c ebo  
r u n - in  p e r i o d  (V 2 ) ,  p l a c ebo  t r e a tm e n t  w i l l  b e  a dm i n i s t e r e d  to  a l l  p a t i e n t s  a n d  w i l l  b e  k n ow n  
by  i n v e s t i g a t o r  s t a f f  a n d  p e r s o n s  p e r f o rm i n g  t h e  a s s e s sm e n t s .
T h e  id en t i ty  o f  th e  t r e a tm en t s  w i l l  b e  con c e a l ed  by  [CONTACT_3433] e  u s e  o f  s tudy  d rug s  th a t  a r e  a l l  id en t i c a l  
i n  p a c k a g i n g ,  l a b e l i n g ,  s c h e d u l e  o f  a dm i n i s t r a t i o n ,  a p p e a r a n c e ,  a n d  o d o r .  
R andom i z a t ion  d a t a  a r e  k e p t  s t r i c t ly  c on f id en t i a l ,  a n d  a r e  a c c e s s i b l e  on ly  t o  au tho r i z ed  
p e r s o n n e l ,  un t i l  unb l ind ing  o f  th e  t r i a l  a s  d e s c r ib ed  in  th e  t ab l e  in  t h e  B l i n d i n g  l ev e l s  t ab l e  in
t h e  S i t e  O p e r a t i o n s  M a n u a l .
T h e  r e s u l t s  o f  t h e  in t e r im  an a ly s e s  m ayb ecommun i c a t e d( e . g .d o s e  e s c a l a t i o n  d e c i s ion ,  
e v a l u a t i o n  o f  PoC  c r i t e r i a  o r  i n f o rm a t i o n  n e ed ed  f o r  p l ann ing /mod i fy ing  a n o t h e r  s tudy )  to  
r e l e v a n t  N o v a r t i s  t e am s  f o r  i n f o rm a t i o n ,  c o n s u l t i n g  a n d / o r  d e c i s i o n  p u r p o s e s .
No va r t i s Con f iden t ia l Page  33
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
U n b l i n d i n g  w i l l  on ly  o c c u r  in  t h e  c a s e  o f  p a t i en t  em e r g e n c i e s  ( s e eS e c t ion  6 . 6)  a n d  a t  th e  
c o n c l u s i o n  o f  t h e  s t u d y .
6 .6 Eme rgency b reak ing  o f  ass igned  t rea tmen tcode
Em erg en cy  u n b l i n d i n g  shou ld  on ly  b e  und e r t ak en  w h e n  i t  i s  e s s e n t i a l  to  t r e a t  t h e  p a t i e n t
s a f e l y  a n d  e f f i c a c i o u s l y . M o s t  o f t e n ,  s tudy  t r e a tm en t  d i s c o n t i n u a t i o n  a n d  k n ow l e d g e  o f  th e
p o s s i b l e  t r e a tm e n t  a s s i g nm e n t s  a r e  s u f f i c i e n t  to  t r e a t  a  s tudy  p a t i e n t  who  p r e se n t s  w i th  a n
em e rg en cy  c ond i t ion .  Em e rg en cy c o d e  b r e a k s  a r e  p e r f o rm e d  u s ing  t h e  IR T  sy s t em .  Wh en  th e
inv e s t ig a to r  con t a c t s  th e  sy s t em  t o  u n b l i n d  a  p a t i e n t ,  h e / s h e  m u s t  p r o v i d e  t h e  r e q u e s t e d  p a t i e n t
id en t i fy ing  in fo rm a t ion  and  c o n f i rm  t h e  n e c e s s i ty  to  unb l in d  t h e  p a t i e n t .  Th e  i n v e s t i g a t o r  w i l l
t h e n  r e c e iv e  d e t a i l s  o f  t h e  d r u g  t r e a tm en t  fo r  t h e  s p e c i f i e d  p a t i en t  and  a  f ax  o r  em a i l
c o n f i rm i n g  th i s  in fo rm a t ion .  T h e  sy s t em  w i l l  au tom a t i c a l ly  i n f o rm  t h e  Nov a r t i s  m o n i t o r  f o r
t h e  s i t e ,  th e  C l i n i c a l  T r i a l  L e a d e r  a n dT r a n s l a t i o n a l  M ed i c a l  E x p e r tt h a t  t h e  cod e  h a s  b e en  
b r o k e n .I t  i s  th e  i n v e s t i g a t o r ’ s  r e spon s ib i l i ty  t o  e n s u r e  th a t  t h e r e  i s  a  p r o c e d u r e  in  p l a c e  to  
a l l ow  a c c e s s  to  t h e  IR Tin  c a s e  o f  em e rg en cy .  I f  a p p r o p r i a t e ,  t h e  i n v e s t i g a t o r  w i l l  i n f o rm  t h e  
p a t i e n th ow  t o  c o n t a c t  h i s / h e r  b a c k u p  i n  c a s e s  o f  em e r g e n c y  w h e n  h e / s h e  i s  u n a v a i l a b l e .
A n  a s s e s sm e n t  w i l l  b e  d o n e  by  t h e  a p p r o p r i a t e  s i t e  p e r s o n n e l  a n d  th e  s p o n s o r  a f t e r  an  
em e rg en cy  u nb l ind ing  to  a s s e s s  w h e t h e r  o r  no t  s tudy  d r u g  sh o u l d  b e  d i s c o n t i n u e d  f o r  a  g iv en  
p a t i e n ta n d ,  i f  a p p l i c a b l e ,  w h e t h e r  t h e  p a t i e n tc an  c o n t i n u ein to  t h e  n e x t  t r i a l  p h a s e  ( e .g ,  an  
u n b l i n d e d  e x t e n s i o n ) .
6 .7 T rea tmen t  exposu re  and  comp l iance
P h a rm a c o k i n e t i c  p a r am e t e r s  (m e a s u r e s  o f  t r e a tm e n t  e x p o s u r e )  w i l l  b e  d e t e rm i n e d  in  a l l  
s u b j e c t s  t r e a t e d  w i thLHW090a s  d e t a i l e d  i n  S e c t i o n  8 . 5.
6 .8 Recommended  t rea tmen t  o f  adve rse  even ts
A d v e r s e  e v e n t s  s h o u l d  b e  t r e a t e d  a t  th e  d i s c r e t ion  o f  t h e  I n v e s t i g a t o r  b a s e d  o n  h i s /h e r  
j u d gm e n t  a n d  b e s t  m ed i c a l  p r a c t i c e s .  M ed i c a t ion  u s e d  to  t r e a t  AE s  mu s t  b e  r e c o r d e d  o n  th e  
C o n c om i t a n t  m e d i c a t i o n s /S i g n i f i c a n t  n o n- d r u g  t h e r a p i e s  CRF .
6 .9 Rescue  med ica t ion
R e s c u e  m e d i c a t i o n  to  t r e a t  s e v e r e  o r  s e r i o u s  c o n d i t i o n s  a s  p e r  s t a n d a r d  o f  c a r e ,  a t  th e  
d i s c r e t i o n  o f  t h e  I n v e s t i g a t o r ,  i s  a l l o w e d .  U s e  o f  r e s c u e  m ed i c a t ion  mu s t  b e  r e c o r d e d  o n  th e  
C o n c om i t a n t  m e d i c a t i o n s /S i g n i f i c a n t  n o n- d rug  th e r ap i e s  CRF  a f t e r  s t a r t  o f  s tudy  d r u g .
6 .10 Concom i tan t  t rea tmen t
A l l  p r e s c r i p t i o n  m ed i c a t ion s ,  o v e r- th e - c o u n t e r  d r u g s  a n d  s i g n i f i c a n t  non- d r u g  th e r ap i e s  
( i n c l u d i n g  phy s i c a l  th e r apy  a n d  b l o o d  t r a n s f u s i o n s )  a dm i n i s t e r e d  o r  t a k e n  w i th in  t h e  
t im e f r am e  d e f in ed  in  th e  en t ry  c r i t e r i ap r io r  to  th e  s t a r t  o f  th e  s tudy  and  du r ing  th e  s tudy ,  mu s t  
b e  r e c o r d e d  o n  t h e  C o n c om i t a n t  m e d i c a t i o n s /  S i g n i f i c a n t  n o n - d r u g  t h e r a p i e s  s e c t i o n  o f  t h e  
CRF .
M e d i c a t i o n  en t r i e s  s h o u l d  b e  s p e c i f i c  to  t r a d e  n am e ,  t h e  s i n g l e  do s e  a n d  un i t ,  t h e  f r e q u e n c y  
a n d  r o u t e  o f  a dm i n i s t r a t i o n ,  t h e  s t a r t  a n d  d i s c o n t i n u a t i o n  d a t e  a n d  t h e  r e a s o n  f o r  t h e r a p y .
No va r t i s Con f iden t ia l Page  34
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
D u e  to  t h e  p o t e n t i a l  f o r  p h a rm a c o k i n e t i c  d rug- d ru g  i n t e r a c t io n s ,  p a t i e n ts  t a k i n g  s t a t in s  s h o u l d  
b e  m o n i t o r e d  f o r  s t a t in - r e l a t e d  myo s i t i s  ( e .g .  mu s c l e  p a i n  o r  e l ev a t ion s  in  c r e a t in ek in a s e )  
d u r i n g  t h e  d u r a t i o n  o f  t h e  s tudy .  U n d e r  t h e  g u i d a n c e  o f  t h e i r  t r e a t i n g  phy s i c i an ,  s u b j e c t s  o n  
r o s u v a s t a t i n  m ay c o n sid e r  h a l v i n g  t h e i r  d o s e  o r  sw i t c h i n g  to  a n o t h e r  s t a t in  f o r  t h e  d u r a t i o n  o f  
th e  s tudy .   
7 D iscon t inua t ionand  s tudy comp le t ion
7 .1 D iscon t inua t ion  o f  s tudy t rea tmen t
S u b j e c t sm ay vo lun t a r i ly  d i s con t inu es tudy  t r e a tm en t  fo r  any  r e a son  a t  any  t im e .Th ey m ay  b e  
c o n s id e r ed  w i thd r awn  i f  th ey  s t a t e  an  in t en t ion  to  w i thd r aw ,  f a i l  to  r e tu rn  fo r  v i s i t s ,  o r  b e com e  
lo s t  to  f o l l ow - u p  f o r  a n y  o t h e r  r e a s o n .  I f  a  sub j e c t  w i t h d r aw a l  o c c u r s  fo r  any  r e a s o n ,  th e  
i n v e s t i g a t o r  mu s t  m ak e  ev e ry  e f fo r t  to  d e t e rm i n e  t h e  p r im a ry  r e a son  f o r  a  s u b j e c t ’ s  
w i t h d r aw a l  f r om  t h e  s t u d y  a n d  r e c o r d  t h i s  i n f o rm a t i o n  o n  t h e  CRF .
T h e  i n v e s t i g a t o r  mu s td i s c o n t i n u e  s tudyt r e a tm en t  f o r  a  g i v e n  p a t i e n ti f ,  o n  b a l a n c e ,  h e / sh e  
b e l i e v e s  t h a t  c o n t i n u a t i o n  w o u l d  b e  d e t r im e n t a l  t o  t h e  p a t i e n t’ s  w e l l - b e ing .
S tudy t r e a tm e n t  mu s tb e  d i s c o n t i n u e d  u n d e r  t h e  f o l l ow i n g  c i r c um s t a n c e s :  
S u b j e c t  w i t h d r aw s  c o n s e n t   
P r egn an cy
D i s con t inu a t ion  o f  i n v e s t i g a t i o n a lt r e a tm en t  w i l l  b e  a t  th e  d i s c r e t ion  o f  th e  Inv e s t ig a to r ,  und e r  
t h e  f o l l ow i n g  c i r c um s t a n c e s :
Em e r g e n c e  o f  t he  f o l l ow i n g  a d v e r s e  e v e n t s :
Symp tom a t i c  hypo t en s ion  o r  o r tho s t a t i c  hy po t en s ion  (hy po t en s iv e  o r  o r tho s t a t i c  
b l o o d  p r e s s u r e  r e a d i n g s  m u s t  b e  c o n f i rm e d  o n  r e p e a t  m e a s u r em e n t  w i t h i n  
3 0m i n u t e s )  t h a t  r e q u i r e s  m e d i c a l  i n t e r v e n t i o n .
Sys t o l i c  b l o o d  p r e s s u r e  < 8 0  mmHg  (m u s t  b e  c o n f i rm ed  o n  r e p e a t  m e a s u r em e n t  
a f t e r  3 0  m i n u t e s )
Sym p t om a t i c  s ev e r e  hy p e r t e n s i o n( e . g . ,  a  s y s t o l i c  b l o o d  p r e s s u r e  > 1 8 0  mmH g  o r  a  
d i a s t o l i c  b l o o d  p r e s s u r e  > 1 20  mmH g )  t h a t  r e q u i r e s  m e d i c a l  i n t e r v e n t i o n
Any o f  th e  fo l low ing  l abo r a to ry  abno rm a l i t i e s :
A  r e p r o d u c i b l e  a n d  p e r s i s t e n t  (>  2 4  h o u r s )  i n c r e a s e  i n  s e r um  c r e a t i n i n e  f r om  
b a s e l i n e  o f  > 0 . 3  m g / dL  u n l e s s  t h e  b e n e f i t / r i s k  a s s e s sm e n t  s u p p o r ts  c o n t i n u i n g  
s tudy  t r e a tm e n t .  Ar e n a l  e v e n t  l e a d i n g  t o  p a t i e n t  d i s c o n t i n u a t i o n  s h o u l d  b e  
f o l l ow e d  u p  u n t i l  e v e n t  r e s o l u t i o n  (S e r um  C r  w i t h i n  1 0%  o f  b a s e l i n e ) ,  o r  ev en t  
s t a b i l i z a t i o n  (S e r um  C r  l e v e l  w i th  ±10%  v a r i ab i l i ty  ov e r  l a s t  6mon th s ).
U s e  o f  p r o h i b i t e d  t r e a tm e n t  a s  p e r  S e c t ion  5 .3
Any o t h e r  p r o t o c o l  d e v i a t i o n  t h a t  r e s u l t s  i n  a  s i g n i f i c a n t  r i s k  t o  t h e  s u b j e c t ’ s  s a f e ty
T h e  a p p r o p r i a t e  p e r sonn e l  f r om  t h e  s i t e  a n d  N o v a r t i s  w i l l  a s s e s s  w h e t h e rinv e s t ig a t ion a l  
t r e a tm e n t  s h o u l d  b e  d i s con t inu ed  fo r  a n y  sub j e c t  w h o s e  t r e a tm en t  cod e  h a s  b e en  b rok en  
i n a d v e r t e n t l y  f o r  a ny  r e a s o n .
No va r t i s Con f iden t ia l Page  35
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
S u b j e c t s  w h o  d i s c o n t i n u e  s tudy  t r e a tm e n t  o r  w h o  d e c i d e  th ey  d o  no t  w i s hto  p a r t i c i p a t e  in  t h e  
s tudy  f u r t h e r  s h o u l d  NOT  b e  c o n s i d e r e d  w i t h d r aw n  f r om  t h e  s tudy  U NLESS  th ey w i thd r aw  
t h e i r  c o n s e n t  ( s e e  S e c t ion  7 . 3) .  W h e r e  p o s s i b l e ,  t h ey  s ho u l d  r e t u r n  fo r  t h e  a s s e s sm en t s  
o u t l i n e d  a t  V 7 7 7in  t h e  a s s e s sm e n t  t a b l e .  I f  th ey  f a i l  to  r e t u r n  f o r  th e s e  a s s e s sm e n t s  fo r  
u n k n ow n  r e a s o n s ,  ev e ry  e f f o r t  ( e .g .  t e l e p h o n e ,  e - m a i l ,  l e t t e r )  s h o u l d  b e  m a d e  to  c o n t a c t  th em  
a s  s p e c i f i e d  i nS e c t ion  7 .2 .1
7 .2 S tudy  comp le t ion  and  pos t-s tud y  t rea tmen t
E a c h  sub j e c t  w i l l  b e  r equ i r ed  to  c om p l e t e  th e  s tudy  i n  i t s  en t i r e ty  a n d  t h e r e a f t e r  no  f u r t h e r  
s tudy  t r e a tm e n t  w i l l  b e  ma d e  a v a i l a b l e  to  t h em .  S tudy c omp l e t ion  i s  d e f i n e d  a s  w h e n  t h e  l a s t  
s u b j e c t  c om p l e t e s  t h e i r  E n d  o f  S tudy v i s i t ,  a n d  any  r e p e a t  a s s e s sm e n t s  a s s o c i a t e d  w i th  t h i s  
v i s i t  h av e  b e en  do cum en t ed  and  fo l low ed- up  a p p r o p r i a t e l y  by  [CONTACT_3433] e  I n v e s t i g a t o r ,  o r  in  th e  ev en t  
o fa n  e a r l y  s t u d y  t e rm i n a t i o n  d e c i s i o n ,  t h e  d a t e  o f  t h a t  d e c i s i o n.
A t  a  m in imum ,  s u b j e c t s  w i l l  b e  c o n t a c t e d  fo r  s a f e ty  e v a l u a t i o n s  d u r i n g  t h e  3 0  d ay s  fo l low ing  
t h e  S tudy C omp l e t ion  v i s i t,  i n c l u d i n g  a  f i n a l  po s t- s tudy  s a f e t y  c o n t a c t  a t  t h e  3 0 - d ay  p o in t .  
D o c ume n t a t i o n  o f  a t t emp t s  to  c o n t a c t  t h e  s u b j e c ts h o u l d  b er e c o r d e d  in  t h e  s o u r c e  
d o c um e n t a t i o n .
7 .2 .1 Lostto  fo l low - up
Fo r  sub j e c t s  who s e  s t a tu s  i s  un c l e a r  b e c au s e  th ey f a i l  to  app e a r  fo r  s tudy  v i s i t s  w i thou t  s t a t ing  
a n  in t en t ion  to  d i s con t inu e  o r  w i t h d r aw ,  t h e  inv e s t ig a to r  s h o u l d  s h ow  " d u e  d i l i g en c e "  by  
d o c um e n t i n g  in  th e  sou r c e  d o c um e n t s  s t ep s  t ak en  to  c on t a c t  th e  s u b j e c t ,  e .g .  d a t e s  o f  
t e l e p h o n e  c a l l s ,  r eg i s t e r ed  l e t t e r s ,  e t c .  A  sub j e c t  s h o u l d  no t  b e  fo rm a l ly  con s id e r ed  lo s t  to  
f o l l ow - up  un t i l  h is / h e r  s c h e d u l e d  e n d  o f  s t u d y  v i s i t  w o u l d  h a v e  o c c u r r e d .
7 .3 W i thd rawa l  o f  consen t
P a t i e n ts  m a y  v o l u n t a r i l y  w i t h d r aw  c o n s e n t  t o  p a r t i c i p a t e  i n  t h e  s t u d y  f o r  a n y  r e a s o n  a t  a n y  t im e .
W i t h d r aw a l  o f  con s en t  o c c u r s  o n ly  w h e n  a  p a t i en td o e s  no t  w an t  to  p a r t i c i p a t e  inth e  s tudy  
anymo r eandd o e s  no t  w a n t  a n y  f u r t h e r  v i s i t s  o r  a s s e s sm e n t sandd o e s  no t  w a n t  a n y  fu r th e r  
s tudy  r e l a t e d  c o n t a c tandd o e s  n o t  a l l ow  a n a ly s i s  o f  a l r e ady  o b t a in e d  b i o l o g i c  m a t e r i a l .
I f  a  p a t i e n tw i t h d r aw s  c o n s e n t ,  t h e  i n v e s t i g a t o r  mu s t  m a k e  ev e ry  e f fo r t  to  d e t e rm i n e  t h e  
p r im a ry  r e a son  f o r  th i s  d e c i s i o n  a n d  r e c o r d  th i s  i n f o rm a t i o n .  S tudy t r e a tm e n t  mu s t  b e  
d i s c o n t i n u e d  and  n o  fu r t h e r  a s s e s sm e n t s  condu c t ed .  A l lb i o l o g i c a l  m a t e r i a l  t h a t  h a s  no t  b e en  
a n a l y z e d  a t  t h e  t im e  o f  w i t h d r aw a l  mu s t  no t  b e  u s e d .  Fu r t h e r  a t t em p t s  to  c o n t a c t  t h e  p a t i e n t
a r e  n o t  a l l ow e d  u n l e s s  s a f e t y  f i n d i n g s  r e q u i r e  c ommu n i c a t i n g  o r  f o l low- u p .
No va r t i s Con f iden t ia l Page  36
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
7 .4 S tudy  S topp ing  ru les
Th e  s tudyw i l l  b e  s topp ed  i fany  o f  th e  fo l low ing  c r i t e r i a  a r e  m e t  and  no  fu r th e rdo s ingw i l l  b e  
t a k e np e n d i n g  a  f u l l  s a fe ty  r ev i ew :
2s e v e r eAE s  a r er epo r t ed
3  s u b j e c t s  e x p e r i e n c e  a  p e r s i s t e n t  (>  2 4  h o u r s )  a n d  r e p r o d u c i b l e  i n c r e a s e  i n  s e r um  
c r e a t i n i n e  > 0 . 3  m g / dL  f rom  b a s e l in e  
3  o r  m o r e  s u b j e c t se x p e r i e n c e  a  s im i l a r  AE  w h i c h  i s  a s s e s s e d  a s  e i t h e r  m o d e r a t e  o r  s e v e r e
in  in t en s i ty
7 .5 Ea r ly  s tudy te rm ina t ion
T h e  s tudy  c an  b e  t e rm in a t ed  a t  any  t im e  fo r  any  r e a son  by  N ov a r t i s .  Shou ld  th i s  b e  n e c e s s a ry ,  
s u b j e c t ss h o u l d  b e  s e e n  a s  s o o n  a s  p o s s i b l e  a n d  t r e a t e d  a s  a  p r em a t u r e ly  w i t h d r aw n  sub j e c t .  
T h e  i n v e s t i g a t o r  m ay b e  i n f o rm e d  o f  a d d i t i o n a l  p r o c e d u r e s  to  b e  fo l low ed  in  o r d e r  to  e n s u r e  
t h a t  a d e q u a t e  c o n s i d e r a t i o n  i s  g i v e n  t o  t h e  p r o t e c t i o n  o f  t h e  s u b j e c t ’ s  i n t e r e s t s .
T h ei n v e s t i g a t o r  w i l l  b e  r e s p o n s i b l e  f o r  i n f o rm i n g  IRB s / IEC s  o f  t h e  e a r ly  t e rm i n a t i o n  o f  t h e  
t r i a l .
No va r t i s Con f iden t ia l Page  38
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
8 .1 In fo rmed  consen t  p rocedu res
E l i g i b l e  p a t i e n ts  m ay o n ly  b e  i n c l u d e d  in  t h e  s tudy  a f t e r  p r o v i d i n g  w r i t t en  (w i t n e s s e d ,  w h e r e  
r e q u i r e d  b y  l aw  o r  r e g u l a t i o n ) ,  I RB / IEC- a p p r o v e d  in f o rm e d  c o n s e n t .
I n f o rm e d  c o n s e n t  mu s t  b e  o b t a i n e d  b e f o r e  c o n d u c t i n g  a n y  s tudy - sp e c i f i c  p r o c e d u r e s  ( i . e .  a l l  
o f  t h e  p r o c e d u r e s  d e s c r ib ed  in  t h e  p r ot o c o l ) .  Th e  p r o c e s s  o f  ob t a in ing  i n f o rm e d  con s en t  
s h o u l d  b e  d o c um e n t e d  i n  t h e  s u b j e c t  s o u r c e  d o c um e n t s .
T h e  d a t e  o f  s ign ing  o f  i n f o r m e d  c o n s e n t  ( and  w i t h d r aw a l ,  i fl a t e r  w i t h d r aw n )  s h o u l d  b e  
d o c um e n t e d  i n  t h e  CRF .
N o v a r t i s  w i l l  p rov id e  to  i n v e s t i g a t o r s  a  p r o p o s e d  i n f o rm e d  c o n s e n t  fo rm  t h a t  c om p l i e s  w i th  
t h e  ICH  GCP  g u i d e l i n e  a n d  r egu l a to ry  r e q u i r em e n t s  a n d  i s  c o n s i d e r e d  a p p r o p r i a t e  fo r  th i s  
s tudy .  A ny  ch ang e s  to  t h e  p r o p o s e d  con s en t  fo rm  sugg e s t ed  by  t h e  inv e s t ig a to r  mu s t  b e  
ag r e ed  to  by  [CONTACT_343842] a r t i s  b e f o r e  s u bm i s s ion  to  th e  I RB / IEC .
P r egn an cy o u t c om e s  mu s t  b e  co l l e c t ed  fo r  t h e  f em a l e  p a r t n e r s  o f  a n y  m a l e s  w h o  took  s tudy  
t r e a tm e n t  in  th i s  s tudy .  C o n s e n t  to  r e p o r t  i n f o rm a t i o n  r e g a r d i n g  t h e s e  p r egn an cy  o u t com e s  
s h o u l d  b e  o b t a i n e d  f r om  t h e  m o t h e r .  
 
 
 
 
I n  th e  ev en t  t h a t  Nov a r t i s  w a n t s  to  p e r f o rm  t e s t i n g  o n  th e  s a m p l e s  t h a t  a r e  no t  d e s c r i b e d  in  
th i s  p ro to co l ,  add i t ion a l  In s t i tu t ion a l  R ev i ew  Bo a rd  and /o r  E th i c s  Comm i t t e e  app rov a l  w i l l  b e  
o b t a i n e d .
A  copy o f  th e  app rov ed  v e r s ion  o f  a l l  con s en t  fo rm s  mu s t  b e  p rov id ed  to  th e  Nov a r t i s  mon i to r  
a f t e r  IR B / IEC  a p p r o v a l .
8 .2 Sub jec t  demog raph ics /o the r  base l ine  cha rac te r is t icsC o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
S u b j e c t  d em o g r a p h i c  a n d  b a s e l i n e  c h a r a c t e r i s t i c  d a t a  w i l lb e  c o l l e c t e d  o n  a l l  s u b j e c t s .
R e l e v a n t  m e d i c a l  h i s to ry / cu r r en t  m ed i c a l  cond i t ion s  d a t a  in c l u d e s  d a t a  un t i l  s i g n a t u r e  o f  
i n f o rm e d  c o n s e n t .  W h e r e  po s s ib l e ,  d i agno s e s  and  no t  sy m p t om s  w i l l  b e  r e c o r d e d .
I n v e s t i g a t o r s  h av e  t h e  d i s c r e t ion  to  r e c o r d  a b n o rm a l  t e s t  f i n d i n g s  on  t h e  m e d i c a l  h i s to ry  C RF  
w h e n e v e r  in  t h e i r  j u d gm e n t ,  t h e  t e s t  abno rm a l i ty  o c c u r r e d  p r i o r  to  t h e  i n f o rm e d  c o n s e n t  
s i g n a t u r e .
No va r t i s Con f iden t ia l Page  39
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
8 .3 E f f icacy/  Pha rmacody nam ics
P h a rm a c o dy n am i c  a s s e s sm en t s  a r e  s p e c i f i e db e low ,  w i th  t h e  m e t h o d s  fo r  a s s e s sm e n t  and  
r e c o r d i n g  s p e c i f i e d  in  th e  S tudy O p e r a t i o n s  M anu a l.A s s e s sm e n t s  w i l l  b e  p e r f o rm e d / s am p l e s  
c o l l e c t e d  a t  t h e  t im e p o i n t ( s )  d e f i n e d  i n  t h e  A s s e s sm e n t  s c h e d u l e.
I n  o r d e r  to  b e t t e r  d e f in e  t h e  PD  p r o f i l e ,  t h e  t im i n g  o f  t h e  s am p l e  co l l e c t ion  m ay b e  a l t e r ed  
b a s e d  o n  em e r g e n t  d a t a .  T h e  n um b e r  o f  s amp l e s /b lood  d r aw s  a n d  to t a l  b l o o d  v o l um e  
c o l l e c t e d  w i l l  no t  ex c e edt h o s e  s t a t e d  in  t h e  p r o t o co l .   T h e  r e s u l t s  n e ed  to  r em a i n  b l ind ed  
d u r i n g  t h e  s t u dy .
8 .3 .1 Ambu la to ry  b lood  p ressu re  mon i to r ing
Con t inuou s  b lood  p r e s su r e  mon i to r ing  w i l l  b e  p e r fo rm ed  ov e r  24  hou r  p e r iod s  to  a s s e s s  b lood  
p r e s s u r e ,  h e a r t  r a t e ,  m e a n  a r t e r i a l  p r e s s u r e ,  a n d  p u l s e  p r e s s u r e .  
T h e  ABPM  d e v i c e  v endo r  w i l l  p r o v i d e  a  r e f e r e n c e / u s e r  m anu a l  g i v i n g  mo r e  s p e c i f i c  d e t a i l s  
o n  p a t i e n tc o n s i d e r a t i o n s  f o r  i n c l u s i o n .  P ro c edu r e s  f o r  s e t - u p ,  v a l id a t i o n ,  qu a l i ty  c o n t r o l ,  u s e  
o f  s o f tw a r e  a n d  t r a n s f e r  o f  d a t a ,  a n d  g u i da n c e  fo r  p e r f o rm i n g  t h e  m e a s u r em e n t s  w i l l  a l s o  b e  
p r o v i d e d  in  t h e  v e n d o r  m a n u a l .  I n v e s t i g a t o r  s i t e  s t a f f  t h a t  w i l l  b e  p e r f o rm i n g  t h e  ABPM  
m e a s u r em e n t s  w i l l  b e  t r a in ed  a p p r o p r i a t e l y  by  t h e  d e v i c e  v e n d o r  to  e n s u r e  t h e  d e v i c e s  a r e  
u s e d  i n  t h e  c o r r e c t  m a n n e r .  T r a i n i n g  w i l l  o c c u r  p r i o r  t o  i n i t i a l  u s e  o f  t h e  d e v i c e s .
8 .4 Sa fe ty
S a f e tya s s e s sm e n t s  a r e  s p e c i f i e db e low ;m e thod s  fo r  a s s e s sm en t  and  r e co rd ing  a r e  sp e c i f i ed  in  
t h e  S i t e  O p e r a t i o n s  M a n u a l,  w i th  t h e  A s s e s sm e n t  s c h e d u l ed e t a i l i n g  wh en  e a c h  a s s e s sm e n t  i s  
t o  b e  p e r f o rm e d .
8 .4 .1 Phys ica l  exam ina t ion
A  c om p l e t e  phy s i c a l  ex am in a t ion  w i l l  i n c l u d e  t h e  ex am in a t ion  o f  g en e r a l  a p p e a r a n c e ,  sk in ,  
n e c k  ( i n c l u d i n g  thy ro id ) ,  ey e s ,  e a r s ,  n o s e ,  th ro a t ,  l u n g s ,  h e a r t ,  a b d om e n ,b a c k ,  ly mph  nod e s ,  
ex t r em i t i e s ,v a s cu l a r  and  n eu ro log i c a l .  I f  ind i c a t ed  b a s ed  on  m ed i c a l  h i s to ry  a nd /o r  sy mp tom s ,  
r e c t a l ,  e x t e r n a l  g e n i t a l i a ,  b r e a s t ,  a n d / o r  p e l v i c  e x am s  m a y  b e  p e r f o rm e d .
I n f o rm a t i o n  f o r  a l l  phy s i c a l  ex am in a t ion s  s h o u l d  b e  i n c l u d e d  in  th es o u r c e  do cum en t s  and  
w i l l  no t  b e  t r an s f e r r ed  to  th e  spon so r  a s  p a r t  o f  th e  s tudy an a l y s i s .  S ign i f i c an t  f ind ing s  th a t  a r e  
p r e s e n t  p r i o r  to  i n f o rm e d  c o n s e n t  a r e  i n c l u d e d  in  t h e  R e l e v a n t  M e d i c a l  H i s to ry s e c t i o n  o f  th e  
s o u r c e  d o c um e n t s .  S i g n i f i c a n t  f i n d i n g s  ob s e r v e d  a f t e r  i n f o rm e d  con s en t  s i g n a t u r e  w h i c h  m e e t  
t h e  d e f i n i t i o n  o f  a n  A d v e r s e  E v e n t  mu s t  b e  a p p r o p r i a t e l y  r e c o r d e d  o n  t h e  A d v e r s e  Ev en t  
eCRF  s e c t i o n .
8 .4 .2  V i ta l  s igns
B o dy  t em p e r a t u r e
B l o o d  p r e s s u r e  (BP )  
Pu l s e  
No va r t i s Con f iden t ia l Page  40
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
8 .4 .3 He igh t  and  we igh t
H e i g h t
B o dy  w e i g h t
B o dy  m a s si n d e x  (BM I )  w i l l  b e  c a l c u l a t e d  ( B o dy  w e i g h t  ( k g )  /  [H e i g h t  (m ) ]2)
8 .4 .4 Labo ra to ry ev a lua t ions
C l in i c a l ly r e l e v a n t  d ev i a t ion s  o f  l a b o r a to r y  t e s t  r e su l t s  o c c u r r i n g  d u r i n g  o r  a t  c om p l e t i o n  o f  
t h e  s tudy  m u s t  b e  r e p o r t e d  a n d  d i s c u s s e d  w i th  N o v a r t i s  p e r s o n n e l .  Th e  r e s u l t s  sh o u l d  b e  
e v a l u a t e d  f o r  c r i t e r i a  d e f in ing  an  a d v e r s e  e v e n t  and  r e p o r t e d  a s  su ch  i f  th e  c r i t e r i a  a r e  m e t .  
R e p e a t e d  ev a lu a t ion s  a r e  m and a to ry u n t i l  no rm a l i z a t ion  o f  t h e  r e su l t ( s )  o r  un t i l  t h e  c h a n g e  i s  
n o  l o n g e r  c l i n i c a l ly  r e l e v a n t .  I n  c a s e  o f  d o u b t ,N o v a r t i s  p e r s o n n e l  s h o u l d  a g a i n  b e  c o n t a c t e d .
Hema to logy
H em o g l o b i n ,  h em a t o c r i t ,  r e d  b l o o d  c e l l  c o u n t ,  w h i t e  b l o o d  c e l l  c o u n t  w i t h  d i f f e r e n t i a l  and  
p l a t e l e t  c o u n t  w i l l  b e  m e a s u r e d .
C l in ica l  chem is t ry
Sod ium ,  p o t a s s i um ,  c r e a t i n i n e ,  u r e a ,  u r i c  a c id ,  c h lo r ide ,  a l b um i n ,  c a l c i um ,  a lk a l in e  
pho sph a t a s e ,  to t a l  b i l i rub in ,  L DH ,  GGT ,  AST ,  ALT ,  g lu co s e ,  to t a l  cho l e s t e ro l ,  c r e a t in e  k in a s e  
(CK ) ,  a n d  t r i g l y c e r i d e s .
I f  t h e  to t a l  b i l i rub in  c o n c e n t r a t i o n  i s  i n c r e a s e d  a b o v e  1 . 5  t im e s  t h e  upp e r  l im i t  o f  n o rm a l ,  
d i r e c t  a n d  i n d i r e c t  r e a c t i n g  b i l i r u b i n  s h o u l d  b e  d i f f e r e n t i a t e d .
U r ina lys is
U r i n e  t e s t  by  d i p s t i c k  e . g .  Combu r9 :  l eu co cy t e s ,  n i t r i t e ,  pH ,  p r o t e i n ,  g l u c o s e ,  k e ton e s ,  
u r o b i l i n o g e n ,  b i l i r u b i n ,  b l o o d /  h em o g l o b i n
I ft h e  d ip s t i ck  r e su l t  i s  po s i t iv e  fo r  p ro t e in ,  n i t r i t e ,  l eu co cy t e s  and /o r  b lood ,  th e  s amp l e  w i l l  b e  
s e n t  f o r  m i c r o s c o p i c  a n a l y s i s  o f  WBC ,  RBC  a n d  c a s t s .
[ADDRESS_1133192] iog ram  (ECG )C o r p o r a t e  C o n f i d e n t i a l  In f o rm a t i o n
E a c h  ECG  t r a c i n g  s h o u l d  b e  l a b e l e d  w i th  s tudy  n um b e r ,  s u b j e c t  in i t i a l s ,  s u b j e c t  n um b e r ,  d a t e  
a n d  t im e ,  b e  a p p r o p r i a t e l y  s i g n e d  a n d  d a t e d  to  c o n f i rm  r e v i ew  a n d  f i l e d  in  t h e  s tudy  s i t e  
s o u r c e  do cum en t s .  F o r  any  E CG s  w i th  s u b j e c t  s a f e t y  c o n c e r n s ,  tw o  add i t ion a l  ECG s  s h o u l d  
b e  p e r f o rm e d  to  c o n f i rmt h e  s a f e t y  f i n d i n g .  C l in i c a l ly s ig n i f i c a nt  ECG  f i n d i n g s  p r i o r  to  
d o s i n g  w i t h  i n v e s t i g a t i o n a l  t r e a tm e n t  m u s t  b e  d i s c u s s e d  w i t h  t h e  s p o n s o r .  
Fu l l  d e t a i l s  o f  a l l  p r o c e d u r e s  r e l a t i n g  to  t h e  ECG  co l l e c t ion  a n d  r e p o r t i n g  w i l l  b e  c o n t a i n e d  i n  
t h e  t e c h n i c a l  m a n u a l  w h i c h  i s  p r o v i d e d  t o  t h e  s i t e  b y  th e  co r e  l abo r a to ry .
No va r t i s Con f iden t ia l Page  41
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
F or  a l l  s tud i e s :
PR  i n t e r v a l ,  QRS  d u r a t i o n ,  h e a r t  r a t e ,  RR ,  QT ,  QT c
T h e  F r i d e r i c i a  QT  c o r r e c t i o n  f o rm u l a  (QT cF )  s h o u l d  b e  u s e d  f o r  c l i n i c a l  d e c i s i o n s .
[ADDRESS_1133193] ed  
s am p l i n g  t im e s  a n d  n o n -c om p a r tm e n t a l  m e thod( s )  w i th  Pho en ix  W i nN o n l i n  (V e r s i o n  6 . 2  o r  
h i g h e r ) :  Cm ax ,  Tm a x ,  AUC l a s t ,  AUC0 - t  f rom  t h e  p l a sm a  c on c e n t r a t i o n - t im e  d a t a .
O t h e rph a rm a cok in e t i c  p a r am e t e r s  m ay  b e  d e t e rm i n ed ,  i f  r e l e v a n t .
8 .6 O the r  assessmen tsC o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
 
 
 
 
 
 
 C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
No va r t i s Con f iden t ia l Page  42
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 Sa fe ty mon i to r ing
9 .1 Adve rse  even ts
A n  a d v e r s e  ev en t  (AE )  i s  any  u n t ow a r d  m ed i c a l  o c c u r r e n c e  ( i . e . ,  any  u n f a v o r a b l e  and  
u n i n t e n d e d  s i g n  [ i n c l u d i n g  a b n o rm a l  l abo r a to ry  f i n d i n g s ] ,  sy mp tom  o r  d i s e a s e )  in  a  p a t i e n to r  
c l i n i c a l  i n v e s t i g a t i o n  sub j e c t  a f t e r  p r o v i d i n g  w r i t t e n  i n f o rm e d  c o n s e n tC o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
fo r  p a r t i c i p a t i o n  in  th e  
s tudy .  Th e r e fo r e ,  an  AE  m ay  o r  m ay  no t  b e  t empo r a l ly  o r  c au s a l l y  a s so c i a t ed  w i th  th e  u s e  o f  a  
m e d i c i n a l  ( i n v e s t i g a t i o n a l )  p r o d u c t .
No va r t i s Con f iden t ia l Page  43
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
T h e  o c c u r r e n c e  o fadv e r s e  ev en t s  shou ld  b e  sough t  by  [CONTACT_105] - d i r e c t iv e  qu e s t ion ing  o f  th e  sub j e c t  
a t  e a c h  v i s i t  du r ing  th e  s tudy .  Adv e r s e  ev en t s  a l so  m ay  b e  d e t e c t ed  wh en  th ey  a r e  vo lun t e e r ed  
by  t h e  s u b j e c t  du r ing  o r  b e tw e e n  v i s i t s  o r  t h r o u g h  phy s i c a l  ex am in a t ion ,  l a b o r a t o ry  t e s t ,  o r  
o t h e r  a s s e s sm e n t s .
A b n o rm a l  l abo r a to ry  v a lu e s  o r  t e s t  r e s u l t s  c o n s t i t u t e  a d v e r s e  e v e n t s  on ly  i f  t h ey  f u l f i l l  a t  l e a s t  
o n e  o f  t h e  f o l l ow i n g  c r i t e r i a :
 th ey  indu c e  c l in i c a l  s ign s  o r  sy mp tom s ,  
 th ey  a r e  con s id e r ed  c l in i c a l ly  s ign i f i c an t ,  
 th ey  r e q u i r e  th e r apy .  
C l in i c a l ly s ig n i f i c an t  a b n o rm a l  l abo r a to ry  v a l u e s  o r  t e s t  r e su l t s  s h o u l d  b e  id en t i f i ed  t h r o u g h  a  
r e v i ew  o f  v a lu e s  o u t s i d e  o f  n o rm a l  r ang e s / c l in i c a l ly  n o t a b l e  r a n g e s ,  s i g n i f i c a n t  c h a n g e s  f rom  
b a s e l i n e  o r  t h e  p r e v i o u s  v i s i t ,  o r  v a l u e s  w h i c h  a r e  c o ns id e r e d  t o  b e  n o n - ty p i c a l  i n  p a t i e n tsw i th  
u n d e r ly i n g  d i s e a s e .  I n v e s t i g a t o r s  h av e  t h e  r e spon s ib i l i ty  f o r  m a n a g i n g  t h e  s a f e t y  o f  i n d i v i d u a l  
s u b j e c ta n d  id en t i fy ing  a d v e r s e  e v e n t s .  A l e r t  r a n g e s  f o r  l i v e r  r e l a t e d  ev en t sa r e  in c lud ed  in
S e c t i o n9 . 3.
A d v e r s e  e v e n t s  mu s t  b e  r e c o r d e d  o n  th e  Adv e r s e  E v e n t s  CRF  fo r  s u b j e c t s  t h a tp a s s  s c r e en ing  
a n d  e n t e rin to  t h e  s tudy .  Th e  a d v e r s e  ev en t s  s h o u l d  b e  r e p o r t e d  a c c o r d i n g  to  t h e  s ign s ,  
sy m p t om s  o r  d i a g n o s i s  a s s o c i a t e dw i th  th em ,  and  a c comp an i ed  by t h e  f o l l ow i n g  i n f o rm a t i o n :
1 .t h e  s e v e r i t y  g r a d e  
m i ld : u su a l ly  t r a n s i e n t  i n  n a t u r e  a n d  g e n e r a l l y  n o t  i n t e r f e r i n g  w i t h  n o rm a l  
a c t i v i t i e s
m o d e r a t e : s u f f i c i e n t l y  d i s c om f o r t i n g  t o  i n t e r f e r e  w i t h  n o rm a l  a c t i v i t i e s
s e v e r e : p r e v e n t s  n o rm a l  a c t i v i t i e s
2 .i t s  r e l a t i o n s h i p  t o  t h einv e s t ig a t ion a l  t r e a tm en t  (no /y e s ) ,  o r  o th e r  s t u d y  t r e a tm e n t( n o n -
i n v e s t i g a t i o n a l )  ( no /y e s ) ,  o rb o t h  o r  i n d i s t i n g u i s h a b l e ,
3 .i t s  d u r a t i o n  ( s t a r t  a n d  e n d  d a t e s )  o r  i f  t h e  e v e n t  i s  o n g o i n g  a n  o u t c om e  o f  n o t  
r e c o v e r e d / n o t  r e s o l v e d  s h o u l d  b e  r e p o r t e d .
4 .w h e t h e r  i t  c o n s t i t u t e s  a  s e r i o u s  a d v e r s e  e v e n t  (SAE ).S e e  S e c t i o n  9 . 2f o r  d e f i n i t i o n  o f  SAE
5 .a c t i o n  t a k e n  r e g a r d i n g  [ s t u d y / inv e s t ig a t ion a l ]  t r e a tm e n t ( s e l e c t  a s  a p p r o p r i a t e ) .  
A l l  a d v e r s e  e v e n t s  s h o u l d  b e  t r e a t e d  a p p r o p r i a t e l y .  T r e a tm e n t  m a y i n c l u d e  o n e  o r  m o r e  o f  
t h e  f o l l ow i n g :  
n o  a c t i o n  t a k e n  ( i . e .  f u r t h e r  o b s e r v a t i o n  o n l y )  
s tudy  t r e a tm e n tdo s ag e  ad ju s t ed / t empo r a r i ly  in t e r rup t ed  
s tudy  t r e a tm e n tp e rm an en t ly  d i s c o n t i n u e d  d u e  t o  t h i s  a d v e r s e  e v e n t  
c o n c om i t a n t  m e d i c a t i o n  g i v e n  
n o n - d r u g  t h e r a py  g i v e n  
s u b j e c tho sp i t a l i z ed /s u b j e c t ’ sh o s p i t a l i z a t i o n  p r o l o n g e d  
6 .i t s  o u t c om e  ( c o n t i n u i n g  a t  f i n a l  e x am ;  r e s o l v e d )
No va r t i s Con f iden t ia l Page  44
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
O n c e  a n  adv e r s e  ev en t  i s  d e t e c t e d ,  i t  s h o u l d  b e  f o l l ow e d  un t i l  i t s  r e so lu t ion  o r  un t i l  i t  i s  
j u d g e d  to  b e  p e rm an en t ,  a n d  a s s e s sm e n t  s h o u l d  b e  m a d e  a t  e a c h  v i s i t  ( o r  m o r e  f r e q u e n t l y ,  i f  
n e c e s s a ry )  o f  a n y  c h a n g e s  in  s e v e r i t y ,  t h e  s u s p e c t e d  r e l a t ion sh ip  to  t h e  s tudy  d r u g ,  th e  
i n t e r v e n t i o n s  r e q u i r e d  t ot r e a t  i t ,  a n d  t h e  o u t c om e .
I n f o rm a t i o n  a b o u t  c omm o n  s i d e  e f f e c t s  a l r e a d y  known  ab o u t  t h e  i n v e s t i g a t i o n a l  d r u g  c a n  b e  
f o u n d  in  t h e  I n v e s t ig a to r  B r o c h u r e  ( IB )  o r  C o r e  D a t a  S h e e t  ( f o r  m a rk e t ed  d r u g s )  o r  w i l l  b e  
c omm u n i c a t e d  b e tw e e n  IB  u p d a t e s  in  t h e  f o rm  o f  I n v e s t i g a t o r  No t i f i c a t ion s .  Th i s  i n f o rm a t i o n  
w i l l  b e  i n c l u d e d  in  t h e  s u b j e c ti n f o rm e d  con s en t  a n d  s h o u l d  b e  d i s cu s s ed  w i th  t h e  sub j e c t
d u r i n g  t h e  s t u dy  a s  n e ed e d .
Th e  inv e s t ig a to r  shou ld  a l so  in s t ru c t  e a ch  s u b j e c tto  r epo r t  any  n ew  adv e r s e  ev en t  (b ey ond  the  
p r o t o c o l  o b s e r v a t i o n  p e r i o d )  t h a t  t h e  s u b j e c t ,  o r  t h e  s u b j e c t ’ sp e r s o n a l  phy s i c i a n ,  b e l i ev e s  
m i g h t  r e a s o n a b l y  b e  r e l a t e d  to  s tudy  t r e a tm e n t .  Th i s  i n f o rm a t i o n  s h o u l d  b e  r e c o r d e d  in  th e  
i n v e s t i g a t o r ’ s  s o u r c e  do cum en t s ,  h ow e v e r ,  i f  t h e  AE  m e e t s  t h e  c r i t e r i ao f  a n  SAE ,  i t  m u s t  b e  
r e p o r t e d  t o  N o v a r t i s .
9 .2 Se r ious  adve rse  even t  repo r t ing
9 .2 .1 De f in i t ion  o f  SAE
A n  SAE  i s  d e f i n e d  a s  any  adv e r s e  e v e n t  ( a p p e a r a n c e  o f  (o r  w o r s e n i n g  o f  a n y  p r e- ex i s t ing )  
u n d e s i r a b l e  s i g n ( s ) ,  sy m p t om ( s )  o r  m e d i c a l  c o n d i t i o n s ( s )  w h i c h  m e e t s  anyon e  o f  t h e  
f o l l ow i n g  c r i t e r i a :
 i s  f a t a l  o r  l i f e - th r e a t en ing  
r e s u l t s  i n  p e r s i s t e n t  o r  s i g n i f i c a n t  d i s a b i l i t y / in c ap a c i ty
c o n s t i t u t e s  a  c o n g e n i t a l  a n om a l y /b i r t h  d e f e c t
r e q u i r e s  i n p a t i e n t  h o s p i t a l i z a t i o n  o r  p r o l o n g a t i o n  o f  e x i s t i n g  h o s p i t a l i z a t i o n ,  u n l e s s  
h o s p i t a l i z a t i o n  i s  f o r :
R o u t i n e  t r e a tm e n t  o r  m o n i t o r i n g  o f  t h e  s t u d i e d  i n d i c a t i o n ,  n o t  a s s o c i a t e d  w i t h  a n y 
d e t e r i o r a t i o n  i n  c o n d i t i o n
e l e c t i v e  o r  p r e - p l a n n e d  t r e a tm e n t  f o r  a  p r e- e x i s t i n g  c o n d i t i o n  t h a t  i s  u n r e l a t e d  t o  t h e  
i n d i c a t i o n  u n d e r  s t u d y  and  h a s  no two r s e n e d  s i n c e  t h e  s t a r t  o f  s t u d y d rug
t r e a tm e n t  o n  a n  em e r g e n c y  o u t p a t i e n t  b a s i s  f o r  a n  e v e n t  n o t  f u l f i l l i n g  a n y  o f  th e  
d e f i n i t i o n s  o f  a  SAE  g i v e n  a b o v e  a n d  n o t  r e s u l t i n g  i n  h o s p i t a l  a dm i s s i o n  
s o c i a l  r e a s o n s  a n d  r e s p i t e  c a r e  i n  t h e  a b s e n c e  o f  a n y  d e t e r i o r a t i o n  i n  t h e  p a t i e n t ’ s  
g e n e r a l  c o n d i t i o n
i s  m ed i c a l ly  s i g n i f i c a n t ,  i . e .  d e f i n e d  a s  a n  e v e n t  t h a t  j e o p a r d i z e s  t h e  s u b j e c to r  m ay  r e q u i r e  
m e d i c a l  o r  s u r g i c a l  i n t e r v e n t i o n .
L i f e- th r e a t en ing  in  th e  con t ex t  o f  a  SAE  r e f e r s  to  a  r e a c t ion  in  wh i ch  th e  s u b j e c tw a s  a t  r i sk  o f  
d e a t h  a t  th e  t im e  o f  th e  r e a c t i o n ;  i t  d o e s  no t  r e f e r  to  a  r e a c t i o n  t h a t  hy po th e t i c a l ly  m ig h t  h av e  
c a u s e d  d e a t h  i f  m o r e  s e v e r e .
A l l  m a l i g n a n t  n eop l a sm s  w i l l  b e  a s s e s s e d  a s  s e r iou s  u n d e r  “m ed i c a l ly  s i g n i f i c a n t ”  i f  o th e r  
s e r i o u s n e s s  c r i t e r i a  a r e  no t  m e t .
Any su sp e c t ed  t r an sm i s s ion  v i a  a  m ed i c in a l  p rodu c t  o f  an  in f e c t iou s  ag en t  i s  a l so  con s id e r ed  a  
s e r i o u s  a d v e r s e  r e a c t i o n .
No va r t i s Con f iden t ia l Page  45
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
M e d i c a l  a n d  s c i e n t i f i c  j u d gm e n t  s h o u l d  b e  e x e r c i s e d  in  d e c i d i n g  wh e th e r  o t h e r  s i tu a t ion s  
s h o u l d  b e  c o n s i d e r e d  s e r i o u s  r e a c t ion s ,  s u c h  a s  im p o r t a n t  m e d i c a l  e v e n t s  t h a t  m i g h t  n o t  b e  
imm ed i a t e ly  l i f e  t h r e a t e n i n g  o r  r e s u l t  in  d e a t h  o r  ho sp i t a l i z a t ion  bu t  m i g h t  j eop a rd i z e  th e  
p a t i e n t  o r  m i g h t  r e q u i r e  i n t e r v e n t i o n  to  p r e v e n t  o n e  o f  t h e  o t h e r  o u t c om e s  l i s t ed  a b o v e .  
Ex amp l e s  o f  su ch  ev e n t s  a r e  in t en s iv e  t r e a tm en t  in  an  em e rg en cy  r oom  o r  a t  hom e  fo r  a l l e rg i c  
b r o n c h o s p a sm ,  b l o o d  dy s c r a s i a s  o r  c o n v u l s i o n s  t h a t  d o  no t  r e s u l t  in  ho sp i t a l i z a t ion  o r
d e v e l o pm e n t  o f  d e p e n d e n c y  o r  a b u s e .
A l l  AE s  ( s e r i o u s  a n d  n o n - s e r i o u s )  a r e  c ap tu r ed  o n  t h e  CRF ,SAE s  a l s o  r e q u i r e  ind iv idu a l  
r e p o r t i n g  t o  DS&E  a s  p e r  S e c t i o n  [ADDRESS_1133194] l e s s  o f  c a u s a l i t y ,  o c c u r r i n g  a f t e r  t h e  sub j e c th a s  
p r o v i d e d  i n f o rm e d  con s en t  a n dun t i l  3 0  d ay s  a f t e r  t h e  l a s t  s tudy  v i s i t  mu s t  b e  r e p o r t e d  to  
N o v a r t i s  w i th in  2 4  h o u r s  o f  l e a r n i n g  o f  i t s  o c c u r r e n c ea s  d e s c r ib e d  b e l ow.  Any S AE s  
e x p e r i e n c e d  a f t e r  th i sshou ld  on ly  b e  r e p o r t e d  to  N o v a r t i s  i f  th e  inv e s t ig a to r  s u sp e c t s  a  c a u s a l  
r e l a t i o n s h i p  to  s tudy  t r e a tm e n t .  
R e c u r r e n t  e p i s o d e s ,  comp l i c a t ion s ,  o r  p r o g r e s s i o n  o f  t h e  in i t i a l  SAE  mu s t  b e  r e p o r t e d  a s  
f o l l ow - u p  to  t h e  o r i g i n a l  e p i s o d e ,  r e g a r d l e s s  o f  w h e n  t h e  e v e n t  o c c u r s .  Th i s  r e p o r t  mu s t  b e  
subm i t t ed  w i th in  2 4  hou r s  o f  th e  inv e s t ig a to r  r e c e iv in g  th e  f o l l ow - u p  in fo rm a t ion .  A n  SAE  
t h a t  i s  c o n s i d e r e d  comp l e t e ly  u n r e l a t ed  to  a  p r ev iou s ly  r e p o r t e d  on e  shou ld  b e  r e p o r t e d  
s ep a r a t e ly  a s  a  n ew  ev en t .
SAE s  ( i n i t i a l  a n d  f o l l ow - u p )  t h a t  a r e  r e c o r d e d  e l e c t r o n i c a l l yin  th e  E l e c t ron i cD a t aC ap tu r e  
sy s t em  s h o u l d  b e  e n t e r e d ,  s a v e d  a n d  e - s i g n e d  w i th in  2 4  h o u r s  o f  aw a r e n e s s  o f  t h e  SAE  o r  
c h a n g e s  to  a n  e x i s t i n g  SAE .  T h e s e  d a t a  w i l l  au tom a t i c a l ly  b e  subm i t t ed  to  Nov a r t i s  D r u g  
S a f e ty &  E p id em io logy  imm ed i a t e ly  a f t e r  inv e s t ig a to r  s i g n a t u r e  o r  24  h o u r s  a f t e ren t ry ,  
w h i c h e v e r  o c c u r s  f i r s t.  S tudy s i t e  p e r s o n n e l  m u s t  a l s o  i n f o rmt h e  C l i n i c a l  T r i a l  L e ad e r .
F o l l ow-up  in fo rm a t ion  p rov id ed  shou ld  d e s c r ib e  wh e th e r  th e  ev en t  h a s  r e so lv ed  o r  con t inu e s ,  
i f  a n d  h ow  i t  w a s  t r e a t ed ,  w h e t h e r  t h e  t r e a tm en t  c o d e  w a s  b rok en  or  no t  a n d  w h e t h e r  th e  
s u b j e c tc o n t i n u e d  o r  w i t h d r ew  f r om  s tudy  p a r t i c i p a t i o n .  E a c h  r e - o c c u r r e n c e ,  c om p l i c a t i o n ,  o r  
p r o g r e s s i o n  o f  t h e  o r ig in a l  e v e n t  s h o u l d  b e  r epo r t ed  a s  a  f o l l ow - u p  to  t h a t  e v e n t  r e g a r d l e s s  o f  
w h e n  i t  o c c u r s .
I f  t h e  SAE  i s  no t  p r ev iou s ly  d o c um e n t e d  in  th e  I n v e s t i g a t o r ’ s  B r o c h u r e  o r  P a c k a g e  I n s e r t  
( n ew  o c c u r r e n c e )  a n d  i s  t h o u g h t  to  b e  r e l a t e d  to  t h e  i n v e s t ig a t i o n a l  t r e a tm e n t  a  D rug  S a f e ty  
a n d  Ep id em io logy D e p a r tm e n t  a s s o c i a t e  m ay u r g e n t l y  r e q u i r e  f u r t h e r  i n f o rm a t i o n  f r om  th e  
i n v e s t i g a t o r  f o r  H e a l th  Au tho r i ty r e p o r t i n g .  Nov a r t i s  m ay n e e d  to  i s s u e  a n  I n v e s t ig a t o r  
N o t i f i c a t i o n  ( IN )  to  i n f o rm  a l l  i n v e s t i g a t o r s  in v o l v e d  in  any  s tudy  w i th  t h e  s am e  
i n v e s t i g a t i o n a l  t r e a tm en t  t h a t  th i s  SAE  h a s  b e e n  r e p o r t e d .Su sp e c t ed  U n e x p e c t e d  S e r i o u s  
A d v e r s e  R e a c tion s  (S[LOCATION_003]R s )  w i l l  b e  c o l l e c t e d  and  r e p o r t e d  to  t h e  comp e t en t  a u th o r i t i e s  a n d  
r e l e v a n t  e t h i c s  c omm i t t e e s  in  a c c o r d a n c e  w i th  EU  G u i d a n c e  2011 /C  1 7 2 / 0 1  o r  a s  p e r  n a t i o n a l  
r egu l a to ry  r e q u i r em e n t s  i n  p a r t i c i p a t i n g  c o u n t r i e s .
No va r t i s Con f iden t ia l Page  46
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
[ADDRESS_1133195] i z ed  p r o c e s s  f o r  id en t i f i c a t ion ,  mon i to r ing  a n d  e v a l u a t i o n  o f  
l i v e r  e v e n t s  h a s  t o  b e  f o l l ow e d .  
T h e  f o l l ow i n g  tw o  c a t ego r i e s  o f  a b n o rm a l i t i e s  /  a d v e r s e  ev en t s  h a v e  to  b e  c o n s i d e r e d  du r ing  
t h e  c o u r s e  o f  t h e  s t u d y :
L iv e r  l abo r a to ry t r i g g e r s ,  w h i c h  w i l l  r e q u i r e  r e p e a t e d  a s s e s sm e n t s  o f  t h e  a b n o rm a l  
l abo r a to ry  p a r am e t e r
L i v e r  e v e n t s ,  w h i c h  w i l l  r e q u i r e  c l o s e  o b s e r v a t i o n ,  f o l l ow -up  mon i to r i n g  a n d  c om p l e t i o n  
o f  t h e  s t a n d a r d  b a s e  l i v e r  CRF  p a g e s
P l e a s e  r e f e r  toT a b l e  9 -1a n d  T a b l e  9 - 2fo r  comp l e t e  d e f i n i t i o n s  o f  l i v e r  l abo r a to ry  t r i g g e r s  
a n d  l i v e r  ev en t s .  
Ev e ry l i v e r  l abo r a to ry  t r i g g e r  o r  l iv e r  ev en t  shou ld  b e  fo l low ed  up  by  t h e  i n v e s t i g a t o r  o r  
d e s i g n a t e d  p e r s o n a l  a t  t h e  t r i a l  s i t e ,  a s  s umm a r i z e d  b e l ow  a n d  d e t a i l e d  i n  inT a b l e  9- 2 .
Fo r  the  l ive r  labo ra to ry t r igge r :
 R e p e a t i n g  t h e  LFT  w i t h i n  t h e  n e x t  w e e k  t o  c o n f i rm  e l e v a t i o n .
T h e s e  LFT  r e p e a t s  shou ld  b e  p e r f o rm e d  u s ing  th e  c e n t r a l  l abo r a to ry  i f  po s s ib l e .  I f  t h i s  i s  n o t  
p o s s i b l e ,  t h e n  t h e  r e p e a t s  c a n  b e  p e r f o rm e d  a t  a  l o c a l  l abo r a to ryto  m o n i t o r  t h e  s a f e t y  o f  th e  
p a t i e n t .  R e p e a t s  l abo r a to ry  shou ld  th en  b e  p e r fo rm ed  a t  c en t r a l  l abo r a to ry  a s  soon  a s  po s s ib l e .  
I f  a  l iv e r  ev en t  i s  sub s equ en t ly  r e p o r t e d ,  a n y  l o c a l  LFT s  p r e v i o u s ly  c o n d u c t e d  t h a t  a r e  
a s s o c i a t e d  w i t h  t h i s  e v e n t  s h o u l d  b e  r e p o r t ed  on  th e  L iv e r  CRF  p ag e s .
Fo r  the  l ive r  even ts :
R e p e a t i n g  t h e  LFT  t o  c o n f i rm  e l e v a t i o n  a s  a p p r o p r i a t e
D i s c o n t i n u a t i o n  o f  t h e  i n v e s t i g a t i o n a l  d r u g( r e f e r  t o  S e c t i o n  7 . 1,i f  a p p r o p r i a t e
Ho sp i t a l i z a t iono f  t h e  s u b j e c ti f  a p p r o p r i a t e
A  c a u s a l i ty  a s s e s sm e n t  o f  t h e  l i v e r  e v e n t  v i a  e x c l u si o n  o f  a l t e r n a t i v e  c a u s e s  ( e . g .d i s e a s e ,  
c o - m ed i c a t ion s )
A n  i n v e s t i g a t i o n  o f  t h e  l i v e r  e v e n t  w h i c h  n e e d s  t o  b e  f o l l ow e d  u n t i l  r e s o l u t i o n .  
T h e s e  i n v e s t i g a t i o n s  c an  i n c l u d e  s e ro logy  t e s t s ,  im a g i n g  a n d  p a tho logy  a s s e s sm en t s ,  
h e p a t o l o g i s t ’ s  c o n s u l t a n c y ,  b a s e d  o n  i n v e s t i g a t o r ’ s  d i s c r e t i o n .  A l l  f o l l ow - u p  i n f o rm a t i o n ,  a n d  
t h e  p r o c e d u r e s  p e r fo rm ed  s h o u l d  b e  r e c o r d e d  a s  a p p r o p r i a t e  in  th e  CRF,  i n c l u d i n g  th e  l iv e r  
e v e n t  o v e r v i ew  CRF  p ag e s .
No va r t i s Con f iden t ia l Page  47
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
Tab le  9 -1 L ive r  Even t  and  Labo ra to ry T r igge r  De f in i t ions
De f in i t ion /  th resho ld
L ive r  labo ra to ry  t r igge rs [ADDRESS_1133196]  <  ALT  /  AST  [ADDRESS_1133197]
[ADDRESS_1133198]  <  TBL  [ADDRESS_1133199]
L ive r  even ts ALT  o r  AST  >  5  ×  ULN
ALP  >  2  ×  ULN  ( in  the  absence  o f  known  bone  pa tho logy )
TBL  >  2  ×  ULN  ( in  the  absence  o f  known  G i lbe r t  synd rome )
ALT  o r  AST  >  3  ×  ULN  and  INR  >  1 .5  
Po ten t ia l  Hy ’s  Law  cases  (de f ined  as  ALT  o r  AST  >  3  ×  ULN  and  
TBL  >  2  ×  ULN  [ma in ly  con juga ted  f rac t ion ]  w i thou t  no tab le  inc rease  
in  ALP  to  >  2  ×  ULN )
Any  c l in ica l  even t  o f  jaund ice  (o r  equ iva len t  te rm )
ALT  o r  AST  >  3  ×  ULN  accompan ied  by  (gene ra l )  ma la ise ,  fa t igue ,  
abdomina l  pa in ,  nausea ,  o r  vom i t ing ,  o r  rash  w i th  e os inoph i l ia
Any  adve rse  even t  po ten t ia l ly  ind ica t ive  o f  a  l ive r  tox ic i ty  *  
Tab le  9 -2 Fo l low  Up  Requ i remen ts  fo r  L ive r  Even ts  and  Labo ra to ry T r igge rs
C r i te r ia Ac t ions  requ i red Fo l low- up  mon i to r ing
Po ten t ia l  Hy ’s  Law  
caseaD iscon t inue  the  s tudy  d rug  
immed ia te ly
Hosp i ta l ize ,  i f  c l in ica l ly  app rop r ia te
Es tab l ish  causa l i ty
Comp le te  l ive r  CRFALT ,  AST ,  TBL ,  A lb ,  PT / INR ,  ALP  
and  γGT  un t i l  reso lu t ionc( f requency  
a t  inves t iga to r  d isc re t ion )
ALT  o r  AST
>  8  ×ULN D iscon t inue  the  s tudy  d rug  
immed ia te ly
Hosp i ta l ize  i f  c l in ica l ly  app rop r ia te
Es tab l ish  causa l i ty
Comp le te  l ive r  CRFALT ,  AST ,  TBL ,  A lb ,  PT / INR ,  ALP  
and  γGT  un t i l  reso lu t ionc( f requency  
a t  inves t iga to r  d isc re t ion )
>  3  ×  ULN  and  
INR  >  1 .5D iscon t inue  the  s tudy  d rug  
immed ia te ly
Hosp i ta l ize ,  i f  c l in ica l ly  app rop r ia te
Es tab l ish  causa l i ty
Comp le te  l ive r  CRFALT ,  AST ,  TBL ,  A lb ,  PT / INR ,  ALP  
and  γGT  un t i l  reso lu t ionc( f requency  
a t  inves t iga to r  d isc re t ion )
>  5  to  ≤  8  ×ULN Repea t  LFT  w i th in  48  hou rs
I f  e leva t ion  pe rs is ts ,  con t inue  fo l low -
up  mon i to r ing
I f  e leva t ion  pe rs is ts  fo r  mo re  than  2  
weeks,  d iscon t inue  the  s tudy  d rug
Es tab l ish  causa l i ty
Comp le te  l ive r  CRFALT ,  AST ,  TBL ,  A lb ,  PT / INR ,  ALP  
and  γGT  un t i l  reso lu t ionc( f requency  
a t  inves t iga to r  d isc re t ion )
No va r t i s Con f iden t ia l Page  48
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
C r i te r ia Ac t ions  requ i red Fo l low- up  mon i to r ing
>  3  ×ULN
accompan ied  by  
[CONTACT_818259]D iscon t inue  the  s tudy  d rug  
immed ia te ly
Hosp i ta l ize  i f  c l in ica l ly  app rop r ia te
Es tab l ish  causa l i ty
Comp le te  l ive r  CRFALT ,  AST ,  TBL ,  A lb ,  PT / INR ,ALP  
and  γGT  un t i l  reso lu t ionc( f requency  
a t  inves t iga to r  d isc re t ion )
>  3  to  ≤  5  ×ULN  
(pa t ien t  is  
asymptoma t ic )Repea t  LFT  w i th in  the  nex t  week
I f  e leva t ion  is  con f i rmed ,  in i t ia te  c lose  
obse rva t ion  o f  the  pa t ien tInves t iga to r  d isc re t ion
Mon i to r  LFT  w i th in  1  to  4  weeks  
ALP  ( iso la ted )
>  2  ×  ULN( in  the  
absence  o f  known  
bone  pa tho logy )Repea t  LFT  w i th in  48  hou rs
I f  e leva t ion  pe rs is ts ,  es tab l ish  
causa l i ty
Comp le te  l ive r  CRFInves t iga to r  d isc re t ion
Mon i to r  LFT  w i th in  1  to  4  weeks  o r  
a t  nex t  v is i t
TBL  ( iso la ted )
>  2  ×  ULN  ( in  the  
absence  o f  known  
G i lbe r t  synd rome )Repea t  LFT  w i th in  48  hou rs
I f  e leva t ion  pe rs is ts ,  d iscon t inue  the  
s tudy  d rug  immed ia te ly
Hosp i ta l ize  i f  c l in ica l ly  app rop r ia te
Es tab l ish  causa l i ty
Comp le te  l ive r  CRFALT ,  AST ,  TBL ,  A lb ,  PT / INR ,  ALP  
and  γGT  un t i l  reso lu t ionc( f requency  
a t  inves t iga to r  d isc re t ion )
Tes t  fo r  hemo lys is  (e .g .  
re t icu locy tes ,  hap tog lob in ,  
uncon juga ted  [ ind i rec t ]  b i l i rub in )
>  1 .5  to  ≤  2  ×ULN
(pa t ien t  is  
asymptoma t ic )Repea t  LFT  w i th in  the  nex t  wee k
I f  e leva t ion  is  con f i rmed ,  in i t ia te  c lose  
obse rva t ion  o f  the  pa t ien tInves t iga to r  d isc re t ion
Mon i to r  LFT  w i th in  1  to  4  weeks  o r  
a t  nex t  v is i t
Jaund ice D iscon t inue  the  s tudy  d rug  
immed ia te ly
Hosp i ta l ize  the  pa t ien t
Es tab l ish  causa l i ty
Comp le te  l ive r  CRFALT ,  AST ,  TBL ,  A lb ,  PT / INR ,  ALP  
and  γGT  un t i l  reso lu t ionc( f requency  
a t  inves t iga to r  d isc re t ion )
Any  AE  po ten t ia l l y  
ind ica t ive  o f  a  l ive r  
tox ic i ty *Cons ide r  s tudy  d rug  in te r rup t ion  o r  
d iscon t inua t ion  
Hosp i ta l iza t ion  i f  c l in ica l ly  app rop r ia te
Es tab l ish  causa l i ty
Comp le te  l ive r  CRFInves t iga to r  d isc re t ion
*These  even ts  cove r  the  fo l low ing :  hepa t ic  fa i lu re ,  f ib ros is  and  c i r rhos is ,  and  o the r  l ive r  damage -
re la ted  cond i t ions ;  the  non - in fec t ious  hepa t i t is ;  the  ben ign ,  ma l ignan t  and  unspec i f ied  l ive rneop lasms
aE leva ted  ALT /AST  >  3  ×  ULN  and  TBL  >  2  ×  ULN  bu t  w i thou t  no tab le  inc rease  in  ALP  to  >  2  ×  ULN
b(Gene ra l )  ma la ise ,  fa t igue ,  abdom ina l  pa in ,  nausea ,  o r  vom i t ing ,  o r  rash  w i th  eos inoph i l ia  
cReso lu t ion  is  de f ined  as  an  ou tcome  o f  one  o f  the  fo l low ing :  (1 )re tu rn  to  base l ine  va lues ,  (2 )s tab le  
va lues  a t  th ree  subsequen t  mon i to r ing  v is i ts  a t  leas t  2  weeks  apa r t ,  (3 )  rema in  a t  e leva ted  leve l  a f te r  a  
max imum o f  6  mon ths ,  (4 )  l ive r  t ransp lan ta t ion ,  and  (5 )  dea th .
No va r t i s Con f iden t ia l Page  49
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
9 .4 Rena l  sa fe ty mon i to r ing
R e n a l  e v e n t s  a r e  d e f i n e d  a s  o n e  o f  t h e  f o l l ow i n g :
c o n f i rm e d  ( a f t e r  ≥  2 4 h )  i n c r e a s e  i n  s e r um  c r e a t i n i n e  o f  ≥  2 5%  c om p a r e d  t o  b a s e l i n e  
d u r i n g  n o rm a l  h y d r a t ion  s t a tu s
n ew  o n s e t  (≥ 1+ )  p r o t e i n u r i a ,  h em a t u r i a  o r  g l u c o s u r i a ;  o r  a s  a
d o u b l i n g  i n  t h e  u r i n a r y  a lbum in - c r e a t in in e  r a t io  (ACR )  o r  u r in a ry  p r o t e i n - c r e a t i n i n e  r a t i o  
(PCR )  ( i f  a p p l i c a b l e ) .
T h e  f o l l ow i n g  tw o  c a t e g o r i e s  o f  a b n o rm a l i t i e s / a d v e r s e  e v e n t s  h a v e  to  b e  c o n s i d e r e d  d u r i ng  
t h e  c o u r s e  o f  t h e  s t u d y :
S e r um  c r e a t i n i n e  t r i g g e r s  t h a t  w i l l  r e q u i r e  f o l l ow  u p  a n d  r e p e at  a s s e s sm e n t s  o f  t h e  
abno rm a l  l abo r a to ry  p a r am e t e r  
U r i n e  d i p s t i c k  t r i g g e r s  t h a t  w i l l  r e q u i r e  f o l l ow  u p  a n d  r e p e a t  a s s e s sm e n t s  o f  t h e  a b n o rm a l  
l abo r a to ry  p a r am e t e r
Tab le  9 -3 Spec i f ic  Rena l  Ale r t  C r i te r ia  and  A c t ions
Rena l  Even t Ac tions
Se rum  c rea t in ine  inc rease
25  –49%  compa red  to  base l ineCon f i rm  25%  inc rease  a f te r  24- 48h  
Fo l low  up  w i th in  2- 5  days
Se rum  c rea t in ine  inc rease   50  %  
compa red  to  base l ineFo l low  up  w i th in  24- 48h  i f  poss ib le
Cons ide r  d rug  in te r rup t ion  
Cons ide r  pa t ien t  hosp i ta l iza t ion  /spec ia l ized  t rea tmen t
A lbum in-o r  P ro te in- c rea t in ine  ra t io  
in c rea se  ≥  2- fo ld
A lbum in- c rea t in ine  ra t io  (ACR )  ≥  30  mg /g  
o r  ≥  3  mg /mmo l ;
New  d ips t ick  p ro te inu r ia  ≥  1+
P ro te in- c rea t in ine  ra t io  (PCR  )≥  150  mg /g  
o r  >15  mg /mmo lCon f i rm  va lue  a f te r  24- 48h
Pe r fo rm  u r ine  m ic roscopy
Cons ide r  d rug  in te r rup t ion  /  d iscon t inua t ion  
New  d ips t ick  g lucosu r ia  ≥  1+  no t  due  to  
d iabe te sB lood  g lucose  ( fas t ing )
Pe r fo rm  se rum  c rea t in ine ,  ACR  
New  d ips t ick  hema tu r ia  no t  due  to  t rauma U r ine  sed imen t  m ic roscopy
Pe r fo rm  se rum  c rea t in ine ,  ACR  
Documen t  con t r ibu t ing  fac to rs :  co- med ica t ion ,  o the r  co- morb id  cond i t ions ,  and  add i t iona l  d iagnos t ic  
p rocedu res  pe r fo rmed  in  the  CRF
Mon i to r  pa t ien t  regu la r ly  ( f requency  a t  inves t iga to r ’s  d isc re t ion )  un t i l  one  o f  the  fo l low ing :
Even t  reso lu t ion :  (sC r  w i th in  10%  o f  base l ine  o r  p ro te in- c rea t in ine  ra t io  w i th in  50%  o f  base l ine )  
Even t  s tab i l iza t ion :  sC r  leve l  w i th  ±10%  va r iab i l i ty  ove r  las t  6  mon ths  o r  p ro te in- c rea tin ine  ra t io  
s tab i l iza t ion  a t  a  new  leve l  w i th  ±50%  va r iab i l i ty  ove r  las t  6  mon ths .
No va r t i s Con f iden t ia l Page  50
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
9 .5 P regnancy repo r t ing
P r egn an cy o u t c om e s  mu s t  b e  co l l e c t ed  fo r  t h e  f em a l e  p a r t n e r s  o f  a n y  m a l e s  w h o  took  s tudy  
t r e a tm e n tin  th i s  s tudy .  C o n s e n t  to  r e p o r t  i n f o rm a t i o n  r e g a r d i n g  t h e s e  p r egn an cy  o u t com e s  
s h o u l d  b e  o b t a i n e d  f rom  t h e  m o t h e r .Th e  p r egn an cy  s h o u l d  b e  fo l low ed  u p  to  d e t e rm in e  
o u t c om e ,  i n c l u d i n g  spon t an eou s  o r  vo lun t a ry  t e rm i n a t i o n ,  d e t a i l s  o f  t h e  b i r t h ,  and  th e  
p r e s e n c e  o r  a b s e n c e  o f  any  b i r t h  d e f e c t s ,  c o n g e n it a l  a b n o rm a l i t i e s ,  o r  m a t e r n a l  and /o r  
n ew b o r n  c om p l i c a t i o n s .
9 .6 P rospec t ive  su ic ida l i ty assessmen t
T h e  Co lumb i a-S u i c i d e  S e v e r i ty  R a t ing  S c a l e  (C - SSRS ) ,  i sa  q u e s t i o n n a i r e  t h a t  p r o s p e c t i v e l y  
a s s e s s e s  S u i c i d a l  I d e a t i o n  a n d  S u i c i d a l  B e h a v i o r .  
T h e  C -SSRS ,  w h i c h  u s e s  a  s em i - s t r u c t u r e d  in t e rv i ew  to  p rob e  s u b j e c tr e s p o n s e s ,  w i l l  b e  
adm in i s t e r ed  by  a n  ind iv idu a l  who  h a s  r e c e iv ed  t r a in ing  and  c e r t i f i c a t ion  in  i t s  adm in i s t r a t ion .  
A t  s c r e e n i n g  a n d  b a s e l i n e  v i s i t s,  t h e  “ b a s e l i n e / s c r e e n i n g ”  v e r s i o n  o f  t h e  C -SSRS ,  w i l l  b e  
a dm i n i s t e r e d .  Th i s  v e r s i o n  a s s e s s e s  S u i c i d a l  I d e a t i o n  a n d  S u i c i d a l  B e h a v i o r  d u r i n g  th e  
s u b j e c t ’ s  l i f e t im e  a n d  d u r i n g  a  p r e d e f i n e d  p e r iod .  A t  su b s e q u e n t  v i s i t s ,  t h e  “ s i n c e  l a s t  v i s i t ”  
v e r s i o n  w i l l  b e  a dm i n i s t e r e d .
I f ,  a t  any  t im e  a f t e r  s c r e e n i n g  a n d / o r  b a s el i n e ,  t h e  s c o r e  i s  “y e s ”  o n  i t em  4  o r  i t em  5  o f  t h e  
Su i c id a l  Id e a t ion  s e c t ion  o f  th e  C- SSRS  o r  “ye s ”  on  any  i t em  o f  th e  Su i c id a l  B eh av io r  s e c t ion ,  
t h e  s u b j e c tmu s tb e  r e f e r r ed  to  a  m en t a l  h e a l t h  c a r e  p r o f e s s i o n a lf o r  fu r th e r  a s s e s sm en t  and /o r  
t r e a tm e n t .  T he  d e c i s ion  o n  w h e t h e r  th e  s tudy  t r e a tm e n t  s h o u l d  b e  d i s con t inu ed  i s  to  b e  t ak en  
by  t h e  i n v e s t i g a t o r  in  con su l t a t ion  w i th  t h e  m e n t a l  h e a l t h  p r o f e s s i o n a lto  w h om  t h e  s u b j e c ti s  
r e f e r r e d .
I n  a dd i t ion ,  a l l  l i f e - t h r e a t e n i n g  e v e n t s  shou ld  b e  r e p o r t e d  a s  SAE s .  F or  ex amp l e ,  i f  a  sub j e c t
a n sw e r s  “y e s ”  to  o n e  o f  t h e  q u e s t i o n s  in  t h e  S u i c i d a l  B e h a v i o r  s e c t ion ,  a n  SAE  mu s t  b e  
r e p o r t e d  i f  th e  ev en t  w a s  l i f e - t h r e a t e n i n g .  A l l  e v e n t s  o f  “N o n - Su i c id a l  S e l f- I n j u r i o u s  
B eh av io r ”  (qu e s t ion  a l so  in c lud ed  in  th e  Su i c id a l  B eh av io rs e c t ion )  shou ld  b e  r epo r t ed  a s  AE s  
a n d  a s s i g n e d  t h e  a p p r o p r i a t e  s e v e r i t y  g r a d e .
A l l  SAE s  r e l a t i n g  to  su i c id a l  b e h a v i o r  s h o u l d  b e  r e v i ew e d  by  t h e  S a f e ty M a n a g em e n t  T e am  
o r  Ea r l y  Pr o j e c t  Te am s .
9 .7 Ea r ly  phase  sa fe ty m on i to r ing
T h e  Inv e s t ig a to r  w i l l  mon i to r  adv e r s e  ev en t s  in  an  ongo ing  m ann e r  and  in fo rm  th e  Spon so r  o f  
any  c l in i c a l ly  r e l e v a n t  o b s e r v a t i o n s .  A ny  r eq u i r e d  s a f e t y  r e v i ew s  w i l l  b e  m ad e  jo in t ly  
b e tw e e n  m ed i c a l ly  qu a l i f i ed  p e r s o n n e l  r e p r e s e n t i n g  th e  Spon so r  a n dI n v e s t i g a t o r .  
S u c he v a l u a t i o n s  m ay o c c u r  v er b a l l y ,  bu t  t h e  o u t c om e  a n d  k ey  d i s cu s s ion  po in t s  w i l l  b e  
s umm a r i z e d  in  w r i t i n g  ( e - m a i l )  a n d  m ad e  a v a i l a b l e  to  bo th  S p o n s o r  and  a l l  I n v e s t i g a to r ( s ) .  
C r i t e r i a  p e r t a i n i n g  to  s topp ing  t h e  s tudy / t r e a tm en t  o r  a d a p t i n g  t h e  s tudy  d e s i g n  a r e  p r e s en t ed  
a b o v e .
No va r t i s Con f iden t ia l Page  51
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
Wh en  tw o  o r  m o r e  c l i n i c a l  s i t e ( s )  a r e  p a r t i c i p a t i n g  in  t h e  c l i n i c a l  s t u d y ,  t h e  S p o n s o r  w i l l  
a d v i s e  t h e  I n v e s t i g a t o r ( s )  a t  a l l  s i t e s  in  w r i t i n g  ( e - m a i l )  ( a n d  by  t e l e p h o n e  i f  p o s s i b l e )  o f  a n y  
n ew ,  c l in i c a l ly  r e l e v a n t  s a f e t y  in fo rm a t ion  r e p o r t e d  f r om  a n o t h e r  s i t e  d u r i n g  t h e  c o n d u c t  o f  
th e  s tudy  i n  a  t im e l y  m a n n e r .
10 Da ta  rev iew  and  da tabase  managemen t
10 .1 S i te  mon i to r ing
B e f o r e  s tudy  i n i t i a t ion ,  a t  a  s i t e  in i t i a t ion  v i s i t  o r  a t  a n  i n v e s t i g a t o r ’ s  m e e t i n g ,  a  Nov a r t i s  
r e p r e s e n t a t i v e  w i l l  r ev i ew  t h e  p r o t o c o l  a n d  CRF s  w i th  t h e  i n v e s t ig a to r s  a n d  t h e i r  s t a f f .  
D u r i n gth e  s tudyNov a r t i s  emp loy s  s ev e r a l  m e t h o d s  o f  e n s u r i n g  p r o to c o l  a n d  GCP  
c om p l i a n c e  a n d  t h e  qu a l i ty / i n t e g r i t y  o f  t h e  s i t e s ’  d a t a .  T h em o n i t o r  w i l l  v i s i t  t h e  s i t e  to  c h e c k  
t h e  c om p l e t e n e s s  o f  sub j e c tr e c o r d s ,  th e  a c c u r a cy  o f  e n t r i e s  on  th e  CRF s ,  th e  adh e r en c e  to  th e  
p r o t o c o l  a n d  to  G o o d  C l i n i c a l  P r a c t i c e ,  th e  p r o g r e s s  o f  e n r o l lm e n t ,  a n d  to  e n s u r e  t h a t  s tud y  
d r u g  i s  b e i n g  s t o r e d ,  d i sp en s ed ,  a n d  a c c o u n t e d  f o r  a c c o r d i n g  to  s p e c i f i c a t i o n s .  K ey s tudy  
p e r s o n n e l  m u s t  b e  a v a il ab l e  t o  a s s i s t  t h e  m o n i t o r  d u r i n g  t h e s e  v i s i t s .
T h e  i n v e s t i g a t o r  mu s t  m a i n t a i n  s o u r c e  do cum en t s  f o r  e a ch  sub j e c t  in  t h e  s tudy ,  c o n s i s t in g  o f  
c a s e  a n d  v i s i t  n o t e s  ( h o s p i t a l  o r  c l i n i c  m e d i c a l  r e c o r d s )  c o n t a i n i n g  d em o g r a p h i c  a n d  m ed i c a l  
i n f o rm a t i o n ,  l a b o r a t o ry  d a t a ,  e l e c t r o c a r d i o g r am s ,  a n d  t h e  r e s u l t s  o f  any  o th e r  t e s t s  o r  
a s s e s sm e n t s .  A l l  in fo rm a t ion  o n  CRF s  mu s t  b e  t r a c e a b l e  to  t h e s e  sou r c e  d o c um en t s  in  th e  
s u b j e c t ' s  f i l e .  Th e  i n v e s t i g a t o r  mu s t  a l s o  k e e p  th e  o r i g i n a l  i n f o rm e d  con s en t  f o rm  s i g n e d  by  
t h e  s u b j e c t  ( a  s i g n e d  c o p y  i s  g iv en  to  th e  sub j e c t ) .
T h e  i n v e s t i g a t o r  mu s t  g iv e  t h e  m o n i t o r  a c c e s s  to  a l l  r e l e v a n t  s o u r c e  do cum en t s  to  c o n f i rm  
t h e i r  con s i s t en cy  w i th  t h e  CRF  e n t r i e s .  N o v a r t i s  m o n i t o r i n g  s t a n d a r d s  r e q u i r e  f u l l  v e r i f i c a t i o n  
f o r  t h e  p r e s en c e  o f  in fo r m e d  c o n s e n t ,  a d h e r e n c e  to  t h e  e l ig ib i l i tyc r i t e r i a ,  d o c um e n t a t i o n  o f  
SAE s ,  a n d  t h e  r e c o r d i n g  o f  d a t a  t h a t  w i l l  b e  u s e d  f o r  a l l  p r im a ry  a nd  s a f e t y  v a r i ab l e s .  
A d d i t i o n a l  c h e c k s  o f  th e  con s i s t en cy  o f  t h e  s o u r c e  d a t a  w i th  t h e  CRF s  a r e  p e r fo rm ed  
a c c o r d i n g  to  th e  s tudy - s p e c i f i c  mon i to r ing  p l an .  N o  i n f o rm a t i o n  in  sou r c e  d o c um e n t s  a b o u t  
th e  id en t i ty  o f  t h e  s u b j e c t s  w i l l  b e  d i s c l o s e d .
[ADDRESS_1133200] a t ab a s e  l o c k ,  th e  i n v e s t i g a t o r  w i l l  r e c e iv e  a  CD- ROM  o r  p ap e r  cop i e s  o f  th e  p a t i e n t
d a t a  f o r  a r c h i v i n g  a t  t h e  i n v e s t i g a t i o n a l  s i t e .
No va r t i s Con f iden t ia l Page  52
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
D a t a  no t  r equ i r ing  a  s ep a r a t e  w r i t t en  r e co rd  w i l l  b e  d e f in ed  in  th e  S i t e  Op e r a t ion s  M anu a l  and  
A s s e s sm e n t  s c h e d u l e
C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o nand  c a nb e  r e c o r d e d  d i r e c t ly  o n  th e  CRF s .A l l  o th e r  d a t a  c a p t u r e d  fo r  
th i s  s tudy  w i l l  h a v e  a n  ex t e rn a l  o r i g i n a t i n g  s o u r c e  ( e i t h e r  w r i t t en  o r  e l e c t ron i c )w i tht h e  CRF  
no t  b e i n g  c o n s i d e r e d  a s  s o u r c e .
A l l  d a t a  s h o u l d  b e  r e c o r d e d ,  h and l ed  a n d  s to r ed  in  a  w ay t h a t  a l l ow s  i t s  a c c u r a t e  r epo r t ing ,  
i n t e r p r e t a t i o n  a n d  v e r i f i c a t i o n .
CRO  w o r k i n g  o n  b e h a l f  o f  N o v a r t i s  w i l lr e v i ew  t h e  d a t a  e n t e r e d  in to  t h e  eCRF s  by  
i n v e s t i g a t i o n a l  s t a f f  f o r  c om p l e t e n e s s  a n d  a c cu r a cy  and  in s t ru c t  th e  s i t e  p e r sonn e l  to  m ak e  any  
r e q u i r e d  c o r r e c t i o n s  o r  a d d i t i o n s .  Q u e r i e s  a r e  s e n t  to  t h e  inv e s t ig a t ion a l  s i t e  u s ing  an  
e l e c t ron i c  d a t a  qu e ry .  D e s ign a t ed  inv e s t ig a to r  s i t e  s t a f f  i s  r equ i r ed  to  r e spond  to  th e  qu e ry  a n d  
c o n f i rm  o r  c o r r e c tth e  d a t a .  I f  t h e  e l e c t r o n i c  qu e ry  s y s t em  i s  no t  u s e d ,  a  p a p e r  D a t a  Qu e ry  
F o rm  w i l l  b e  f ax ed  to  th e  s i t e .  S i t e  p e r sonn e l  w i l l  comp l e t e  and  s ign  th e  f ax ed  copy  a nd  f ax  i t  
b a c k  t o  th eCRO  w o r k i n g  o n  b e h a l f  o f  N o v a r t i sw h o  w i l l  m a k e  t h e  c o r r e c t i o n  t o  t h e  d a t a b a s e .
C o n c om i t a n t  m e d i c a t i o n s  e n t e r e d  in to  t h e  d a t a b a s e  w i l l  b e  c o d e d  u s i n g  t h e  WHO  D rug  
R e f e r e n c e  L is t ,  w h i c h  emp loy s  t h e  A n a t om i c a l  T h e r a p e u t i c  C h em i c a l  c l a s s i f i c a t i o n  sy s t em .  
M e d i c a l  h i s to ry / cu r r en t  m e d i c a l  c o n d i t i o n s  a n d  a d v e r s e  ev en t s  w i l l  b e  c o d e d  u si n g  th e  
M ed i c a l  d i c t ion a ry fo r  r egu l a to ry  a c t iv i t i e s  (M edDRA )  t e rm ino logy .
L abo r a to ry s am p l e s  w i l l  b e  p r o c e s s e d  c e n t r a l l y  a n d  t h e  r e s u l t s  w i l l  b e  s e n t  e l e c t ron i c a l ly  t o  
N o v a r t i s  ( o r  a  d e s i g n a t e d  CRO ) .
R andom i z a t ion  c o d e s  w i l l  b e  t r a c k e d  u s ing  I n t e r a c t i v eRe spon s e  T e c h n o l o g y ( IRT ) .  
T h esy s t em  w i l l  b e  supp l i ed  by  a  v endo r ,  who  w i ll  a l s o  m a n a g e  th e  d a t ab a s e .  T h ed a t ab a s e  
w i l l  b e  s e n t  e l e c t r o n i c a l l y  t o  N o v a r t i s  ( o r  a  d e s i g n a t e d  CRO ) .
ABPM  d a t a  w i l l  b e  c o l l e c t e d  by  a  d e s i g n a t e d  CRO  a n d  t h e  r e s u l t s  w i l l  b e  s e n t  e l e c t r o n i c a l l y  
t o  N o v a r t i s  a n d  t h e  d a t a  m a n a g em e n t  CRO
E a c h  o c c u r r e n c e  o f  a  cod e  b r e a k  v i a  IRT  w i l l  b e  r e p o r t e d  to  t h e  c l in i c a l  t e am  a n d  mon i to r .  
T h ec o d e  b r e ak  fun c t ion a l i ty  w i l l  r em a in  a v a i l a b l e  un t i l  s tudy  s hu t  down  o r  u p o n  r e q u e s t  o f  
N o v a r t i s .
T h eo c c ur r e n c e  o f  a n y  p ro to co l  d e v i a t i o n s  w i l l  b e  d e t e rm i n e d .  A f t e r  t h e s e  a c t i o n s  h a v e  b e en  
c om p l e t e d  a n d  th e  d a t a b a s e  h a s  b e en  d e c l a r e d  to  b e  comp l e t e  a n d  a c c u r a t e ,  i t  w i l l  b e  lo ck ed  
a n d  t h e  t r e a tm e n t  c o d e s  w i l l  b e  u n b l i n d e d  a n d  m a d e  a v a i l a b l e  f o r  d a t a  an a ly s i s .  A ny  ch ang e s  
to  t h e  d a t a b a s e  a f t e r  th a t  t im e  c a n  on ly  b e  m ad e  by  j o in t  w r i t t e n  ag r e em en t  b e tw e e n  th e  
G l o b a l  H e a d  o f  C l i n i c a l  I n f o rm a t i o n  S c i e n c e s  a n d  t h e  C l i n i c a l  F r a n c h i s e  H e a d .
 
 
 
 
 
No va r t i s Con f iden t ia l Page  53
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
10 .3 Da ta  Mon i to r ing  Comm i t tee
N o t  r e q u i r e d .
10 .4 Adjud ica t ion  Comm i t tee
N o t  r e q u i r e d .
11 Da ta  ana lys is
A l l  d a t a  a n a ly s e s  w i l l  b e  p e r f o rm e d  u n d e r  t h e  d i r e c t i o n  o f  N o v a r t i s  p e r s o n n e l .   
11 .1 Ana lys is  se ts
F o r  a l l  a n a ly s i s  s e t s ,  s u b j e c t s  w i l l  b e  a n a l y z e d  a c c o r d i n g  t o  t h e  s tudy  t r e a tm e n t ( s )  r e c e i v e d .
T h e  f u l l  a n a ly s i s  s e t  w i l l  i n c l u d e  a l l  su b j e c t s  w h o  r e c e i v e d  s tudy  t r e a tm e n t .
Th e  s a f e ty an a l y s i s  s e t  w i l l  i n c l u d e  a l l  s u b j e c t s  t h a t  r e c e i v e d  a n y  s tudy  d rug .
T h e  PK  a n a l y s i s  s e t  w i l l  i n c l u d e  a l l  s u b j e c t s  w i th  a v a i l a b l e  PK  d a t a  a n d  n o  p ro to co l  
d e v i a t i o n s  w i t h  r e l e v a n t  im p a c t  o n  PK  d a t a .
T h e  p r im a ry  P D  a n a l y s i s  s e t  w i l l  i n c l u d e  a l l  s u b j e c t s  w i th  a v a i l a b l e  PD  d a t a.  T h e  s e cond a ry  
PD  an a ly s i s  s e t  w i l l  i n c l u d e  a l l  s u b j e c t s  w i th  a v a i l a b l e  PD  d a t a  a n d  n o  p r o t o c o l  d e v i a t i o n s  
w i th  r e l e v a n t  im p a c t  o n  PD  d a t a .
11 .2 Sub jec t  demog raph ics  and  o the r  base l ine  cha rac te r is t ics
A l l  d a t a  f o r  b a ckg round  a n d  d emog r aph i c  v a r i ab l e s  w i l l  b e  l i s t ed  by  t r e a tm e n t  g r o u p  and  
s u b j e c t .  Summ a ry s t a t i s t i c s(m e a n[o r  g e om e t r i c  m e a n  f o r  l o g  t r a n s f o rm e d  d a t a ] ),  s t a nd a rd  
d e v i a t i o n,  m i n im um ,  m e d i a n  a n d  m ax imum )w i l l  b e  p r o v i d e d  by  t r e a tm e n t  g r o u p .
R e l e v a n t  m ed i c a l  h i s t o r y ,  c u r r e n t  m ed i c a l  c o n d i t i o n s ,  r e s u l t s  o f  l abo r a to ry  s c r e e n s ,  d r u g  t e s t s  
a n d  a n y  o t h e r  r e l e v a n t  i n f o rm a t i o n  w i l l  b e  l i s t e d  b yt r e a tm e n t  g r o u p  a n d  s u b j e c t .
A l l  d a t a  fo r  b a c k g r o u n d  a n d  d em o g r a p h i c  v a r i ab l e s  w i l l  b e  l i s t ed  by  t r e a tm en t  s e q u e n c e  and  
s u b j e c t .  Summ a ry s t a t i s t i c s  w i l l  b e  p r o v i d e d  fo r  a l l  s u b j e c t s ,  a s  w e l l  a s  f o r  e a c h  t r e a tm en t  
s e q u e n c e .
R e l e v a n t  m ed i c a l  h i s t o r y ,  c u r r e n t  m ed i c a l  c o n d i t i o n s ,  r e s u l t s  o f  l abo r a to ry  s c r e e n s ,  d r u g  t e s t s  
a n d  a n y  o t h e r  r e l e v a n t  i n f o rm a t i o n  w i l l  b e  l i s t e d  b y  t r e a tm e n t  s e q u e n c e  a n d  s u b j e c t .
11 .3 T rea tmen ts  (s tudy d rug ,  rescue  med ica t ion ,  o the r  concom i tan t  
the rap ies ,  comp l iance )
D a t a  fo r  s tudy  d r u g  adm in i s t r a t ion  ( r e s c u e  m ed i ca t i o n )  a n d  con com i t an t  t h e r a p i e s  w i l l  b e  
l i s t ed  by  t r e a tm e n t  g r o u p  a n ds u b j e c t .
No va r t i s Con f iden t ia l Page  54
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
11 .4 Ana lys is  o f  the  p r ima ry v a r iab le (s )
T h e  p r im a ry  e f f i c a cy  v a r i a b l e  w i l l  b e  th e  c h a n g e  in  t h e  1 2  h o u r  a v e r a g e  o f  sy s to l i c  b lood  
p r e s s u r e  m e a s u r e d  by  a mbu l a to ry b lood  p r e s su r e  moni t o r i n g  (ABPM )  28  d ay s  f o l l ow i n g  th e  
s t a r t  o f  t r e a tm e n t .
11 .4 .1 Va r iab le (s )
T h e  p r im a ry  e f f i c a cy  v a r i a b l e  w i l l  b e  th e  c h a n g e  in  t h e  1 2  h o u r  a v e r ag e  o f  sy s to l i c  b lood  
p r e s s u r e  m e a s u r e d  by  a mbu l a to ry b lood  p r e s su r e  m o n i t o r in g  (ABPM )  28  d ay s  f o l l ow i n g  th e  
s t a r t  o f  t r e a tm e n t .Th i s  i s  d e f i n e d  a s  t h e  1 2  hou r  d ay t im e  a v e r a g e  sy s to l i c  b l o o d  p r e s s u r e  on  
d ay28  m inu s  th e  12  hou r  d ay t im e  a v e r a g e  s y s to l i c  b lood  p r e s su r e  on  d ay  - 1 .
11 .4 .2 S ta t is t ica l  mode l ,  hypo thes is ,  and  me thod  o f  ana lys is
T h e  p r im a ry  e f f i c a cy  v a r i a b l e  w i l l  b e  th e  c h a n g e  in  t h e  1 2  h o u r  a v e r a g e  o f  sy s to l i c  b lood  
p r e s s u r e  m e a s u r e d  by  a mbu l a to ry b lood  p r e s su r e  m o n i t o r i n g  (ABPM )  28  d ay s  f o l l ow i n g  th e  
s t a r t  o f  t r e a tm e n t .  O u t-o f - o f f i c e  ABPM  i s  a  m o r e  r e l i a b l e  m e a su r e  o f  a  p a t i e n t ' s  b lood  
p r e s s u r e  t h a n  o f f i c e- b a s ed  BP  r e ading s  wh i ch  m ay  b e  f a l s e ly  e l ev a t ed  b e c a u s e  o f  "wh i t e- co a t "  
p h e n om e n a  ( B a k r i s  e t  a l  2 0 1 0) .  T h e  c h a n g e  f rom  b a s e l i n e  in  t h e  p l a c e b o  g r o u p  w i l l  b e  
c om p a r e d  to  th e  ch ang e  f rom  b a s e l i n e  in  th e  p o o l edLHW 0 9 0  do s e s .  T h e  c r i t e r i a  to  
d emon s t r a t e  e f f i c a cy  ( su c c e s s )  w i l l  b e  b a s ed  on  s t a t i s t i c a l ly  s ign i f i c an t  (1 - s id ed  p<0 .1 )  g r e a t e r  
r e d u c t i o n  f r om  b a s e l i n e  in  m e a n  d ay t im e  SBP  w i th  a c t i v e  t r e a tm e n t  (poo l ed  d o s e s )  t h a n  w i t h  
p l a c ebo ,  a s  w e l l  a s  an  e s t im a t ed  m ed i an  r edu c t ion  on  a c t iv e  t r e a tm en t  (poo l ed  a c t iv e  do s e s )  o f  
a t  l e a s t  7  mmH g  h igh e r  t h a n  o n  p l a c eb o .  Th e  t h r e s h o l d  of  a  7  mmHg  r e d u c t io n  in  
p l a c e b o- a d j u s t e d  sy s to l i c  BP  by  A BPM  i s  c o n s i d e r e d  c l i n i c a l l y  s i g n i f i c a n t  s i n c e  s im i l a r  
m a g n i t u d e  c h a n g e s  w e r e  o b s e r v e d  in  a  ph a s e  3  t r i a l  o f  a n  e n d o t h e l i n - r e c e p t o r  an t agon i s t ,  
d a r u s e n t a n ,  f o r  t h e  s am e  i n d i c a t i o n  (W e b e r  e t  a l  2 0 0 9) .
S tudy p a t i e n t s  w i l l  b e  r a n d om i z e d  in to  o n e  o f  3  g r o u p s ,p l a c e b o ,  1 0 0  m g  LHW 0 9 0  and  
2 0 0m g  LHW 0 9 0 ,  a s  an  add - on  th e r apy  toconv en t ion a l  b a ckg round  an t i - hy p e r t en s iv e  th e r apy .  
4 0  p a t i e n t s  w i l l  b e  r a n d om i z e d  to  p l a c e b o ,  a n d  2 0  to  e a c h  d o s e  o f  a c t i v e  t r e a tm e n t .  Th i s  w i l l  
g i v e  a round  3 2  c om p l e t e r s  in  t h e  p l a c e b o  g r o u p  a n d  1 6  o n  e a c h  a c t i v e  d o s e  g r o u p .  Th e  
p r im a ry  a n a ly s i s  o f  ch ang e  in  m e a n  d ay t im e  sy s to l i c  b l o o d  p r e s s u r e  w i l l  b e  p e r f o rm e d  u s ing  
t h e  d a t a  c o l l e c t e d  du r ing  t h e  p e r i o d  0 9 0 0  to  2 1 0 0  c o n s i s t e n t  w i th  r e c omm e n d a t i o n s  f r om  th e  
E u r op e an  S o c i e ty  fo r  Hyp e r t en s ion  ( O 'B r i e n  e t  a l  2 0 1 3) .  T he  a v e r a g e  o f  th e s e  1 2h o u r s  o f  
d a t a  w i l l  b e  p r o d u c e d  u s ing  d a t a  f rom  t h e  b a se l in e  ambu l a to ry  b lood  p r e s s u r e  mon i to r ing  on  
D ay - 2  a n d  D ay 2 7 .T h e  c h a n g e  f rom  b a s e l i n e  in  m e a n  d ay t im e  SBP  w i l l  b e  e s t im a t e d  f r om  a  
l o n g i t u d i n a l  m o d e l  u s i n g  a l l  d a t a  c o l l e c t e d  f o r  ev e ry  p a t i en t  un t i l  D ay2 7 .  T h e  m o d e l  w i l l  
i n c l u d e  f ix ed  e f f e c t s  f o r  b a s e l i n e ,  t r e a tm e n t  ( i n c l u d i n g  d o s e ) ,  a n d  v i s i t ,  and  a  r a n d om  e f f e c t  
f o r  e a ch  p a t i e n t.  Th i s  an a ly s i s  i s  unb i a s ed  und e r  t h e  a s s um p t i o n  t h a t  th e  d a t a  a r e  m i s s ing  a t  
r a n d om  (MAR ) .
11 .4 .3 Hand l ing  o f  m iss ing  va lues /censo r ing /d iscon t inua t ions
C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n  
  
No va r t i s Con f iden t ia l Page  55
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
11 .4 .4 Suppo r t ive  ana lyses
A s  a  s u p p o r t i v e  an a ly s i s ,  t h e  d i f f e r e n c e  in  e f f i c a cy  b e tw e e n  th e  tw oa c t i v e  d o s e s  w i l l  b e  
ex am in ed  by  c om p u t i n g  t h e  t - s t a t i s t i c  a s s o c i a t e d  w i t h  t h e  d i f f e r e n c e  i n  m e a n s .
11 .5 Ana lys is  o f  seconda ry and  exp lo ra to ry  va r iab les
T h e  s e cond a ry  o b j e c t iv e  v a r i a b l e s  a r e  o b t a i n e d  f rom  p h a rm a c o k i n e t i c  an a ly s e s ,  a s  d e s c r ib ed  
in  S e c t i o n  1 1 . 5 . 3.   T h e s e  a n a l y s e s  o f  t h e s e  d a t a  a r e  d e s c r i b e din  th i s  s e c t ion .   
11 .5 .1 E f f icacy /  Pha rmacodynam ics
T h e r e  a r e  n o  e f f i c a c y s e cond a ry  v a r i a b l e s .   
 
11 .5 .2 Sa fe ty
V i ta l  s igns
A l l  v i t a l  s i g n s  d a t a  w i l l  b e  l i s t ed  by  t r e a tm e n t ,  s u b j e c t ,  a n d  v i s i t / t im e  a n d  i f  r a n g e s  a r e  
a v a i l a b l e  a b n o rm a l i t i e s  ( and  r e l e v a n t  o r tho s t a t i c  c h a n g e s )  w i l l  b e  f l a g g e d .  Summ a ry s t a t i s t i c s  
w i l l  b e  p r o v i d e d  by  t r e a tm e n t  a n d  v i s i t / t im e .
ECG  eva lua t ions
A l l  ECG  d a t a  w i l l  b e  l i s t ed  by t r e a tm en t ,  sub j e c t  and  v i s i t / t im e ,  abno rm a l i t i e s  w i l l  b e  f l agg ed .  
Summ a ry s t a t i s t i c s  w i l l  b e  p r o v i d e d  b y  t r e a tm e n t  a n d  v i s i t / t im e .
C l in ica l  labo ra to ry eva lua t ions
A l l  l abo r a to ry d a t a  w i l l  b e  l i s t ed  by  t r e a tm en t ,  sub j e c t ,  and  v i s i t / t im e  and  i f  no rm a l  r ang e s  a r e  
a v a i l a b l e  abno rm a l i t i e s  w i l l  b e  f l a g g e d .  Summ a ry s t a t i s t i c s  w i l l  b e  p r o v i d e d  by  t r e a tm e n t  a nd  
v i s i t / t im e .
Adve rse  even tsC o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
A l l  i n f o rm a t i o n  o b t a i n e d  o n  a d v e r s e  e v e n t s  w i l l  b e  d i s p l a ye d  b y  t r e a tm e n t  a n ds u b j e c t .
T h e  n um b e r  a n d  p e r c e n t a g e  o f  sub j e c t s  w i th  a d v e r s e  e v e n t s  w i l l  b e  t abu l a t ed  by  b ody  sy s t em  
a n d  p r e f e r r e d  t e rm  w i th  a  b r e a k d ow n  by  t r e a tm e n t .A  s u b j e c t  w i th  mu l t ip l e  a d v e r s e  ev en t s  
w i th in  a  body s y s t em  i s  on ly  coun t ed  on c e  tow a rd s  th e  to t a l  o f  th i s  body  s y s t em .
No va r t i s Con f iden t ia l Page  56
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
11 .5 .3 Pha rmacok ine t ics
 
D e s c r i p t iv e  summ a ry  s t a t i s t i c s  w i l l  b ep r o v i d e d  by  t r e a tm e n t  and  
v i s i t / s am p l i n g  t im e  p o i n t ,  i n c l u d i n gt h e  f r e q u e n c y  ( n ,  % )  o f  con c en t r a t ion s  b e l ow  t h e  LLOQ  
a n d  r e p o r t e d  a s  z e r o .
Summ a ry s t a t i s t i c s  w i l l  i n c l u d e  m e a n  ( a r i t hm e t i c  a n d  g e om e t r i c ) ,  SD ,  CV  ( a r i t hm e t i c  a nd  
g e om e t r i c ) ,  m e d i a n ,  m in imum  a n d  m ax imum .  A ne x c e p t i o n  to  th i s  i s  Tm ax  w h e r e  m ed i an ,  
m in imum  a n d  m a x im um  w i l l  b e  p r e s e n t e d .  C o n c e n t r a t i o n s  b e l ow  LLOQ  w i l l  b e  t r e a t e d  a s  
z e r o  in  summ a ry  s t a t i s t i c sa n d  f o r  PK  p a r am e t e r  c a l c u l a t i o n s .  A  g e om e t r i c  m e a n  w i l l  n ot  b e  
r e p o r t e d  i f  t h e  d a t a s e t  i n c l u d e s  z e r o  v a l u e s .P h a rm a c o k i n e t i c  p a r am e t e r s  w i l l  b e  c a l c u l a t e d  a s  
d e s c r i b e d  inS e c t i o n  8 . 5a n d  w i l l  b e  l i s t ed  by  t r e a tm e n t  a n d  s u b j e c t .PK- PD  r e l a t i o n s h i p s  w i l l  
b e  e x p l o r e d  a s  r e l e v a n t .
 
11 .5 .4 Pha rmacok ine t ic  /  pha rmacodynam ics  in te rac t ions
T h e  r e l a t ion sh ip  b e tw e en  PK  and  k ey  P D  p a r am e t e r s  m ay b e  exp lo r ed  u s ing  a  g r a p h i c a l
a p p r o a c h .  D e s c r i p t i v e  s t a t i s t i c s  m ay b e  p rov id ed .  
11 .5 .5 O the r  assessmen ts
 C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
 
 
 
 
 
 
 
 
 
 
 C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
No va r t i s Con f iden t ia l Page  57
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
 
 
 
 
 
 
 
 
 
11 .7 Powe r  fo r  ana lys is  o f  key  seconda ry va r iab les
T h e r e  a r e  n o  p ow e r  a n a ly s e s  f o r  t h e  s e c o n d a r y  s a f e t y  v a r i a b l e s .
11 .8 In te r im  ana ly sesC o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
 
 
 
 
 
 
 
 
 
 
 
 
 C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
C o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
No va r t i s Con f iden t ia l Page  58
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
 
 
 
 
 
 
 
 
 
12 E th ica l  cons ide ra t ions
12 .1 Regu la to ry and  e th ica l  comp l ia nce
Th i s  c l i n i c a l  s tudy  w a s  d e s i g n e d  a n d  s h a l l  b e  im p l em e n t e d  a n d  r epo r t ed  in  a c c o r d a n c e  w i th  
t h e  ICH  H a rmon i z ed  T r i p a r t i t e  G u i d e l i n e s  f o r  Good  C l i n i c a l  P r a c t i c e ,  w i th  a p p l i c a b l e  lo c a l  
r e g u l a t i o n s  ( i n c l u d i n g  E u r o p e a n  D i r e c t i v e  2001 /20 /EC ,  US  Cod e  o f  F e d e r al  R e g u l a t i o n s  T i t l e  
2 1 ,  a n d  J ap an e s e  M in i s t ry o f  H e a l th ,  L a b o r ,  and  W e l f a r e ) ,  a n d  w i th  t h e  e th i c a l  p r i n c i p l e s  l a id  
d ow n  i n  t h e  D e c l a r a t i o n  o f  H e l s i n k i .
12 .2 Respons ib i l i t ies  o f  the  inves t iga to r  and  IRB / IECC o r p o r a t e  C o n f i d e n t i a l  I n f o rm a t i o n
B e f o r e  i n i t i a t i n g  a  t r i a l ,  t h e  i n v e s t i g a to r / i n s t i t u t i o ns h o u l d  o b t a i n  a p p r o v a l / f a v o r a b l e  op in ion  
f r om  t h e  I n s t i tu t ion a l  R e v i ew  B o a r d / I n d e p e n d e n t  E t h i c s  C omm i t t e e  ( I RB / IEC )  f o r  t h e  t r i a l  
p r o t o c o l ,  w r i t t e n  in fo rm ed  c o n s e n t  fo rm ,  con s en t  f o rm  upd a t e s ,  sub j e c t  r e c ru i tm en t  
p r o c e d u r e s  ( e . g .a d v e r t i s em e n t s )  a n d  a n y  ot h e r  w r i t t en  i n f o rm a t i o n  to  b e  p r o v i d e d  to  s u b j e c t s .  
P r i o r  to  s tudy  s t a r t ,  t h e  i n v e s t i g a t o r  i s  r e q u i r e d  to  s i g n  a  p ro to co l  s i gn a t u r e  p ag e  con f i rm ing  
h i s / h e r  a g r e em e n t  to  c o n d u c t  t h e  s tudy  i n  a c c o r d a n c e  w i th  t h e s e  do cum en t s  a n d  a l l  o f  t h e  
i n s t r u c t i o n s  a n d  p r o c ed u r e s  found  in  th i s  p ro to co l  a n d  to  g i v e  a c c e s s  to  a l l  r e l e v a n t  d a t a  and  
r e co rd s  to  Nov a r t i s  mon i to r s ,  aud i to r s ,  Nov a r t i s  Qu a l i ty  A s s u r a n c e  r e p r e s e n t a t i v e s ,  d e s i g n a t e d  
a g e n t s  o f  Nov a r t i s ,  IR B s / IEC s ,  a n d  r egu l a to ry  a u tho r i t i e s  a s  r equ i r ed .  I f  an  i n s p e c t ion  o f  th e  
c l i n i c a l  s i t e  i s  r equ e s t ed  by  a  r egu l a to ry  a u tho r i ty ,  t h e  inv e s t ig a to r  mu s t  i n f o rm  Nov a r t i s  
imm ed i a t e ly  t h a t  t h i s  r e q u e s t  h a s  b e e n  m a d e .
F o r  mu l t i- c e n t e r  t r i a l s ,  a  C o o r d i n a t i n g  I nv e s t ig a to r  w i l l  b e  s e l e c t e d  by  N o v a r t i s  a r o u n d  t h e  
t im e  o f  L a s t  P a t i e n t  L a s t  V i s i t  t o  b e  a  r e v i ew e r  a n d  s ign a to ry  f o r  t h e  c l in i c a l  s tudy  r e p o r t .
No va r t i s Con f iden t ia l Page  59
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
12 .3 Pub l ica t ion  o f  s tudy p ro toco l  and  resu l ts
N o v a r t i s  a s s u r e s  t h a t  t h e  k ey  d e s i g n  e l em e n t s  o f  th i s  p r o t o c o l  w i l l  b e  p o s t e d  in  a  p u b l i c ly  
a c c e s s i b l e  d a t a b a s e  su ch  a s  c l i n i c a l t r i a l s . g o v .  I n  a d d i t i o n ,  u p o n  s tudy  c omp l e t ion  and  
f in a l i z a t ion  o f  t h e  s tudy  r e p o r t  th e  r e su l t s  o f  th i s  t r i a l  w i l l  b e  e i th e r  subm i t t ed  fo r  pub l i c a t ion  
a n d / o r  p o s t e d  i n  a  p u b l i c l y  a c c e s s i b l e  d a t a b a s e  o f  c l i n i c a l  t r i a l  r e s u l t s .
13 P ro toco l  adhe rence
Th i s  p r o t o c o l  d ef i n e s  t h e  s tudy  o b j e c t iv e s ,  t h e  s tudy  p r o c e d u r e s  a n d  t h e  d a t a  to  b e  c o l l e c t e d  
o n  s tudy  p a r t i c i p a n t s .  Add i t ion a l  a s s e s sm e n t s  r eq u i r e d  to  e n s u r e  s a f e t y  o f  s u b j e c t s  s h o u l d  b e  
a dm i n i s t e r e d  a s  d e em e d  n e c e s s a ry  o n  a  c a s e  by  c a s e  b a s i s .  U n d e r  n o  c i r c um s t a n c e s  s h ou ld  an  
i n v e s t i g a t o r  co l l e c t  a d d i t i o n a l  d a t a  o r  c o n d u c t  any  a dd i t ion a l  p r o c e du r e s  f o r  any  r e s e a r ch  
r e l a t e d  p u r p o s e  i n v o l v i n g  a n y  inv e s t ig a t ion a l  d rug s .
I n v e s t i g a t o r s  mu s t  app ly  d u e  d i l i g e n c e  to  a v o i d  p ro to co l  d e v i a t i o n s .  I f  t h e  i n v e s t i g a t o r  f e e l s  a  
p r o t o c o ld e v i a t i o n  w o u l d  im p r o v e  t h e  c o n d u c t  o f  th e  s tudy  t h i s  mu s t  b e  c o n s i d e r e d  a  p ro to co l  
am e n dm e n t ,  and  u n l e s s  su ch  a n  am e n dm e n t  i s  a g r e e d  upon  by  N ov a r t i s  and  a p p r o v ed  by  t h e  
IR B / IEC /REB  i t  c a n n o t  b e  im p l em e n t e d .  A l l  s i g n i f i c a n t  p r o t o c o l  d e v i a t io n s  w i l l  b e  r e co rd ed  
a n d  r e p o r t e d  i n  t h e  CSR .
13 .1 P ro toco l  Amendmen ts
Any c h a n g e  o r  a d d i t i o n  t o  t h e  p r o t o c o l  c a n  o n l y  b e  m a d e  i n  a  w r i t t e n  p r o t o c o l  am e n dm e n t  t h a t  
mu s t  b e  a p p r o v e d  by  N ov a r t i s ,  H e a l t h  Au tho r i t i e s  w h e r e  r e q u i r e d ,  a n d  t h e  IR B / IECp r i o r  to  
im p l em e n t a t i o n .  
On lyam endm en t s  t h a t  a r ei n t e n d e d  to  e l im in a t e  a n  a p p a r e n t  imm ed i a t e  h a z a r d  to  s u b j e c t s  
m ay b e  im p l em e n t e d ,p r o v i d e d  t h e  H e a l th  Au tho r i t i e s  a n d  t h e  r e v i ew i n g  IR B / IEC  a r e  
sub s equ en t lyn o t i f i e d  by  p r o t o c o l  am e n dm e n t .
N o tw i t h s t a n d i n g  th e  n e ed  f o r  a p p r o v a l  o f  fo rm a l  p r o t o c o l  am endm en t s ,  t h e  i n v e s t i g a t o r  i s  
e x p e c t e d  to  t ak e  a n y  imm ed i a t e  a c t ion  r e q u i r e d  f o r  th e  s a f e ty  o f  a n y  sub j e c t  in c lud ed  in  th i s  
s tudy ,  e v e n  i f  th i s  a c t i o n  r e p r e s e n t s  a  d ev i a t ion  f r om  t h e  p r o t o c o l .  I n  s u c h  c a s e s ,t h e  CTL  
s h o u l d  b e  i n f o rm e d  a n d  ( s e r i o u s )  a d v e r s ee v e n t  r e p o r t i n g  r e q u i r em e n t s  ( S e c t i o n  9)  fo l low ed  
a s  a p p r o p r i a t e .
No va r t i s Con f iden t ia l Page  60
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
14 Re fe rences
A v a i l a b l e  u p o n  r e q u e s t
B a k r i s  GL ,  L in d h o lm  LH ,  B l a c k  HR ,  e t  a l  ( 2 0 1 0 )  D i v e r g e n t  r e s u l t s  u s i n g  c l i n i c  a n d  
ambu l a to ry  b l o o d  p r e s s u r e s :  r e p o r t  o f  a  d a r u s e n t a n- r e s i s t a n t  h y p e r t e n s i o n  t r i a l .  H y p e r t e n s i o n  
p .  8 2 4 - 3 0 .
B a v i s h i  C ,  M e s s e r l i  FH ,  K a d o s h  B  e t  a l  ( 2 0 1 5 )  R o l e  o f  n e p r i ly s i n  i n h ib i t o r  c om b i n a t i o n s  in  
hy p e r t en s ion :  in s igh t s  f rom  hy p e r t e n s i o n  a n d  h e a r t  f a i l u r e  t r i a l s .  E u r  H e a r t  J  p i i :  e h v 1 4 2  
[E p u b  a h e a d  o f  p r i n t ]
C a l h o u n  DA ,  J o n e s  D ,  T e x t o r  S ,  e t  a l  ( 2 0 0 8 )  R e s i s t a n t  h yp e r t e n s i o n :  d i a g n o s i s ,  e v a l u a t i o n ,  
a n d  t r e a tm e n t .  A  s c i e n t i f i c  s t a t em e n t  f r om  t h e  Am e r i c a n  H e a r t  A s s o c i a t i o n  P r o f e s s i o n a l  
E d u c a t i o n  C omm i t t e e  o f  t h e  C o u n c i l  fo r  H i g h  B l o o d  P r e s s u r e  R e s e a r c h .  H y p e r t en s ion  p .  
1 4 0 3 - 1 9 .
C h o b a n i a n  AV ,  B a k r i s  GL ,  B l a c k  HR ,  e t  a l  ( 2 0 0 3 )  N a t i o n a l  H e a r t ,  L u n g ,  a n d  B l o o d  I n s t i t u t e  
J o i n t  N a t i o n a l  C omm i t t e e  o n  P r e v e n t i o n ,  D e t e c t i o n ,  Ev a l u a t i o n ,  a n d  T r e a tm e n t  o f  H i g h  B l o o d  
P r e s s u r e ;  N a t i o n al  H i g h  B l o o d  P r e s s u r e  E d u c a t i o n  P r o g r am  C o o r d i n a t i n g  C omm i t t e e .  T h e  
S e v e n t h  R e p o r t  o f  t h e  J o i n t  N a t i o n a l  C omm i t t e e  o n  P r e v e n t i o n ,  D e t e c t i o n ,  E v a l u a t i o n ,  a n d  
T r e a tm e n t  o f  H i g h  B l o o d  P r e s s u r e :  t h e  JNC  7  r e p o r t .  JAMA  2 8 9 : 2 5 6 0- 7 2 .
G u  J ,  N o e  A ,  C h a n d r a  P ,  e t  a l( 2 0 1 0 )  P h a rm a c o k i n e t i c s  a n d  p h a rm a c o d y n am i c s  o f  LCZ 6 9 6 ,  an o v e l  
d u a l - a c t i n g  a n g i o t e n s i n  r e c e p t o r - n e p r i l y s i n  i n h i b i t o r  (ARN i ) .  J  C l i n  P h a rm a c o l  5 0 : 4 0 1 - 1 4 .
J am e s  PA ,  O p a r i l  S ,  C a r t e r  BL ,  e t  a l  ( 2 0 1 4 )  2 0 1 4  e v i d e n c e - b a s e d  g u i d e l i n e  f o r  t h e  
m a n a g em e n t  o f  h i g h  b l o o d  p r e s s u r e  i n  a d u l t s :  r e p o r t  f r om  t h e  p a n e l  m em b e r s  a p p o i n t e d  t o  t h e  
E i g h t h  J o i n t  N a t i o n a l  C omm i t t e e  ( JNC  8 ) .  JAMA  3 1 1 : 5 0 7 - 2 0 .
M a n c i a  G ,  F a g a r d  R ,  N a r k i ew i c z  K ,  e t  a l  ( 2 0 1 3 )  ESH /ESC  G u i d e l i n e s  f o r  t h e  m a n a g em e n t  o f  
a r t e r i a l  h y pe r t e n s i o n .  J  H y p e r t en s  31:1281 - 1 3 5 7 .
O 'B r i e n  E ,  P a r a t i  G ,  S t e r g i o u  G ,  e t  a l  ( 2 0 1 3 )  E u r o p e a n  S o c i e ty  o f  Hy pe r t e n s i o n  p o s i t i o n  p a p e r  
on  ambu l a to ry  b l o o d  p r e s s u r e  m o n i t o r i n g .  J .  Hy p e r t e n s .  p .  1 7 3 1- 6 8 .
Ru i lop e  LM ,  D u k a t  A ,  B o hm  M ,  e t  a l  ( 2 0 1 0 )  B l o o d - p r e s su r e  r edu c t ion  w i th  L CZ6 9 6 ,  a  nov e l  
d u a l- a c t i n g  i n h i b i t o r  o f  t h e  a n g i o t e n s i n  I I  r e c e p t o r  a n d  n e p r i l y s in :  a  r andom i s ed ,  doub l e - b l ind ,  
p l a c e b o- c o n t r o l l e d ,  a c t i v e  c om p a r a t o r  s t u d y .  L a n c e t  3 7 5 : 1 2 5 5- 5 6 .
V a l d e r r am a  AL ,  G i l l e s p i eC ,  K i n g  SC ,  e t  a l  ( 2 0 1 2 )  V i t a l  S i g n s :  Aw a r e n e s s  a n d  T r e a tm e n t  o f
Un con t ro l l ed  Hyp e r t e n s i o n  Am o n g  A d u l t s  —Un i t ed  S t a t e s ,  2003– 2 0 1 0Mo rb id i ty a n d  
Mo r t a l i ty W e e k l y  R e p o r t .  6 1 ( 3 5 ) : 7 0 3- 7 0 9 .
V o n g p a t a n a s i n  W  ( 2 0 1 4 )  R e s i s t a n t  h yp e r t e n s i o n :  a  r e v i ew  o f  d i ag n o s i s  a n d  m a n a g em en t .  
JAMA  p .  2216 - 2 4 .
W e b e r  MA ,  B l a c k  H ,  B a k r i s  G ,  e t  a l  ( 2 0 0 9 )  A  s e l e c t i v e  e n d o t h e l i n - r e c ep t o r  a n t a g o n i s t  t o  
r e d u c e  b l o o d  p r e s s u r e  i n  p a t i e n t s  w i t h  t r e a tm e n t - r e s i s t an t  hy p e r t e n s i o n :  a  r a n d om i s e d ,  d o u b l e-
b l i n d ,  p l a c e b o - c o n t r o l l e d  t r i a l .  L a n c e t  p .  1 4 2 3 - 3 1 .
No va r t i s Con f iden t ia l Page  61
AmendedP ro toco lVe rs ion  v05  (C lean) P ro to co l  No .  CLHW090X2202
W e b e r  MA ,  S c h i f f i r n  EL ,  W h i t e  WB ,  e t  a l  ( 2 0 1 4 )   C l i n i ca l  P r a c t i c e  G u i d e l i n e s  f o r  t h e  
M an ag em en t  o f  Hyp e r t en s ion  in  th e  Commun i ty .  A  S t a t em en t  by  t h e  Am e r i c a n  So c i e t y  o f  
Hyp e r t e n s i o n  a n d  t h e  I n t e r n a t i o n a l  S o c i e t y  o f  Hy p e r t e n s i o n .Th e  Jou rn a l  o f  C l in i c a l  
Hyp e r t e n s i o n  V o l  1 6  ( 1 ):  14 - 2 6